



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/16, 31/535, 31/165, 31/44, 31/40, 31/195, 31/47, 31/495, 31/445, 31/00</p>	A1	<p>(11) International Publication Number: WO 99/39704</p> <p>(43) International Publication Date: 12 August 1999 (12.08.99)</p>												
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>(21) International Application Number: PCT/GB99/00386</p> <p>(22) International Filing Date: 5 February 1999 (05.02.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">9802549.7</td> <td style="width: 40%;">7 February 1998 (07.02.98)</td> <td style="width: 30%;">GB</td> </tr> <tr> <td>9806300.1</td> <td>25 March 1998 (25.03.98)</td> <td>GB</td> </tr> <tr> <td>9810463.1</td> <td>16 May 1998 (16.05.98)</td> <td>GB</td> </tr> <tr> <td>9828318.7</td> <td>22 December 1998 (22.12.98)</td> <td>GB</td> </tr> </table> <p>(71) Applicant (for all designated States except US): BRITISH BIOTECH PHARMACEUTICALS LIMITED [GB/GB]; Watlington Road, Cowley, Oxford OX4 5LY (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): HUNTER, Michael, George [GB/GB]; British Biotech Pharmaceuticals Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB). BECKETT, Raymond, Paul [GB/GB]; British Biotech Pharmaceuticals Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB). CLEMENTS, John, Martin [GB/GB]; British Biotech Pharmaceuticals Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB). WHITTAKER, Mark [GB/GB]; British Biotech Pharmaceuticals Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB). DAVIES, Stephen, John [GB/GB]; British Biotech Pharma-</p> </div> <div style="width: 48%;"> <p>ceuticals Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB). PRATT, Lisa, Marie [GB/GB]; British Biotech Pharmaceuticals Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB). SPAVOLD, Zoe, Marie [GB/GB]; British Biotech Pharmaceuticals Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB). LAUNCHBURY, Steven [GB/GB]; British Biotech Pharmaceuticals Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB).</p> <p>(74) Agent: WALLS, Alan, J.; British Biotech Pharmaceuticals Limited, Watlington Road, Cowley, Oxford OX4 5LY (GB).</p> <p>(81) Designated States: AU, BR, CA, CN, CZ, GB, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> </div> </div>			9802549.7	7 February 1998 (07.02.98)	GB	9806300.1	25 March 1998 (25.03.98)	GB	9810463.1	16 May 1998 (16.05.98)	GB	9828318.7	22 December 1998 (22.12.98)	GB
9802549.7	7 February 1998 (07.02.98)	GB												
9806300.1	25 March 1998 (25.03.98)	GB												
9810463.1	16 May 1998 (16.05.98)	GB												
9828318.7	22 December 1998 (22.12.98)	GB												
<p>(54) Title: ANTIBACTERIAL AGENTS</p> <p>(57) Abstract</p> <p>Compounds of formula (I) are antibacterials; wherein R₁ represents hydrogen, or C₁-C₆ alkyl or C₁-C₆ alkyl substituted by one or more halogen atoms; R₂ represents a group R₁₀-(X)_n-(ALK)_m wherein R₁₀ represents hydrogen, or a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C₁-C₆) alkyl, (C₁-C₆) alkoxy, hydroxy, mercapto, (C₁-C₆) alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C₁-C₆) alkyl group, and ALK represents a straight or branched divalent C₁-C₆ alkylene, C₂-C₆ alkenylene, or C₂-C₆ alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages, X represents -NH-, -O- or -S-, and m and n are independently 0 or 1; and A represents a group as defined in the specification.</p> <div style="text-align: center; margin-top: 20px;"> <p style="text-align: right; margin-right: 50px;">(I)</p> </div>														

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Antibacterial Agents

This invention relates to the use of N-formyl hydroxylamine derivatives as antibacterial agents, to a novel class of such compounds, and to pharmaceutical and veterinary compositions comprising such compounds.

Background to the Invention

In general, bacterial pathogens are classified as either Gram-positive or Gram-negative. Many antibacterial agents (including antibiotics) are specific against one or other Gram-class of pathogens. Antibacterial agents effective against both Gram-positive and Gram-negative pathogens are therefore generally regarded as having broad spectrum activity.

Many classes of antibacterial agents are known, including the penicillins and cephalosporins, tetracyclines, sulfonamides, monobactams, fluoroquinolones and quinolones, aminoglycosides, glycopeptides, macrolides, polymyxins, lincosamides, trimethoprim and chloramphenicol. The fundamental mechanisms of action of these antibacterial classes vary.

Bacterial resistance to many known antibacterials is a growing problem. Accordingly there is a continuing need in the art for alternative antibacterial agents, especially those which have mechanisms of action fundamentally different from the known classes.

Amongst the Gram-positive pathogens, such as Staphylococci, Streptococci, Mycobacteria and Enterococci, resistant strains have evolved/arisen which makes them particularly difficult to eradicate. Examples of such strains are methicillin resistant *Staphylococcus aureus* (MRSA), methicillin resistant coagulase negative Staphylococci (MRCNS), penicillin resistant *Streptococcus pneumoniae* and multiply resistant *Enterococcus faecium*.

Pathogenic bacteria are often resistant to the aminoglycoside, β -lactam (penicillins and cephalosporins), and chloramphenicol types of antibiotic. This resistance involves the enzymatic inactivation of the antibiotic by hydrolysis or by formation of inactive derivatives. The β -lactam (penicillin and cephalosporin) family of antibiotics are characterised by the presence of a β -lactam ring structure. Resistance to this family of antibiotics in clinical isolates is most commonly due to the production of a "penicillinase" (β -lactamase) enzyme by the resistant bacterium which hydrolyses the β -lactam ring thus eliminating its antibacterial activity.

Recently there has been an emergence of vancomycin-resistant strains of enterococci (Woodford N. 1998 Glycopeptide-resistant enterococci: a decade of experience. Journal of Medical Microbiology. 47(10):849-62). Vancomycin-resistant enterococci are particularly hazardous in that they are frequent causes of hospital based infections and are inherently resistant to most antibiotics. Vancomycin works by binding to the terminal D-Ala-D-Ala residues of the cell wall peptidoglycan precursor. The high-level resistance to vancomycin is known as VanA and is conferred by a genes located on a transposable element which alter the terminal residues to D-Ala-D-lac thus reducing the affinity for vancomycin.

In view of the rapid emergence of multidrug-resistant bacteria, the development of antibacterial agents with novel modes of action that are effective against the growing number of resistant bacteria, particularly the vancomycin resistant enterococci and β -lactam antibiotic-resistant bacteria, such as methicillin-resistant *Staphylococcus aureus*, is of utmost importance.

Brief Description of the Invention

This invention is based on the finding that certain N-formyl hydroxylamine derivatives have antibacterial activity, and makes available a new class of antibacterial agents. The inventors have found that the compounds with which this invention is concerned are antibacterial with respect to a range of Gram-positive and Gram-negative organisms. Furthermore, there is evidence that some compounds

are antibacterial with respect to bacteria which are resistant to commonly used antibiotics such as vancomycin and the β -lactam antibiotics, for example methicillin-resistant *Staphylococcus aureus*.

Although it may be of interest to establish the mechanism of action of the compounds with which the invention is concerned, it is their ability to inhibit bacterial growth which makes them useful. However, it is presently believed that their antibacterial activity is due, at least in part, to intracellular inhibition of bacterial polypeptide deformylase (PDF) enzyme.

Bacterial polypeptide deformylases (PDF) (EC 3.5.1.31), are a conserved family of metalloenzymes (Reviewed: Meinnel T, Lazennec C, Villoing S, Blanquet S, 1997, Journal of Molecular Biology 267, 749-761) which are essential for bacterial viability, their function being to remove the formyl group from the N-terminal methionine residue of ribosome-synthesised proteins in eubacteria. Mazel et al. (EMBO J. 13(4):914-923, 1994) have recently cloned and characterised an *E. coli* PDF. As PDF is essential to the growth of bacteria and there is no eukaryotic counterpart to PDF, Mazel et al. (ibid), Rajagopalan et al. (J. Am. Chem. Soc. 119:12418-12419, 1997) and Becker et al., (J. Biol Chem. 273(19):11413-11416, 1998) have each proposed that PDF is an excellent anti-bacterial target.

Certain N-formyl hydroxylamine derivatives have previously been claimed in the patent publications listed below, although very few examples of such compounds have been specifically made and described:

EP-B-0236872	(Roche)
WO 92/09563	(Glycomed)
WO 92/04735	(Syntex)
WO 95/19965	(Glycomed)
WO 95/22966	(Sanofi Winthrop)
WO 95/33709	(Roche)


WO 96/23791	(Syntex)
WO 96/16027	(Syntex/Agouron)
WO 97/03783	(British Biotech)
WO 97/18207	(DuPont Merck)
WO 98/38179	(GlaxoWellcome)
WO 98/47863	(Labs Jaques Logeais)

The pharmaceutical utility ascribed to the N-formyl hydroxylamine derivatives in those publications is the ability to inhibit matrix metalloproteinases (MMPs) and in some cases release of tumour necrosis factor (TNF), and hence the treatment of diseases or conditions mediated by those enzymes, such as cancer and rheumatoid arthritis. That prior art does not disclose or imply that N-formyl hydroxylamine derivatives have antibacterial activity.

In addition to these, US-A-4,738,803 (Roques et al.) also discloses N-formyl hydroxylamine derivatives, however, these compounds are disclosed as enkephalinase inhibitors and are proposed for use as antidepressants and hypotensive agents. Also, WO 97/38705 (Bristol-Myers Squibb) discloses certain N-formyl hydroxylamine derivatives as enkephalinase and angiotensin converting enzyme inhibitors. This prior art does not disclose or imply that N-formyl hydroxylamine derivatives have antibacterial activity either.

Detailed description of the invention

According to the first aspect of the present invention there is provided the use of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof in the preparation of an antibacterial composition:



wherein:

R_1 represents hydrogen, or C_1 - C_6 alkyl or C_1 - C_6 alkyl substituted by one or more halogen atoms;

R_2 represents a group $R_{10}-(X)_n-(ALK)_m$ - wherein


R_{10} represents hydrogen, or a C_1 - C_6 alkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by $(C_1$ - C_6)alkyl, $(C_1$ - C_6)alkoxy, hydroxy, mercapto, $(C_1$ - C_6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, $-COOH$, $-CONH_2$, $-COOR^A$, $-NHCOR^A$, $-CONHR^A$, $-NHR^A$, $-NR^A R^B$, or $-CONR^A R^B$ wherein R^A and R^B are independently a $(C_1$ - C_6)alkyl group, and

ALK represents a straight or branched divalent C_1 - C_6 alkylene, C_2 - C_8 alkenylene, or C_2 - C_8 alkynylene radical, and may be interrupted by one or more non-adjacent $-NH-$, $-O-$ or $-S-$ linkages,


X represents $-NH-$, $-O-$ or $-S-$, and

m and n are independently 0 or 1; and


A represents (i) a group of formula (IA), (IB), (IC) or (ID)



(IA)



(IB)



(IC)



(ID)

wherein:

R_3 represents hydrogen and R_4 represents the side chain of a natural or non-natural alpha amino acid or R_3 and R_4 when taken together with the nitrogen and carbon atoms to which they are respectively attached form an optionally substituted saturated heterocyclic ring of 5 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring,

R_5 and R_6 , independently represent hydrogen, or optionally substituted C_1 - C_8 alkyl, cycloalkyl, aryl, aryl(C_1 - C_6 alkyl), heterocyclic, or heterocyclic(C_1 - C_6 alkyl), or R_5 and R_6 when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring, and

R_7 represents hydrogen, C_1 - C_6 alkyl, or an acyl group.

In another aspect, the invention provides a method for the treatment of bacterial infections in humans and non-human mammals, which comprises administering to a subject suffering such infection an antibacterially effective dose of a compound of formula (I) as defined above.

In a further aspect of the invention there is provided a method for the treatment of bacterial contamination by applying an antibacterially effective amount of a compound of formula (I) as defined above to the site of contamination.

The compounds of formula (I) as defined above may be used as component(s) of antibacterial cleaning or disinfecting materials.

According to a preferred embodiment, the various aspects of the invention can be applied against vancomycin-, quinolone- and " β -lactam"-resistant bacteria and the infections they cause.

On the hypothesis that the compounds (I) act by inhibition of intracellular PDF, the most potent antibacterial effect may be achieved by using compounds which efficiently pass through the bacterial cell wall. Thus, compounds which are highly active as inhibitors of PDF in vitro and which penetrate bacterial cells are preferred for use in accordance with the invention. It is to be expected that the antibacterial potency of compounds which are potent inhibitors of the PDF enzyme in vitro, but are poorly cell penetrant, may be improved by their use in the form of a prodrug, ie a structurally modified analogue which is converted to the parent molecule of formula (I), for example by enzymic action, after it has passed through the bacterial cell wall.

The invention also provides novel compounds of formula (I) above, or pharmaceutically or veterinarily acceptable salts thereof, wherein:

R_1 represents hydrogen, C_1 - C_6 alkyl or C_1 - C_6 alkyl substituted by one or more halogen atoms;

R_2 represents a group $R_{10}-(ALK)_m$ wherein

R_{10} represents hydrogen, or a C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, a cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by $(C_1$ - C_6)alkyl, $(C_1$ - C_6)alkoxy, hydroxy, mercapto, $(C_1$ - C_6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a $(C_1$ - C_6)alkyl group,

ALK represents a straight or branched divalent C_1 - C_6 alkylene, C_2 - C_6 alkenylene, C_2 - C_6 alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages, and

m represents 0 or 1;

A represents a group of formula (IA), (IB), (IC) or (ID) above wherein:

R_3 represents hydrogen and R_4 represents the side chain of a natural or non-natural alpha amino acid or R_3 and R_4 when taken together with the nitrogen and carbon atoms to which they are respectively attached form an optionally substituted saturated heterocyclic ring of 5 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring,

R_5 and R_6 , independently represent hydrogen, or optionally substituted C_1 - C_8 alkyl, cycloalkyl, aryl(C_1 - C_6 alkyl), non-aromatic heterocyclic, or heterocyclic(C_1 - C_6 alkyl), or R_5 and R_6 when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring, and

R_7 represents hydrogen, C_1 - C_6 alkyl, or an acyl group.

PROVIDED THAT (i) when A is a group of formula (IA) or (IB) and R_2 is C_2 - C_5 alkyl then R_4 is not the side chain of a natural alpha amino acid or the side chain of a natural alpha-amino acid in which any functional substituents are protected, any amino groups are acylated, and any carboxyl groups are esterified;

(ii) when A is a group of formula (IA) or (IB) then R_4 is not a bicyclicarylmethyl group; and

(iii) when A is a group of formula (IA) and R_2 is cyclopropylmethyl, cyclobutylmethyl or cyclopentylmethyl and one of R_5 and R_6 is hydrogen, then R_4 is not tert-butyl.

As used herein the term "(C_1 - C_6)alkyl" means a straight or branched chain alkyl moiety having from 1 to 6 carbon atoms, including for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.

As used herein the term "divalent (C_1-C_6)alkylene radical" means a saturated hydrocarbon chain having from 1 to 6 carbon atoms and two unsatisfied valencies.

As used herein the term " (C_2-C_6) alkenyl" means a straight or branched chain alkenyl moiety having from 2 to 6 carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. The term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl.

As used herein the term "divalent (C_2-C_6)alkenylene radical" means a hydrocarbon chain having from 2 to 6 carbon atoms, at least one double bond, and two unsatisfied valencies.

As used herein the term " C_2-C_6 alkynyl" refers to straight chain or branched chain hydrocarbon groups having from two to six carbon atoms and having in addition one triple bond. This term would include for example, ethynyl, 1-propynyl, 1- and 2-butenyl, 2-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl.

As used herein the term "divalent (C_2-C_6)alkynylene radical" means a hydrocarbon chain having from 2 to 6 carbon atoms, at least one triple bond, and two unsatisfied valencies.

As used herein the term "cycloalkyl" means a saturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

As used herein the term "cycloalkenyl" means an unsaturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. In the case of cycloalkenyl rings of from 5-8 carbon atoms, the ring may contain more than one double bond.

As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic group, and to groups consisting of two covalently linked monocyclic carbocyclic aromatic groups. Illustrative of such groups are phenyl, biphenyl and naphthyl.

As used herein the term "heteroaryl" refers to a 5- or 6- membered aromatic ring containing one or more heteroatoms, and optionally fused to a benzyl or pyridyl ring; and to groups consisting of two covalently linked 5- or 6- membered aromatic rings each containing one or more heteroatoms; and to groups consisting of a monocyclic carbocyclic aromatic group covalently linked to a 5- or 6- membered aromatic rings containing one or more heteroatoms;. Illustrative of such groups are thienyl, furyl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, 4-([1,2,3]-thiadiazol-4-yl)phenyl and 5-isoxazol-3-ylthienyl.

As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular means a 5-7 membered aromatic or non-aromatic heterocyclic ring containing one or more heteroatoms selected from S, N and O, and optionally fused to a benzene ring, including for example, pyrrolyl, furyl, thienyl, piperidinyl, imidazolyl, oxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, benzimidazolyl, maleimido, succinimido, phthalimido and 1,3-dioxo-1,3-dihydro-isoindol-2-yl groups.

As used herein the term "acyl" means a group $R_{20}C(O)-$ where R_{20} is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_3-C_7) cycloalkyl, phenyl, heterocyclyl, phenyl (C_1-C_6) alkyl, heterocyclyl (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl (C_1-C_6) alkyl, phenyl (C_2-C_6) alkenyl, heterocyclyl (C_2-C_6) alkenyl, (C_3-C_7) cycloalkyl (C_2-C_6) alkenyl, any of which R_{20} groups may be substituted.

As used herein, the term "bicyclicarylmethyl" means (i) a methyl group substituted by a monocyclic aryl or heteroaryl group which in turn is substituted by a monocyclic aryl or heteroaryl group, or (ii) a methyl group substituted by a monocyclic aryl or

heteroaryl group to which is fused a second monocyclic aryl or heteroaryl group; and includes both unsubstituted and substituted bicyclicarylmethyl. Examples of such bicyclicarylmethyl groups include naphthyl, indolyl, quinolyl and isoquinolyl.

Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with up to four substituents, each of which independently may be (C₁-C₈)alkyl, benzyl, (C₁-C₆)alkoxy, phenoxy, hydroxy, mercapto, (C₁-C₆)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, -COOH, -CONH₂, -COR^A, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C₁-C₈)alkyl group. In the case where "substituted" means benzyl, the phenyl ring thereof may itself be substituted with any of the foregoing, except benzyl.

As used herein the terms "side chain of a natural alpha-amino acid" and "side chain of a non-natural alpha-amino acid" mean the group R^x in respectively a natural and non-natural amino acid of formula NH₂-CH(R^x)-COOH.

Examples of side chains of natural alpha amino acids include those of alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, histidine, 5-hydroxylysine, 4-hydroxyproline, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, α-amino adipic acid, α-amino-n-butyric acid, 3,4-dihydroxyphenylalanine, homoserine, α-methylserine, ornithine, pipecolic acid, and thyroxine.

In natural alpha-amino acid side chains which contain functional substituents, for example amino, carboxyl, hydroxy, mercapto, guanidyl, imidazolyl, or indolyl groups as in arginine, lysine, glutamic acid, aspartic acid, tryptophan, histidine, serine, threonine, tyrosine, and cysteine, such functional substituents may optionally be protected.

Likewise, in the side chains of non-natural alpha amino acids which contain

functional substituents, for example amino, carboxyl, hydroxy, mercapto, guanidyl, imidazolyl, or indolyl groups, such functional substituents may optionally be protected.

The term "protected" when used in relation to a functional substituent in a side chain of a natural or non-natural alpha-amino acid means a derivative of such a substituent which is substantially non-functional. The widely used handbook by T. W. Greene and P. G. Wuts "Protective Groups in Organic Synthesis" Second Edition, Wiley, New York, 1991 reviews the subject. For example, carboxyl groups may be esterified (for example as a C₁-C₈ alkyl ester), amino groups may be converted to amides (for example as a NHCOC₁-C₈ alkyl amide) or carbamates (for example as an NHC(=O)OC₁-C₈ alkyl or NHC(=O)OCH₂Ph carbamate), hydroxyl groups may be converted to ethers (for example an OC₁-C₈ alkyl or a O(C₁-C₈ alkyl)phenyl ether) or esters (for example a OC(=O)C₁-C₈ alkyl ester) and thiol groups may be converted to thioethers (for example a tert-butyl or benzyl thioether) or thioesters (for example a SC(=O)C₁-C₈ alkyl thioester).

There are several actual or potential chiral centres in the compounds according to the invention because of the presence of asymmetric carbon atoms. The presence of several asymmetric carbon atoms gives rise to a number of diastereoisomers with R or S stereochemistry at each chiral centre. The invention includes all such diastereoisomers and mixtures thereof. Currently, the preferred stereoconfiguration of the carbon atom carrying the R₂ group is R; that of the carbon atom carrying the R₄ group (when asymmetric) is S; and that of the carbon atom carrying the R₁ group (when asymmetric) is R.

In the compounds of formula (I) as defined above for use according to the invention, and in the novel compounds of the invention of formula (II) as defined above (but subject to the provisos therein):

R₁ may be, for example, hydrogen, methyl, or trifluoromethyl. Hydrogen is currently

preferred.

R₂ may be, for example:

optionally substituted C₁-C₈ alkyl, C₃-C₈ alkenyl, C₃-C₈ alkynyl or cycloalkyl;

phenyl(C₁-C₆ alkyl)-, phenyl(C₃-C₆ alkenyl)- or phenyl(C₃-C₆ alkynyl)-
optionally substituted in the phenyl ring;

cycloalkyl(C₁-C₆ alkyl)-, cycloalkyl(C₃-C₆ alkenyl)- or cycloalkyl(C₃-C₆ alkynyl)-
optionally substituted in the cycloalkyl ring;

heterocyclyl(C₁-C₆ alkyl)-, heterocyclyl(C₃-C₆ alkenyl)- or heterocyclyl(C₃-C₆
alkynyl)- optionally substituted in the heterocyclyl ring; or

CH₃(CH₂)_pO(CH₂)_q- or CH₃(CH₂)_pS(CH₂)_q-, wherein p is 0, 1, 2 or 3 and q is 1,
2 or 3.

Specific examples of R₂ groups include

methyl, ethyl, n- and iso-propyl, n- and iso-butyl, n-pentyl, iso-pentyl 3-methyl-
but-1-yl, n-hexyl, n-heptyl, n-octyl, methylsulfanylethyl,
ethylsulfanylmethyl, 2-methoxyethyl, 2-ethoxyethyl, 2-ethoxymethyl, 3-
hydroxypropyl, allyl, 3-phenylprop-3-en-1-yl, prop-2-yn-1-yl, 3-phenylprop-2-
yn-1-yl, 3-(2-chlorophenyl)prop-2-yn-1-yl, but-2-yn-1-yl, cyclopentyl,
cyclohexyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl,
cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, furan-2-ylmethyl, furan-3-
methyl, tetrahydrofuran-2-ylmethyl, tetrahydrofuran-2-ylmethyl,
piperidinylmethyl, phenylpropyl, 4-chlorophenylpropyl, 4-methylphenylpropyl,
4-methoxyphenylpropyl, benzyl, 4-chlorobenzyl, 4-methylbenzyl, and 4-
methoxybenzyl.

Presently preferred groups at R₂ are n-propyl, n-butyl, n-pentyl, benzyl and

cyclopentylmethyl.

In the case of R_3 , hydrogen is presently preferred.

R_4 may be, for example

the characterising group of a natural α amino acid, for example benzyl, or 4-methoxyphenylmethyl, in which any functional group may be protected, any amino group may be acylated and any carboxyl group present may be amidated; or

a group $-\text{[Alk]}_n\text{R}_9$ where Alk is a $(\text{C}_1\text{-C}_6)$ alkylene or $(\text{C}_2\text{-C}_6)$ alkenylene group optionally interrupted by one or more $-\text{O}-$, or $-\text{S}-$ atoms or $-\text{N}(\text{R}_{12})-$ groups [where R_{12} is a hydrogen atom or a $(\text{C}_1\text{-C}_6)$ alkyl group], n is 0 or 1, and R_9 is hydrogen or an optionally substituted phenyl, aryl, heterocyclyl, cycloalkyl or cycloalkenyl group or (only when n is 1) R_9 may additionally be hydroxy, mercapto, $(\text{C}_1\text{-C}_6)$ alkylthio, amino, halo, trifluoromethyl, nitro, $-\text{COOH}$, $-\text{CONH}_2$, $-\text{COOR}^A$, $-\text{NHCOR}^A$, $-\text{CONHR}^A$, $-\text{NHR}^A$, $-\text{NR}^A\text{R}^B$, or $-\text{CONR}^A\text{R}^B$ wherein R^A and R^B are independently a $(\text{C}_1\text{-C}_6)$ alkyl group; or

a benzyl group substituted in the phenyl ring by a group of formula $-\text{OCH}_2\text{COR}_8$ where R_8 is hydroxyl, amino, $(\text{C}_1\text{-C}_6)$ alkoxy, phenyl $(\text{C}_1\text{-C}_6)$ alkoxy, $(\text{C}_1\text{-C}_6)$ alkylamino, di $((\text{C}_1\text{-C}_6)$ alkyl)amino, phenyl $(\text{C}_1\text{-C}_6)$ alkylamino; or

a heterocyclic $(\text{C}_1\text{-C}_6)$ alkyl group, either being unsubstituted or mono- or di-substituted in the heterocyclic ring with halo, nitro, carboxy, $(\text{C}_1\text{-C}_6)$ alkoxy, cyano, $(\text{C}_1\text{-C}_6)$ alkanoyl, trifluoromethyl $(\text{C}_1\text{-C}_6)$ alkyl, hydroxy, formyl, amino, $(\text{C}_1\text{-C}_6)$ alkylamino, di $(\text{C}_1\text{-C}_6)$ alkylamino, mercapto, $(\text{C}_1\text{-C}_6)$ alkylthio, hydroxy $(\text{C}_1\text{-C}_6)$ alkyl, mercapto $(\text{C}_1\text{-C}_6)$ alkyl or $(\text{C}_1\text{-C}_6)$ alkylphenylmethyl; or

a group $-\text{CR}_a\text{R}_b\text{R}_c$ in which:

each of R_a , R_b and R_c is independently hydrogen, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl (C_1-C_6) alkyl, (C_3-C_8) cycloalkyl; or

R_c is hydrogen and R_a and R_b are independently phenyl or heteroaryl such as pyridyl; or

R_c is hydrogen, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl (C_1-C_6) alkyl, or (C_3-C_8) cycloalkyl, and R_a and R_b together with the carbon atom to which they are attached form a 3 to 8 membered cycloalkyl or a 5- to 6-membered heterocyclic ring; or

R_a , R_b and R_c together with the carbon atom to which they are attached form a tricyclic ring (for example adamantyl); or

R_a and R_b are each independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl (C_1-C_6) alkyl, or a group as defined for R_c below other than hydrogen, or R_a and R_b together with the carbon atom to which they are attached form a cycloalkyl or heterocyclic ring, and R_c is hydrogen, -OH, -SH, halogen, -CN, -CO₂H, (C_1-C_4) perfluoroalkyl, -CH₂OH, -CO₂ (C_1-C_6) alkyl, -O (C_1-C_6) alkyl, -O (C_2-C_6) alkenyl, -S (C_1-C_6) alkyl, -SO (C_1-C_6) alkyl, -SO₂ (C_1-C_6) alkyl, -S (C_2-C_6) alkenyl, -SO (C_2-C_6) alkenyl, -SO₂ (C_2-C_6) alkenyl or a group -Q-W wherein Q represents a bond or -O-, -S-, -SO- or -SO₂- and W represents a phenyl, phenylalkyl, (C_3-C_8) cycloalkyl, (C_3-C_8) cycloalkylalkyl, (C_4-C_8) cycloalkenyl, (C_4-C_8) cycloalkenylalkyl, heteroaryl or heteroarylalkyl group, which group W may optionally be substituted by one or more substituents independently selected from, hydroxyl, halogen, -CN, -CO₂H, -CO₂ (C_1-C_6) alkyl, -CONH₂, -CONH (C_1-C_6) alkyl, -CONH (C_1-C_6) alkyl)₂, -CHO, -CH₂OH, (C_1-C_4) perfluoroalkyl, -O (C_1-C_6) alkyl, -S (C_1-C_6) alkyl, -SO (C_1-C_6) alkyl, -SO₂ (C_1-C_6) alkyl, -NO₂, -NH₂, -NH (C_1-C_6) alkyl, -N (C_1-C_6) alkyl)₂, -NHCO (C_1-C_6) alkyl, (C_1-C_6) alkyl, $(C_2-$

C_6)alkenyl, (C_2-C_6) alkynyl, (C_3-C_8) cycloalkyl, (C_4-C_8) cycloalkenyl, phenyl or benzyl.

Examples of particular R_4 groups include methyl, ethyl, benzyl, 4-chlorobenzyl, 4-hydroxybenzyl, phenyl, cyclohexyl, cyclohexylmethyl, pyridin-3-ylmethyl, tert-butoxymethyl, naphthylmethyl, iso-butyl, sec-butyl, tert-butyl, 1-benzylthio-1-methylethyl, 1-methylthio-1-methylethyl, 1-mercapto-1-methylethyl, 1-methoxy-1-methylethyl, 1-hydroxy-1-methylethyl, 1-fluoro-1-methylethyl, hydroxymethyl, 2-hydroxyethyl, 2-carboxyethyl, 2-methylcarbamoyl, 2-carbamoyl, and 4-aminobutyl. Presently preferred R_4 groups include tert-butyl, iso-butyl, benzyl and methyl.

R_3 and R_4 when taken together with the nitrogen and carbon atoms to which they are respectively attached may form an optionally substituted saturated heterocyclic ring of 5 to 8 atoms. For example, R_3 and R_4 may form a bridge between the nitrogen and carbon atoms to which they are attached, said bridge being represented by the divalent radical $-(CH_2)_{3-6}-$, or $-(CH_2)_r-O-(CH_2)_s-$, or $-(CH_2)_r-S-(CH_2)_s-$, wherein r and s are each independently 1, 2 or 3 with the proviso that $r+s = 2, 3, 4$, or 5 .

R_5 and R_6 may independently be, for example, hydrogen, methyl, ethyl, tert-butyl, cyclopentyl, cyclohexyl, 1,1,3,3-tetramethylbutyl, benzyl, or 2-hydroxyethyl; or R_5 and R_6 when taken together with the nitrogen atom to which they are attached may form a saturated 5- to 8-membered monocyclic N-heterocyclic ring which is attached via the N atom and which optionally contains $-N(R_{11})-$ wherein R_{11} is hydrogen or C_1-C_6 alkyl, benzyl, acyl, or an amino protecting group, O, S, SO or SO_2 as a ring member, and/or is optionally substituted on one or more C atoms by hydroxy, C_1-C_6 alkyl, hydroxy(C_1-C_6 alkyl)-, C_1-C_6 alkoxy, oxo, ketalised oxo, amino, mono(C_1-C_6 alkyl)amino, di(C_1-C_6 alkyl)amino, carboxy, C_1-C_6 alkoxycarbonyl, hydroxymethyl, C_1-C_6 alkoxymethyl, carbamoyl, mono(C_1-C_6 alkyl)carbamoyl, di(C_1-C_6 alkyl)carbamoyl, or hydroxyimino.

Examples of such rings are substituted or unsubstituted 1-pyrrolidinyl,

piperidin-1-yl, 1-piperazinyl, hexahydro-1-pyridazinyl, morpholin-4-yl, tetrahydro-1,4-thiazin-4-yl, tetrahydro-1,4-thiazin-4-yl 1-oxide, tetrahydro-1,4-thiazin-4-yl 1,1-dioxide, hexahydroazipino, or octahydroazocino. Substituted examples of the foregoing are 2-(methylcarbamoyl)-1-pyrrolidinyl, 2-(hydroxymethyl)-1-pyrrolidinyl, 4-hydroxypiperidino, 2-(methylcarbamoyl)piperidino, 4-hydroxyiminopiperidino, 4-methoxypiperidino, 4-methylpiperidin-1-yl, 4-benzylpiperidin-1-yl, 4-acetylpiperidin-1-yl, 4-methyl-1-piperazinyl, 4-phenyl-1-piperazinyl, 1,4-dioxo-8-azaspiro[4,5]decan-8-yl, hexahydro-3-(methylcarbamoyl)-2-pyridazinyl, and hexahydro-1-(benzyloxycarbonyl)-2-pyridazinyl, decahydroisoquinolin-2-yl, and 1,2,3,4-tetrahydroisoquinolin-2-yl.

When A is a group of formula (IA), it is currently preferred that R_5 be methyl or hydrogen, and R_6 be methyl.

R_7 may be, for example, hydrogen, or a group $R_{20}C(O)-$ where R_{20} is a (C_1-C_6) alkyl group such as methyl or ethyl.


Specific examples of compounds useful as antibacterial agents in accordance with the invention include those of the specific Examples herein. Preferred novel compounds of the invention include

2R (orS)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-ethyl)-amide and

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-3-cyclopentyl-propionic acid (1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide



and their pharmaceutically and veterinarily acceptable salts.

Compounds with which the invention is concerned the invention may be prepared by deprotecting an O-protected N-formyl-N-hydroxyamino compound of formula (II):




in which R_1 , R_2 , and A are as defined in general formula (I) and R_{25} is a hydroxy protecting group removable to leave a hydroxy group by hydrogenolysis or hydrolysis. Benzyl is a preferred R_{25} group for removal by hydrogenolysis, and tert-butyl and tetrahydropyranyl are preferred groups for removal by acid hydrolysis.


Compounds of formula (II) wherein A is a group of formula (IA), (IB), (IC) or (ID) may be prepared by causing an acid of formula (III) or an activated derivative thereof to react with an amine of formula (IVA), (IVB), (IVC) or (IVD) respectively



(IVA)



(IVB)




(IVC)



(IVD)


wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and R_7 are as defined in general formula (I) except that the -OH group in (IVB) and any substituents in R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and R_7 which are potentially reactive in the coupling reaction may themselves be protected from such reaction, and R_{25} is as defined in relation to formula (II) above, and optionally removing protecting groups from the -OH group in (IVB) and R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and R_7 .

Compounds of formula (III) may be prepared by N-formylation, for example using acetic anhydride and formic acid, or 1-formylbenzotriazole, of compounds of formula (V)




wherein R_1 , R_2 and R_{25} are as defined in relation to formula (II) and X is either a chiral auxiliary or an OR_{26} group wherein R_{26} is hydrogen or a hydroxy protecting group. In the case where X is an OR_{26} group or a chiral auxiliary the hydroxy protecting group or auxiliary is removed after the formylation step to provide the compound of formula (V). Suitable chiral auxiliaries include substituted oxazolidinones which may be removed by hydrolysis in the presence of base.

In an alternative procedure compounds of general formula (II) may be prepared by N-formylation, for example using acetic anhydride and formic acid, or 1-formylbenzotriazole, of compounds of formula (VI)




wherein R_1 , R_2 , R_{25} and A are as defined in relation to formula (II).

Compounds of formula (VI) wherein A is a group of formula (IA), (IB), (IC) or (ID) may be prepared by causing an acid of general formula (VII) or an activated derivative thereof



wherein R_1 , R_2 and R_{25} are as defined in relation to formula (II) to react with an amine of formula (IVA), (IVB), (IVC) or (IVD) respectively as defined above.

Alternatively compounds of general formula (VI) may be prepared by reduction of an oxime of general formula (VIII).




Reducing agents include certain metal hydrides (e.g. sodium cyanoborohydride in acetic acid, triethylsilane or borane / pyridine) and hydrogen in the presence of a suitable catalyst.

In an alternative procedure compounds of general formula (II) wherein R_1 and R_2 are as defined in general formula (I), R_{25} is a hydroxy protecting group as defined above and A is a group of formula (IA) wherein R_3 , R_4 , R_5 are as defined in general formula (IA) and R_6 is hydrogen may be prepared by a 4-component Ugi reaction of carboxylic acid of general formula (III) as defined above, an amine of formula (IX), an aldehyde of formula (X) and an isonitrile of formula (XI)




wherein R_3 , R_4 and R_5 are as defined above.

A compound of general formula (V) may be prepared by reduction of an oxime of general formula (XI)




wherein R_1 , R_2 , and R_{25} are as defined above, and X is either an OR_{26} group as defined above or a chiral auxiliary. Reducing agents include certain metal hydrides (eg sodium cyanoborohydride in acetic acid, triethylsilane or borane/pyridine) and hydrogen in the presence of a suitable catalyst. Following the reduction when the group X is a chiral auxiliary it may be optionally converted to a OR_{26} group.

A compound of general formula (XI) can be prepared by reaction of a β -keto carbonyl compound of general formula (XII)




wherein R_1 , R_2 , and X are as defined above, with an O-protected hydroxylamine.

β -keto carbonyl compounds (XII) may be prepared in racemic form by formylation or acylation of a carbonyl compound of general formula (XIII)




wherein R_2 and X are as defined above, with a compound of general formula (XIV)



wherein R_1 is as defined above and Z is a leaving group such as halogen or alkoxy, in the presence of a base.

Another method for the preparation of a compound of general formula (V) is by Michael addition of a hydroxylamine derivative to α,β -unsaturated carbonyl compounds of general formula (XV)



wherein R_1 , R_2 , and X are as defined above. Following the Michael addition reaction, when the group X is a chiral auxiliary it may be optionally converted to a OR_{26} group. The α,β -unsaturated carbonyl compounds (XV) may be prepared by standard methods.

Salts of the compounds of the invention include physiologically acceptable acid addition salts for example hydrochlorides, hydrobromides, sulphates, methane sulphonates, p-toluenesulphonates, phosphates, acetates, citrates, succinates, lactates, tartrates, fumarates and maleates. Salts may also be formed with bases,

for example sodium, potassium, magnesium, and calcium salts.

Compositions with which the invention is concerned may be prepared for administration by any route consistent with the pharmacokinetic properties of the active ingredient(s).

Orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

For topical application to the skin, the active ingredient(s) may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceuticals such as the British

Pharmacopoeia.

The active ingredient(s) may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. Intra-venous infusion is another route of administration for the compounds used in accordance with the invention.

Safe and effective dosages for different classes of patient and for different disease states will be determined by clinical trial as is required in the art. It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

The finding that compounds with PDF inhibitory activity can inhibit or prevent bacterial growth, opens up a novel approach for identifying new antibacterial agents by screening test compounds for activity as inhibitors of PDF *in vitro*, followed by confirmation of their antibacterial ability using bacterial growth inhibition studies. This finding also makes available (i) the use of compounds with PDF inhibitory activity as antibacterial agents, and (ii) a method for the treatment of bacterial infection or contamination by applying or administering a compound which inhibits the activity of bacterial PDF.

According to a further aspect of the invention therefore, there is provided a method for the identification of antibacterial compounds, comprising screening test compounds for their ability to inhibit PDF *in vitro*, selecting those compounds which exhibit said ability and testing these for their ability to inhibit bacterial growth. The ability to inhibit bacterial growth can be performed using classical plate or broth

culture bacterial growth inhibition studies, such as those performed in the Biological Examples herein.


A suitable *in vitro* PDF inhibition screen may comprise mixing together PDF, a PDF substrate, preferably, labelled with a detectable marker, and the test compound and assessing after a suitable length of time whether or not the presence of the test compound inhibits the ability of PDF to deformylate the substrate.

In a preferred embodiment, the cleaved substrate is detected with a fluorogenic marker such as fluorescamine. On removal of the formyl group from the N-terminal methionine of the PDF substrate, the free amino group reacts with fluorescamine generating a fluorescent product.

An alternative screen involves assessing whether a protein expressed by bacteria that express endogenous (or recombinantly expressed) PDF, when grown in the presence of a test compound, yields suitable substrate for N-terminal sequencing, or yields a lesser amount of substrate, than protein expressed from the same bacteria grown in the absence of the test compound. Such a method could be based on that used in the Biological Examples herein.

The person skilled in the art will be able to develop, without inventive input, alternative methods for screening test compounds for their ability to inhibit bacterial PDF.


The natural antibiotic actinonin (see for example J.C.S Perkin I, 1975, 819) is a hydroxamic acid derivative of Structure (A):



In addition to actinonin, various structural analogues of actinonin have also been shown to have antibacterial activity (see for example Broughton et al. (Devlin et al. Journal of the Chemical Society. Perkin Transactions 1 (9):830-841, 1975; Broughton et al. Journal of the Chemical Society. Perkin Transactions 1 (9):857-860, 1975)


To date, however, the mechanism underlying the antibacterial activity of actinonin has not been known. The present inventors have found that actinonin inhibits the activity of bacterial PDF.

The matlystatin group of compounds share a number of structural similarities with actinonin. Both are peptidic molecules with functional hydroxamic acid metal binding groups (Ogita et al., J. Antibiotics. 45(11):1723-1732; Tanzawa et al., J. Antibiotics. 45(11):1733-1737; Haruyama et al., J. Antibiotics. 47(12):1473-1480; Tamaki et al., J. Antibiotics. 47(12):1481-1492). The matlystatins and their close structural analogues are characterised by the presence in the molecule of a divalent piperazin-1, 6-diyl group, i.e.



In view of their close structural similarity to actinonin, the observation that actinonin inhibits PDF implies that matlystatin compounds may also inhibit PDF.


According to a further aspect of the present invention there is provided the use of a compound which inhibits the activity of bacterial PDF, in the preparation of an antibacterial composition or agent, provided that (i) the compound is not of formula (XI)



wherein,

- (a) R is a cyclic amino group, W is hydrogen, methyl, isopropyl, isobutyl or benzyl, and Y is hydrogen, C₁-C₆ alkyl, phenyl, benzyl, 4-chlorophenylmethyl, 4-nitrophenylmethyl, or 4-aminophenylmethyl; or,
- (b) R is 2-pyridylamino or 2-thiazolylamino, W is isopropyl and Y is n-pentyl; or,
- (c) R is diethylamino, W is methyl or isopropyl and Y is n-pentyl;

or (ii) the compound is not one containing a divalent piperazin-1, 6-diyl group, i.e. a group of formula (XII):



According to a further aspect of the invention there is provided a method of treating bacterial infection or contamination by administering to a patient suffering such infection or contamination, or applying to the site of such infection or contamination, an antibacterially effective amount of a compound which inhibits the activity of bacterial PDF enzyme, provided that the compound is not one provided in the provisos in the immediately preceding paragraph.

These provisos exclude actinonin and its antibacterially active analogues as disclosed in Devlin et al., Journal of the Chemical Society. Perkin Transactions 1 (9):830-841, 1975 and Broughton et al. Journal of the Chemical Society. Perkin Transactions 1 (9):857-860, 1975, and the matlystatin compounds disclosed in Ogita et al., J. Antibiotics. 45(11):1723-1732; Tanzawa et al., J. Antibiotics. 45(11):1733-1737; Haruyama et al., J. Antibiotics. 47(12):1473-1480 and Tamaki et al., J. Antibiotics. 47(12):1481-1492.

The following examples illustrate embodiments of the invention.

L-*tert*-Leucine-N-methylamide and L-*tert*-leucine-N,N-dimethylamide and other amino acid derivatives were prepared according to established literature methods.


The following abbreviations have been used throughout:

DMF	N,N-Dimethylformamide
EDC	N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride
HOAt	1-Hydroxy-7-aza-benzotriazole
HOBt	1-Hydroxybenzotriazole
HPLC	High performance liquid chromatography
LRMS	Low resolution mass spectrometry
TLC	Thin layer chromatography

¹H and ¹³C NMR spectra were recorded using a Bruker AC 250E spectrometer at 250.1 and 62.9 MHz, respectively. Mass spectra were obtained using a Perkin Elmer Sciex API 165 spectrometer using both positive and negative ion modes. Infra-red spectra were recorded on a Perkin Elmer PE 1600 FTIR spectrometer.


Example 1

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid-(2,2-dimethyl-1S-methyl-carbamoyl-propyl)-amide



The title compound was prepared according to the route outlined in Scheme 1 and as described in detail below:

29
Scheme 1



Reagents and conditions: A. piperidine, HCHO, EtOH, 80°C, o/n; B. H₂NOBzl, 80°C, o/n; C. HCOOH, Ac₂O; D. Pentaffluorophenol, EDC, CH₂Cl₂; E. H-tert-LeuNHMe, DMF, 35°C; F. H₂, 10% Pd/C, EtOAc/EtOH.

STEP A: 2-Butyl-acrylic acid

Butylmalonic acid (25g, 156 mmol) was dissolved in ethanol (250 ml) and 37% formaldehyde solution (15.45 ml, 156 mmol) was added followed by piperidine (47 ml, 624 mmol). The mixture was stirred overnight at 80°C under a reflux condenser. The solvents were removed under reduced pressure and the residue was diluted with 1M hydrochloric acid and extracted with dichloromethane (3x30 ml). The combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, filtered and evaporated to afford the desired product as a yellow oil (25 g, with residual solvent). ¹H-NMR: δ (CDCl₃), 10.04 (1H, br s), 6.22 (1H, s), 5.57 (1H, d, J = 1.3 Hz), 2.30 (2H, t, J = 6.9 Hz), 1.38 (4H, m), and 0.91 (3H, t, J = 7.2 Hz).

STEP B: 2RS-(Benzyloxy-amino-methyl)-hexanoic acid

A mixture of 2-butyl-acrylic acid (3.43 g, 27.1 mmol) and O-benzylhydroxylamine (5 g, 40.65 mmol) were heated at 80°C overnight. The mixture was cooled to room temperature, diluted with ethyl acetate (40 ml), and washed with 1M hydrochloric acid (3x20 ml), saturated sodium hydrogen carbonate solution (2x20 ml) and brine (2x20 ml), dried over anhydrous magnesium sulfate, filtered and evaporated to leave the title compound as a white solid (2.62 g, 39%). ¹H-NMR: δ (CDCl₃), 8.05 (1H, br s), 7.35 (5H, m), 5.00 (2H, m), 3.28 (2H, m), 2.98 (1H, m), 1.31 (6H, m) and 0.88 (3H, t, J = 5.0 Hz).

Step C: 2RS-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid

2RS-(Benzyloxyamino-methyl)-hexanoic acid (2.62 g, 10.51 mmol) was dissolved in formic acid (4 ml, 105 mmol) and acetic anhydride (1.9 ml, 21.02 mmol) and stirred overnight at room temperature. The solution was diluted with ethyl acetate (40 ml), washed with water (2x20 ml), saturated sodium hydrogen carbonate solution (20 ml) and brine (20 ml), dried over anhydrous magnesium sulfate, filtered and evaporate

to leave the desired product as a yellow oil (2.9 g, 99%). $^1\text{H-NMR}$: δ (CDCl_3 , rotamers), 8.21 (0.5H, s), 8.14 (0.5H, s), 7.37 (5H, m), 4.98 (2H, m), 3.86 (1H, m), 3.27 (0.5H, dd, $J = 6.0, 14.0$ Hz), 2.93 (0.5H, m), 2.77 (1H, m), 1.50 (2H, m), 1.30 (4H, m) and 0.88 (3H, m).

STEP D: 2RS-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid pentafluorophenyl ester

2RS-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid (30.72 g, 110 mmol) and penta-fluorophenol (26.31 g, 143 mmol) were dissolved in dichloromethane (150 ml) and the solution was stirred and cooled in an ice bath during addition of EDC (25.3 g, 131 mmol). The reaction mixture was allowed to warm to room temperature and stirred overnight. The solution was washed successively with 1M hydrochloric acid (2x50 ml), 0.5M sodium carbonate (2x50 ml) and brine (50 ml), dried over anhydrous magnesium sulfate and filtered. The filtrate was evaporated under reduced pressure and the residue was purified by flash chromatography (silica gel, dichloromethane) to afford the title compound as a colourless oil (15.0 g, 31%). $^1\text{H-NMR}$: δ (CDCl_3 , rotamers), 8.17 (1H, br s), 7.37 (5H, m), 4.95 - 4.70 (2H, br m), 4.10 - 3.75 (2H, br m), 3.10 (1H, br s), 1.88 - 1.55 (2H, m), 1.39 (4H, m) and 0.92 (3H, t, $J = 7.0$ Hz).

STEP E: 2R (or S)-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid-(2,2-dimethyl-1-methyl-carbamoyl-propyl)-amide

2RS-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid pentafluorophenyl ester (5 g, 11 mmol) and *tert*-leucine N-methylamide (1.62 g, 11 mmol) were dissolved in DMF (60 ml) and the mixture was stirred overnight at 35 °C. The solvent was removed under reduced pressure and the residue was redissolved in dichloromethane. The solution was washed successively with 0.5 M sodium carbonate, 1.0 M hydrochloric acid and brine, dried over anhydrous magnesium sulfate and filtered. The two diastereoisomeric products were separated by flash chromatography (silica gel, gradient elution with 30% to 0% hexane in ethyl acetate). Diastereoisomer A (higher

R_f): $^1\text{H-NMR}$: δ (CDCl_3 , rotamers), 8.12, 7.87 (1H, 2br s), 7.27 (5H, m), 6.26 (1H, d, $J = 8.7$ Hz), 5.78 (1H, br s), 4.91 - 4.60 (2H, br m), 4.15 (1H, d, $J = 9.2$ Hz), 3.75 (2H, br m), 2.79 (3H, d, $J = 4.8$ Hz), 2.56 (1H, m), 1.60 - 1.35 (2H, br m), 1.24 (4H, m), 0.96 (9H, s) and 0.86 (3H, t, $J = 6.7$ Hz). Diastereoisomer B (lower R_f): $^1\text{H-NMR}$: δ (CDCl_3 , rotamers), 8.16, 7.88 (1H, 2br s), 7.27 (5H, m), 6.28 (1H, d, $J = 8.9$ Hz), 5.70 - 5.44 (1H, br s), 4.98 - 4.61 (2H, br m), 4.14 (1H, d, $J = 9.2$ Hz), 3.78 - 3.62 (2H, br m), 2.85 - 2.60 (3H, br m), 2.47 (1H, m), 1.72 - 1.25 (6H, br m), 0.98 (9H, s) and 0.88 (3H, t, $J = 6.7$ Hz).

STEP F: 2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid-(2,2-dimethyl-1S-methylcarbamoyl-propyl)-amide


2-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid-(2,2-dimethyl-1-methylcarbamoyl-propyl)-amide (diastereoisomer A) (1.0 g, 2.5 mmol) was dissolved in a mixture of ethyl acetate (20 ml) and ethanol (1 ml) and the solution was placed under an argon atmosphere. 10% palladium on charcoal was added and a fine stream of hydrogen gas was bubbled through the suspension. After 40 minutes TLC analysis revealed that all the starting material had been consumed leaving a more polar, ferric chloride positive species. The system was flushed with argon before removing the catalyst by filtration. The filtrate was evaporated to dryness to leave the title compound as an off-white foam (810 mg, including residual solvent). $^1\text{H-NMR}$: δ ($(\text{CD}_3)_2\text{SO}$, rotamers), 9.81, 9.41 (1H, 2br s), 7.82 - 7.60 (3H, m), 4.04 (1H, d, $J = 9.3$ Hz), 3.50 - 3.02 (2H, m), 2.87 - 2.60 (1H, m), 2.41 (3H, d, $J = 4.5$ Hz), 1.39 - 0.93 (6H, m), 0.75 (9H, s) and 0.67 (3H, t, $J = 5.7$ Hz). $^{13}\text{C-NMR}$: δ ($(\text{CD}_3)_2\text{SO}$), 172.5, 170.2, 157.5, 59.9, 42.8, 33.3, 29.0, 28.4, 28.2, 26.4, 24.8, 21.7 and 13.3. IR (KBr disc), ν_{max} 3309, 2959, 2873, 1646 and 1540 cm^{-1} .

2-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid-(2,2-dimethyl-1-methylcarbamoyl-propyl)-amide (diastereoisomer B) (1.0 g, 2.5 mmol) was similarly deprotected to give diastereoisomer B of the title compound (740 mg, 97%). $^1\text{H-NMR}$: δ ($(\text{CD}_3)_2\text{SO}$, rotamers), 9.75, 9.30 (1H, 2br s), 7.81 - 7.42 (3H, m), 4.04 (1H,

d, $J = 9.5$ Hz), 3.53 - 3.02 (2H, m), 2.80 - 2.55 (1H, m), 2.41 (3H, d, $J = 4.5$ Hz), 1.33 - 0.82 (6H, m), 0.72 (9H, s) and 0.67 (3H, t, $J = 6.7$ Hz). $^{13}\text{C-NMR}$: δ ($(\text{CD}_3)_2\text{SO}$), 172.6, 170.4, 161.7, 157.0, 59.8, 34.0, 29.4, 28.6, 26.7, 25.2, 22.1 and 14.1. IR (KBr disc), ν_{max} 3312, 2959, 1640, 1541, 1369 and 1240 cm^{-1} .

Example 2

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid-(2,2-dimethyl-1S-*tert*-butyl-carbamoyl-propyl)-amide




The title compounds were prepared by analogy with Example 1, using the L-*tert*-leucine-N-*tert*-butylamide in place of L-*tert*-leucine-N-methylamide in Step E. The diastereoisomers were not separable by flash chromatography (silica gel, ethyl acetate) at Step E and were converted to a mixture of the desired N-formyl hydroxylamine derivatives by hydrogenolysis. White solid. $^{13}\text{C-NMR}$: δ ($(\text{CD}_3)_2\text{SO}$), 172.8, 172.5, 170.1, 169.6, 161.6, 156.9, 59.9, 59.7, 51.9, 51.7, 50.2, 49.6, 48.3, 43.2, 43.1, 42.7, 34.2, 34.0, 29.6, 29.3, 29.2, 28.8, 28.6, 26.7, 22.2, 22.1, 20.3 and 13.9. IR (KBr), ν_{max} 3311, 2964, 1639, 1548, 1456, 1394, 1364 and 1226 cm^{-1} .

Example 3

2R (orS)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-methyl-2-morpholin-4-yl-2-oxo-ethyl)-amide

34




A solution of 2RS-[(benzyloxy-formyl-amino)-methyl]-hexanoic acid pentafluorophenyl ester (Example 1, Step D) (445 mg, 1 mmol) in DMF (5 ml) was added to L-alanine-N-morpholinoamide (158 mg, 1 mmol) in a boiling tube and stirred at 35 °C overnight. DMF was removed *in vacuo* and the residue was redissolved in dichloromethane (2 ml) and passed through a purification cartridge (Isolute-NH₂), eluting with dichloromethane (4 ml) in order to remove pentafluorophenol. Dichloromethane was removed under reduced pressure and the residue was redissolved in formic acid (2 ml) and ethyl acetate (2 ml). The solution was then treated with 10% palladium on charcoal (200 mg) and stirred at room temperature for 2 hours. Catalyst was removed by filtration through celite, washing well with methanol and solvents were removed *in vacuo*. Compounds were purified by reverse phase HPLC (gradient elution, 10-90% acetonitrile/water). Diastereoisomer A: ¹H-NMR; δ (CD₃OD), 8.03 (0.5H, s), 7.84 (0.5H, s), 4.75 (1H, m), 3.65 (8H, m), 3.39 (1H, m), 3.24 (1H, dd, J=4.0, 13.2 Hz), 2.84 (1H, m), 1.57 (2H, m), 1.34 (7H, m), and 0.92 (3H, m). LRMS: -ve ion 328 [M-H]. Diastereoisomer B: ¹H-NMR; δ (CD₃OD), 3.66 (8H, m), 3.41 (1H, dd, J=9.98, 13.1Hz), 3.23 (1H, m), 2.90 (0.5H, m), 2.71 (0.5H, m), 1.62 (2H, m), 1.33 (7H, m), and 0.92 (3H, t, J=6.7Hz). LRMS: -ve ion 328 [M-H].

The compounds of Examples 4 to 12 were prepared by analogy with Example 3 using the appropriate amine component in place of L-alanine-N-morpholinoamide. Where both diastereoisomers were prepared, diastereoisomer A is the faster eluting and more potent against PDF *in vitro*. In some cases only the faster running diastereoisomer was taken through to the final product.

Example 4

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-ethyl)-amide




Diastereoisomer A: $^1\text{H-NMR}$; δ (CD_3OD), 4.72 (1H, m), 3.53 (1H, dd, $J=8.9, 13.0$ Hz), 3.23 (1H, m), 3.14 (3H, s), 2.95 (3H, s), 2.83 (0.5H, m), 2.74 (0.5H, m), 1.57 (2H, m), 1.33 (7H, m) and 0.92 (3H, m). LRMS; +ve ion 288 $[\text{M}+\text{H}]$, -ve ion 286 $[\text{M}-\text{H}]$.

Diastereoisomer B: $^1\text{H-NMR}$; δ (CD_3OD), 4.74 (1H, m), 3.41 (1H, dd, $J=9.9, 13.0$ Hz), 3.25 (1H, dd, $J=4.0, 13.1$ Hz), 3.15 (3H, s), 2.97 (3H, s), 2.89 (0.5H, m), 2.72 (0.5H, m), 1.53 (2H, m), 1.33 (7H, m) and 0.93 (3H, t, $J=6.7$ Hz). LRMS: +ve ion 310 $[\text{M}+\text{Na}]$, -ve ion 286 $[\text{M}-\text{H}]$.

Example 5

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-hydroxymethyl-3-methyl-butyl)-amide

36




Diastereoisomer A: $^1\text{H-NMR}$; δ (CD_3OD), 4.07 (1H, m), 3.55 (1H, m), 3.45 (2H, m), 3.20 (1H, m), 2.85 (0.5H, m), 2.80 (0.5H, m), 1.60 (3H, m), 1.35 (6H, m) and 0.93 (9H, m). LRMS: +ve ion 289 [M+H], -ve ion 287 [M-H].

Diastereoisomer B: $^1\text{H-NMR}$; δ (CD_3OD), 4.07 (1H, m), 3.59 (1H, m), 3.45 (2H, m), 3.24 (1H, m), 2.70 (1H, m), 1.62 (3H, m), 1.35 (6H, m) and 0.93 (9H, m). LRMS: +ve ion 311 [M+Na], 289 [M+H], -ve ion 287 [M-H].

Example 6

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-hydroxymethyl-2-phenyl-ethyl)-amide




Diastereoisomer A: $^1\text{H-NMR}$; δ (CD_3OD), 7.24 (5H, m), 4.15 (1H, m), 3.54 (2H, d, $J=5.4\text{Hz}$), 3.38 (1H, dd, $J=7.8, 13.1\text{ Hz}$), 3.14 (1H, dd, $J=4.7, 13.2\text{ Hz}$), 2.95 (1H, dd, $J=7.3, 13.7\text{ Hz}$), 2.68 (2H, m), 1.58 (2H, m), 1.32 (4H, m), and 0.91 (3H, t, $J=6.7\text{ Hz}$). LRMS: +ve ion 345 [M+Na], 323 [M+H], -ve ion 321 [M-H].

Diastereoisomer B: LRMS: +ve ion 345 [M+Na], 323 [M+H], -ve ion 321 [M-H].

Example 7

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2,2-dimethyl-1S-pyridin-2-yl-carbamoyl]-propyl]-amide




Diastereoisomer A: colourless oil. $^1\text{H-NMR}$; δ (CD_3OD), 8.34 (1H, m), 8.06 (1H, m), 7.90 (1H, m), 7.33 (1H, m), 4.45 (1H, s), 3.55 (1H, dd, $J=8.3, 13.2$ Hz), 3.25 (1H, m), 3.05 (1H, m), 1.61 (2H, m), 1.32 (4H, m), 1.11 (9H, s) and 0.85 (3H, m). LRMS: +ve ion 379 $[\text{M}+\text{H}]$, -ve ion 377 $[\text{M}-\text{H}]$.

Diastereoisomer B: colourless oil. $^1\text{H-NMR}$; δ (CD_3OD), 8.33 (1H, m), 8.20 (0.5H, m), 7.93 (1H, m), 7.41 (0.5H, m), 7.28 (1H, m), 4.48 (1H, s), 3.52 (1H, dd, $J=8.8, 13.1$ Hz), 3.23 (1H, dd, $J=3.9, 13.1$ Hz), 3.05 (0.5H, m), 2.87 (0.5H, m), 1.62 (2H, m), 1.36 (4H, m), 1.11 (9H, s) and 0.93 (3H, m). LRMS: +ve ion 393 $[\text{M}+\text{Na}]$, 379 $[\text{M}+\text{H}]$, -ve ion 377 $[\text{M}-\text{H}]$.

Example 8

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2-methyl-propyl) amide


38



Diastereoisomer A: colourless oil. LRMS: +ve ion 338 [M+Na], -ve ion 319 [M-H].

Example 9

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2-phenyl-ethyl) amide




Diastereoisomer A: colourless oil. LRMS: +ve ion 386 [M+Na], -ve ion 362 [M-H]

Diastereoisomer B: colourless oil. LRMS: +ve ion 386 [M+Na], -ve ion 362 [M-H]

Example 10

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-3-methyl-butyl) amide


39



Diastereoisomer A: colourless oil. LRMS: +ve ion 352 [M+Na], -ve ion 328 [M-H].

Example 11

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [3-methyl-1S-pyrrolidine-1-carbonyl]-butyl] amide




Diastereoisomer A: colourless oil. LRMS: -ve ion 354 [M-H].

Example 12

1-{2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoyl}-pyrrolidine-2S-carboxylic acid dimethylamide

40




Diastereoisomer A: colourless oil. LRMS: +ve ion 336 [M+Na], -ve ion 312 [M-H].

Diastereoisomer B: colourless oil. LRMS: +ve ion 336 [M+Na], -ve ion 312 [M-H].

Example 13


2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid-(1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide



Method I

A synthetic route to the title compound is outlined in Scheme 2 and is described in detail below.

41
Scheme 2



Step A: 2RS-Formyl-heptanoic acid ethyl ester

Sodium metal (4.38 g, 0.191 mmol) was cut into small pieces and placed in a two-neck oven-dried round bottom flask under a blanket of argon. Anhydrous diethyl ether (100 ml) was added and the suspension was stirred and cooled to 0°C. The flask was fitted with a reflux condenser before dropwise addition of ethanol (1.03 ml, 17.3 mmol). A mixture of ethyl formate (15.41 g, 0.208 mmol) and ethyl caproate (25 g, 0.173 mmol) was added dropwise via a dropping funnel over a period of about 20 minutes. The resulting orange suspension (sodium metal still visible) was allowed to warm to room temperature and stirred overnight. The resulting thick orange suspension (no sodium metal visible) was cooled to 0 °C and diluted with ice-cold water (100 ml). The mixture was transferred to a separating funnel and the aqueous phase was removed, washed with diethyl ether, cooled to 0 °C and acidified with 1 M hydrochloric acid (200 ml). The emulsion was extracted with ethyl acetate and the organic layer was separated, washed with brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give a yellow oil containing primarily the title compound (11.09 g), which was used without further purification in Step B.

Step B: 2RS-(Benzyloxyimino-methyl)-heptanoic acid ethyl ester

The crude Claisen product from Step A (11.0 g, 63.9 mmol) was dissolved in ethanol (100 ml) and water (10 ml) and cooled to 0 °C during the addition of sodium acetate (6.2 g, 76.6 mmol) and O-benzyl hydroxylamine hydrochloride (12.23 g, 76.6 mmol). The mixture was allowed to warm to room temperature and stirred overnight. The resulting suspension was filtered and the filtrate was concentrated under reduced pressure. The residual yellow paste was partitioned between ethyl acetate and water. The organic layer was washed with 1 M hydrochloric acid and brine, dried over anhydrous magnesium sulfate, filtered and evaporated to a yellow oil. The desired product was obtained by flash chromatography (silica gel, gradient elution with 10% to 25% ethyl acetate in hexane. Yield 9.19 g (52%). ¹H-NMR: δ (CDCl₃,

mixture of *syn*- and *anti*-isomers), 7.46 (0.6H, d, $J = 8.0$ Hz), 7.38-7.28 (5H, m), 6.79 (0.4H, d, $J = 7.1$ Hz), 5.11 (0.8H, s), 5.08 (1.2H, s), 4.16 (1.2H, q, $J = 7.0$ Hz), 4.13 (0.6H, q, $J = 7.0$ Hz), 3.91 (0.4H, q, $J = 7.2$ Hz), 3.21 (0.6H, td, $J = 8.0$ and 6.1 Hz), 1.90-1.48 (2H, m), 1.37-1.20 (7H, m), 0.87 (3H, t, $J = 7.0$ Hz).

Step C: 2RS-(Benzyloxyimino-methyl)-heptanoic acid

2RS-(Benzyloxyimino-methyl)-heptanoic acid ethyl ester (7.0 g, 25.24 mmol) was dissolved in methanol (125 ml) and the solution was cooled to 0 °C. 1 M Sodium hydroxide (26 ml, 26 mmol) was added in portions over 2 minutes to give a pale yellow emulsion. Additional methanol was added until a clear solution was obtained. The solution was allowed to stir for 90 minutes at 0°C then for 5 hours at room temperature whereupon TLC analysis suggested that all of the starting material had been consumed. The solvent was removed under reduced pressure and the residue was partitioned between water and ethyl acetate. The aqueous layer was cooled to 0 °C and acidified with 1 M hydrochloric acid. The emulsion thus formed was extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to provide the title compound as a yellow oil (5.15 g, 82%) which was used without further purification in Step D. ¹H-NMR: δ (CDCl₃, mixture of *syn*- and *anti*- isomers), 8.00 (1H, br s), 7.46 (0.6H, d, $J = 7.9$ Hz), 7.36-7.24 (5H, m), 6.80 (0.4H, d, $J = 7.0$ Hz), 5.13 (0.8H, s), 5.09 (1.2H, s), 3.94 (0.4H, q, $J = 7.1$ Hz), 3.27 (0.6H, td, $J = 6.4$ and 8.0 Hz), 1.94-1.58 (2H, m), 1.48-1.24 (4H, m) and 0.94-0.84 (3H, m).

Step D: 2RS-(Benzyloxyimino-methyl)-heptanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl) amide

2-(Benzyloxyimino-methyl)-heptanoic acid (5.16 g, 20.7 mmol), *tert*-leucine N,N-dimethylamide (3.60g, 22.77mmol) and EDC (4.76g, 24.84 mmol) were stirred together in DMF (75 ml) and cooled to 0 °C. HOAt (250 mg, cat.) was added and

the bright yellow mixture was allowed to warm to room temperature and stirred overnight. The solvent was removed under reduced pressure and the residual oil was partitioned between ethyl acetate and 1M hydrochloric acid. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated to dryness under reduced pressure. The title compound was obtained as a colourless oil by flash chromatography (silica gel, gradient elution with 33% to 66% ethyl acetate in hexane). Yield 6.84 g (85%). $^1\text{H-NMR}$: δ (CDCl_3 , mixture of *syn*- and *anti*- isomers), 7.45 (0.6H, 2d), 7.40-7.26 (5H, m), 6.72 (0.4H, 2d), 6.58 (1H, m), 5.20-4.69 (3H, m), 3.82 (0.4H, m), 3.16-3.10 (3H, m), 3.05 (0.6H, m), 2.99-2.92 (3H, m), 1.90-1.54 (2H, m), 1.39-1.17 (4H, m), 0.97 (2.7H, s), 0.96 (1.8H, s), 0.94 (2.7H, s), 0.92 (1.8H, s) and 0.92-0.82 (3H, m).

Step E: 2R (or S)-(Benzyloxyamino-methyl)-heptanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl) amide

To a solution of 2RS-(benzyloxyimino-methyl)-heptanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl) amide (5.0g, 12.84 mmol) in acetic acid (40 ml) was added sodium cyanoborohydride (2.02 g, 32.0 mmol) in one portion. Over the course of 1 hour the reagent dissolved slowly with mild effervescence to give a colourless solution, which was left to stir overnight. The solvent was removed by evaporation under reduced pressure and azeotroping with toluene. The remaining oil was partitioned between diethyl ether and 1 M sodium carbonate (CAUTION: some gas evolved). The organic layer was washed with brine (70 ml), washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated to dryness under reduced pressure. The two diastereoisomers of title compound were purified and separated by flash chromatography (silica gel, gradient elution with 50% to 100% ethyl acetate in hexane).

Diastereoisomer A (faster eluting): colourless oil (2.27 g, 45%). $^1\text{H-NMR}$: δ (CDCl_3), 7.43-7.28 (5H, m), 6.76 (1H, br d, $J = 9.4$ Hz), 5.69 (1H, br s), 4.93 (1H, d, $J = 9.4$ Hz), 4.72 (2H, s), 3.15 (3H, s), 3.18-3.00 (2H, m), 2.96 (3H, s), 2.49 (1H, m), 1.66-1.49 (2H, m), 1.46-1.19 (4H, m), 0.99 (9H, s) and 0.86 (3H, t, $J = 6.8$ Hz).

Diastereoisomer B (slower eluting): colourless oil (1.44 g, 46%). ¹H-NMR: δ (CDCl₃), 7.40-7.27 (5H, m), 6.70 (1H, br d, J = 9.0 Hz), 5.99 (1H, br s), 4.85 (1H, d, J = 9.0 Hz), 4.71 (2H, d, J = 1.6 Hz), 3.16 (3H, s), 3.06-2.97 (2H, m), 2.95 (3H, s), 2.57 (1H, m), 1.74-1.21 (6H, m), 1.00 (9H, s) and 0.88 (3H, br t, J = 6.7 Hz).

Step F: 2R (or S)-[(Benzyloxy-formyl-amino)-methyl]-heptanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl) amide

2-(Benzyloxyamino-methyl)-heptanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl) amide (diastereoisomer A) (2.02 g, 5.13mmol) was dissolved in anhydrous THF (50 ml) and placed under a blanket of argon. N-formyl-benzotriazole (A.R. Katritzky *et al.*, *Synthesis* 1995, 503) (0.83 g, 5.65 mmol) was added and the mixture was allowed to stir at room temperature for 4 hours. The solvent was evaporated under reduced pressure and the residual oil was partitioned between dichloromethane and 1 M sodium hydroxide. The organic layer was washed with more sodium hydroxide and brine, dried over anhydrous magnesium sulfate, filtered and concentrated to dryness under reduced pressure. The title compound was obtained as a white crystalline solid by flash chromatography (silica gel, elution with 33% ethyl acetate in hexane). Yield 1.60 g (74%). ¹H-NMR: δ (CDCl₃, rotamers), 8.00 (1H, br m), 7.47-7.29 (5H, m), 6.25 (1H, br d, J = 9.3 Hz), 5.08-4.74 (2H, br m), 4.87 (1H, d, J = 9.4 Hz), 3.89-3.52 (2H, br m), 3.13 (3H, s), 2.94 (3H, s), 2.54 (1H, m), 1.67-1.11 (6H, m), 0.95 (9H, s) and 0.85 (3H, br t, J = 6.9 Hz).

2-(Benzyloxyamino-methyl)-heptanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl) amide (diastereoisomer B) was similarly prepared from the the slower eluting diastereoisomer in Step E. Yield 0.38 g (41%). ¹H-NMR: δ (CDCl₃, rotamers), 8.00 (1H, br m), 7.47-7.28 (5H, br m), 6.29 (1H, br d, J = 9.3 Hz), 5.01-4.63 (2H, br m), 4.88 (1H, d, J = 9.3 Hz), 3.82-3.51 (1.5H, br m), 3.20-2.78 (6.5H, br m), 2.50 (1H, br m), 1.76-1.17 (6H, br m), 0.97 (9H, s) and 0.85 (3H, br t, J = 6.7 Hz).

Step G: 2R (or S)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid-(1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide


2-[(Benzyloxy-formyl-amino)-methyl]-heptanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl) amide (diastereoisomer A) (1.43 g, 3.41 mmol) was dissolved in methanol (50 ml) and placed under a blanket of argon. A suspension of 10% palladium on charcoal (100 mg, cat.) in ethyl acetate (2 ml) was added and the mixture was stirred vigorously while hydrogen gas was bubbled through the solution. After 10 minutes the mixture was placed under an atmosphere of hydrogen and left to stir for 3 hours, whereupon TLC analysis indicated that all of the starting material had been consumed. The system was purged with argon and the catalyst was removed by filtration. The filtrate was concentrated under reduced pressure to provide the title compound as a colourless hygroscopic foam (1.11 g, 99%). ¹H-NMR: δ (CDCl₃, rotamers), 8.41 (0.35H, s), 7.83 (0.65H, br s), 6.80 (0.35H, br d, J = 8.9 Hz), 6.62 (0.65H, br d, J = 9.4 Hz), 4.91 (0.65H, br d, J = 9.4 Hz), 4.88 (0.35H, br d, J = 8.9 Hz), 4.04 (1H, dd, J = 14.7 and 7.4 Hz), 3.82 (0.65, dd, J = 14.0 and 9.7 Hz), 3.56 (0.35H, dd, J = 14.7 and 3.3 Hz), 3.48 (0.65H, dd, J = 14.0 and 4.0 Hz), 3.16 (1.05H, s), 3.15 (1.95H, s), 2.98 (1.05H, s), 2.96 (1.95H, s), 2.90-2.74 (0.65H, br m), 2.74-2.61 (0.35H, br m) 1.73-1.17 (6H, br m), 0.99 (3.15H, s), 0.95 (5.85H, s) and 0.87 (3H, br t, J = 6.7 Hz). ¹³C-NMR; δ (CDCl₃), 174.6, 171.2, 162.2, 157.2, 60.1, 54.5, 54.3, 52.3, 48.4, 44.8, 44.3, 35.6, 35.4, 29.6, 29.0, 26.3, 20.8, 20.2, 14.0 and 13.7. LRMS: +ve ion 352 (M+Na), -ve ion 328 (M-H).

2-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid-(1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide (diastereoisomer B) was similarly prepared from diastereoisomer B in Step E ¹H-NMR; δ (CDCl₃, rotamers), 9.37 (0.5H, s), 8.40 (0.5H, s), 7.75 (0.5H, br s), 6.62 (0.5H, br s), 6.41 (0.5H, br d, J=7.1 Hz), 4.87 (0.5H, br d, J=6.6 Hz), 4.66 (0.5H, br d, J=7.6 Hz), 3.84-3.39 (2H, m), 3.21 (1.5H, br s), 3.14 (1.5H, br s), 2.98 (3H, br s), 2.91-2.54 (1H, m), 1.79-1.23 (6H, m) and 1.08-0.83 (12H, m). ¹³C-NMR; δ (CDCl₃, rotamers), 174.9, 173.3, 56.3, 54.8, 51.6, 50.3, 45.5, 45.1, 38.6, 38.4, 36.2, 36.0, 35.3, 34.4, 29.5, 29.4, 29.3, 29.2, 26.6, 26.5, 22.6, 22.5 and 13.9. LRMS: +ve ion 352 [M+Na], -ve ion 328 [M-H].

Method II

An alternative asymmetric synthetic route to the compound of Example 13 is outlined in Scheme 3 and is described in detail below.

Scheme 3



Reagents and conditions: A. piperidine, HCHO, EtOH, 80°C, o/n; B. EtCOCl , Et₃N then 3-ethoxy-4-benzyl-5,6-dimethyl-oxazolidin-2-one; C. HNOBzl, room temp., o/n then pTsOH, EtOAc; D. LiOH, aq THF, 0°C; E. H-TianMg, HOBT, EDC, DMF; F. HCOBt, THF; G. H₂, Pd/C, EtOH.

Step A: 2-Butyl acrylic acid

To a solution of n-butylmalonic acid (17.2 g, 107 mmol) in ethanol (200 ml) was added piperidine (12.76 ml, 129 mmol) and 37% aq. formaldehyde (40.3 ml, 538 mmol). The solution was heated to 80 °C during which time a precipitate appeared and then gradually redissolved over 1 hour. The reaction mixture was stirred at 80 °C overnight then cooled to room temperature. The solvents were removed under reduced pressure and the residue was dissolved in ethyl acetate (200 ml), washed successively with 1 M hydrochloric acid and brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated to give the title compound as a clear oil (13.37 g, 97%). ¹H-NMR; δ (CDCl₃), 6.29 (1H, s), 5.65 (1H, s), 2.34-2.28 (2H, m), 1.54-1.26 (4H, m) and 0.94 (3H, t, J=7.1 Hz).

Step B: 4S-Benzyl-3-(2-butyl-acryloyl)-5,5-dimethyl-oxazolidin-2-one

2-Butyl acrylic acid (21.5 g, 168 mmol) was dissolved in dry THF (500 ml) and cooled to -78 °C under a blanket of argon. Triethylamine (30 ml, 218 mmol) and pivaloyl chloride (21ml, 168mmol) were added at such a rate that the temperature remained below -60 °C. The mixture was stirred at -78 °C for 30 minutes, warmed to room temperature for 2 hours and finally cooled back to -78 °C.

In a separate flask, 4S-benzyl-5,5-dimethyl-oxazolidin-2-one was dissolved in dry THF (500ml) and cooled to -78 °C under a blanket of argon. n-Butyllithium (2.4 M solution in hexanes, 83 ml, 200 mmol) was added slowly and the mixture was stirred for 30 minutes at room temperature. The resulting anion was transferred *via* a cannula into the original reaction vessel. The mixture was allowed to warm to room temperature and was stirred overnight at room temperature. The reaction was quenched with 1 M potassium hydrogen carbonate (200 ml) and the solvents were removed under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous magnesium sulphate, filtered and concentrated under reduced pressure to give an

orange oil. TLC analysis revealed the presence of unreacted chiral auxiliary in addition to the required product. A portion of the material (30 g) was dissolved in dichloromethane and flushed through a silica pad to give pure title compound as a yellow oil (25.3 g). ¹H-NMR;δ (CDCl₃), 7.31-7.19 (5H, m), 5.41 (2H,s), 4.51 (1H, dd, J=9.7, 4.2 Hz), 3.32 (1H, dd, J=14.2, 4.2 Hz), 2.82 (1H, dd, J=14.2, 9.7 Hz), 2.40-2.34 (2H, m), 1.48-1.32 (4H, m), 1.43 (3H, s), 1.27 (3H, s) and 0.91 (3H, t, J=7.1 Hz). Some chiral auxiliary was recovered by flushing the silica pad with methanol.

Step C: 4S-Benzyl-3-[2-(benzyloxyamino-methyl)-hexanoyl]-5,5-dimethyl-oxazolidin-2-one (p-toluenesulfonic acid salt)

4S-Benzyl-3-(2-butyl-acryloyl)-5,5-dimethyl-oxazolidin-2-one (19.8 g, 62.8 mmol) was mixed with O-benzylhydroxylamine (15.4 g, 126 mmol) and stirred overnight at room temperature. The mixture was dissolved in ethyl acetate and the solution was washed with 1 M hydrochloric acid, 1 M sodium carbonate and brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a pale yellow oil (25.3 g) which was shown by NMR and HPLC analysis to contain 4S-Benzyl-3-[2-(benzyloxyamino-methyl)-hexanoyl]-5,5-dimethyl-oxazolidin-2-one (ca. 82% d.e.) along with a trace of starting material. The product was combined with another batch (26.9g, 76% d.e.) and dissolved in ethyl acetate (200 ml). p-Toluenesulfonic acid (22.7 g, 119 mmol) was added and the mixture was cooled to 0 °C. The title compound was obtained as a white crystalline solid by seeding and scratching. Yield: 25.2g, (34%, single diastereoisomer). A second crop (14.7 g, 20%, single diastereoisomer) was also obtained. ¹H-NMR;δ (CDCl₃), 7.89 (2H, d, J=8.2 Hz), 7.37-7.12 (10H, m), 7.02 (2H, d, J=6.9 Hz), 5.28-5.19 (2H, m), 4.55 (1H, m), 4.23 (1H, m), 3.93 (1H, m), 3.58 (1H, m), 2.58 (1H, m), 2.35 (3H, s), 1.67-1.51 (2H, m), 1.29-1.16 (4H, m), 1.25 (3H, s), 1.11 (3H, s) and 0.80-0.75 (3H, m).

Step D: 2R-Benzzyloxyamino-methyl)-hexanoic acid

4S-Benzyl-3-[2R-(benzyloxyamino-methyl)-hexanoyl]-5,5-dimethyl-oxazolidin-2-one p-toluenesulfonic acid salt (25.2 g, 40.2 mmol) was partitioned between ethyl acetate and 1 M sodium carbonate. The organic phase was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residual oil was dissolved in THF (150 ml) and water (50 ml) and cooled to 0 °C and treated with lithium hydroxide (1.86 g, 44.2 mmol). The solution was stirred for 30 minutes at 0 °C, then overnight at room temperature. The reaction was acidified to pH4 with 1 M citric acid and the solvents were removed. The residue was partitioned between dichloromethane and 1 M sodium carbonate. The basic aqueous layer was acidified to pH4 with 1M citric acid and extracted three times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, filtered and concentrated to provide the title compound as a colourless oil (7.4 g, 73%). ¹H-NMR; δ (CDCl₃), 8.42 (2H, br s), 7.34-7.25 (5H, m), 4.76-4.66 (2H, m), 3.20-3.01 (2H, m), 2.73 (1H, m), 1.70-1.44 (2H, m), 1.34-1.22 (4H, m) and 0.92-0.86 (3H, m).

Step E: 2R-(Benzyloxyamino-methyl)-hexanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-1-propyl) amide

2R-Benzoyloxyamino-methyl)-hexanoic acid (7.98 g, 31.8 mmol) was dissolved in DMF (150 ml) and the solution was cooled to 0 °C. EDC (6.1 g, 31.8 mmol) and HOBt (430 mg, 3.2 mmol) were added and the mixture was stirred for 15 minutes. *tert*-Leucine-N,N-dimethylamide (5.53 g, 34 mmol) was added and the reaction was allowed to warm to room temperature and was stirred overnight. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate, washed successively with 1 M hydrochloric acid, saturated sodium hydrogen carbonate and brine, dried and filtered. The solvent was removed to leave the title compound as a yellow oil (8.7 g, 69%) which was used in Step F without further purification. ¹H-NMR; δ (CDCl₃), 7.35-7.28 (5H, m), 6.77 (1H, br d, J=9.2 Hz), 5.69 (1H, br s), 4.93 (1H, d, J=9.4 Hz), 4.72 (2H, s), 3.15 (3H, s), 3.10-3.00 (2H, m), 2.95 (3H, s), 2.49 (1H, m), 1.64-1.21 (6H, m), 0.99 (9H, s) and 0.86 (3H, t, J=6.8 Hz).

Step F: 2R-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-1-propyl) amide

2R-(Benzyloxyamino-methyl)-hexanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-1-propyl) amide (7.8 g, 19.9mmol) was dissolved in dry THF (100 ml) and treated with 1-formyl-benzotriazole (3.08 g, 21.0 mmol). The reaction was stirred overnight at room temperature. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate, washed with 2 M sodium hydroxide solution and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated to dryness under reduced pressure. The product was crystallised from ether-hexane (4.83 g, 57% in two crops). ¹H-NMR; δ (CDCl₃, rotamers), 8.12 (0.6H, br s), 7.89 (0.4H, br s), 7.37 (5H, s), 6.25 (1H, d, J=9.3 Hz), 4.96 (0.6H, br s), 4.86 (1H, d, J=9.4 Hz), 4.80 (0.4H, br s), 3.74 (2H, br s), 3.13 (3H, s), 2.94 (3H, s), 2.53 (1H, m), 1.38-1.21 (6H, m), 0.95 (9H, s) and 0.85 (3H, t, J=6.9 Hz). Note: A small sample was crystallised from ether-hexane to provide crystals suitable for X-ray crystallography. The stereochemistry was proven to be as stated herein.

Step G: 2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-1-propyl) amide


2R-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-1-propyl) amide (4.72 g, 11.3 mmol) was dissolved in ethanol (80 ml) and placed under a blanket of argon. A suspension of 10% palladium on charcoal (940 mg) in ethyl acetate (2 ml) was added and the mixture was stirred vigorously as hydrogen gas was bubbled through the system. After 30 minutes the suspension was placed under a balloon of hydrogen and stirred overnight at room temperature. The flask was purged with argon before removing the catalyst by filtration. The filtrate was concentrated under reduced pressure to provide the title compound as a colourless foam which crystallised on standing (3.65 g, 98%). ¹H-NMR; δ (CDCl₃, rotamers), 9.32 (0.4H, br s), 8.41 (0.4H, s), 7.88 (0.6H, br s), 7.27 (0.6H, s), 6.75

(0.4H, br d, $J=8.8$ Hz), 6.58 (0.6H, br d, $J=9.3$ Hz), 4.89 (1H, m), 4.04 (0.4H, m), 3.82 (0.6H, m), 3.53 (1H, m), 3.16 (1.2H, s), 3.15 (1.8H, s), 2.98 (1.2H, s), 2.96 (1.8H, s), 2.79 (0.6, m), 2.65 (0.4H, m), 1.78-1.58 (6H, m), 0.99 (3.6H, s), 0.95 (5.4H, s) and 0.87, 3H, t, $J=6.7$ Hz). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 175.8, 173.3, 172.0, 55.4, 54.9, 52.2, 48.8, 46.3, 38.9, 38.8, 36.3, 36.1, 30.3, 30.2, 29.7, 26.9, 23.0 and 14.3. LRMS: +ve ion 352 $[\text{M}+\text{Na}]$, -ve ion 328 $[\text{M}-\text{H}]$.

The compounds of Examples 14 to 27 were prepared by analogy with Example 13, Method I, substituting the appropriate ester for ethyl caproate in Step A. Where both diastereoisomers were prepared, diastereoisomer A is the faster eluting and usually the more potent against PDF *in vitro*. In some cases only the faster running diastereoisomer (Step E) was taken through to the final product.

Example 14

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-3-cyclopentyl-propionic acid (1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide




Diastereoisomer A. Colourless glass. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 9.33 (0.4H, br s), 8.94 (0.6H, br s), 8.40 (0.4H, s), 7.82 (0.6H, s), 6.82 (0.4H, br d, $J=8.6$ Hz), 6.62 (0.6H, br d, $J=9.3$ Hz), 4.90 (1H, m), 4.06 (0.4H, br dd, $J=14.7$, 7.3 Hz), 3.81 (0.6H, br dd, $J=14.0$, 9.7 Hz), 3.50 (1H, m), 3.16 (1.2H, s), 3.14 (1.8H, s), 2.97 (1.2H, s), 2.95 (1.8H, s), 2.80 (1H, m), 1.87-1.32 (9H, m), 1.16-0.95 (2H, m), 0.99 (3.6H, s) and 0.95 (5.4H, s). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 172.9, 171.3, 55.0, 54.5, 52.0,

48.6, 45.4, 44.2, 38.5, 38.4, 37.9, 37.6, 36.4, 36.3, 35.8, 35.6, 35.5, 32.7, 32.6, 26.5, 26.4 and 25.1. LRMS: +ve ion 378 [M+Na], -ve ion 354 [M-H].

Diastereoisomer B. Colourless glass. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 9.30 (0.6H, br s), 8.41 (0.6H, s), 7.75 (0.4H, s), 6.52 (0.4H, br d, $J=8.7$ Hz), 6.41 (0.6H, br d, $J=7.3$ Hz), 4.85 (0.4H, br d, $J=9.5$ Hz), 4.63 (0.6H, br d, $J=7.5$ Hz), 3.85-3.40 (2H, m), 3.25-2.95 (6H, 3br s), 2.78 (1H, 2br m), 1.90-1.40 (8H, m), 1.30 (1H, m), 1.20-1.00 (2H, m) and 1.05-0.95 (9H, 2s). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 174.9, 173.3, 172.8, 56.5, 54.7, 51.5, 50.5, 44.7, 44.6, 38.6, 38.4, 38.0, 37.8, 36.2, 36.0, 35.7, 35.5, 35.3, 34.3, 33.0, 32.9, 32.4, 32.3, 30.9, 26.6, 26.5, 25.1, 25.0 and 24.9. LRMS: +ve ion 378 [M+Na], -ve ion 354 [M-H].

Example 15

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-heptanoic acid-(1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide




Diastereoisomer A. Dark orange oil. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.32 (0.33H, s), 7.76 (0.67H, br s), 6.78 (0.33H, br d, $J=9.1$ Hz), 6.68 (0.67H, br d, $J=9.1$ Hz), 4.87-4.79 (1H, m), 3.96 (0.33H, br dd, $J=14.6, 7.6$ Hz), 3.74 (0.67H, br dd, $J=13.9, 9.7$ Hz), 3.51-3.36 (1H, m), 3.09 (1H, s), 3.08 (2H, s), 2.90 (1H, s), 2.89 (2H, s), 2.86-2.55 (1H, m), 1.53-1.19 (8H, br m), 0.92 (3H, s), 0.88 (6H, s) and 0.79 (3H, m). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 174.3, 172.0, 170.5, 170.4, 54.0, 53.5, 53.4, 50.8,

49.7, 47.4, 44.9, 43.8, 37.5, 37.4, 34.8, 34.7, 34.6, 30.6, 29.2, 29.1, 25.8, 25.5, 21.4 and 12.9. LRMS: +ve ion 344 [M+H], -ve ion 342 [M-H].

Diastereoisomer B. Dark orange oil. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.36 (0.5H, s), 7.74 (0.5H, s), 6.69 (0.5H, br s), 6.57 (0.5H, br d, $J=7.6$ Hz), 4.89 (0.5H, br s), 4.70 (0.5H, d, $J=7.8$ Hz), 3.76-3.40 (2H, m), 3.21 (1.5H, s), 3.16 (1.5H, s), 2.98 (3H, s), 2.81 (1H, br s), 2.72-2.60 (1H, m), 1.67 (2H, br s), 1.42-1.22 (6H, m), 1.02 (4.5H, s), 0.99 (4.5H, s), 0.90 (1.5H, s) and 0.87 (1.5H, s). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 175.2, 173.8, 173.1, 56.5, 55.1, 52.3, 51.1, 50.6, 45.8, 45.5, 39.0, 38.9, 36.6, 36.3, 35.6, 34.9, 32.1, 32.0, 30.1, 29.9, 27.4, 27.4, 27.0, 26.9, 22.9 and 14.3. LRMS: +ve ion 344 [M+H], -ve ion 342 [M-H].

Example 16


2R (or S)-[(Formyl-hydroxy-amino)-methyl]-pentanoic acid-(1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide



Diastereoisomer A. White hygroscopic foam. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.40 (0.33H, s), 7.83 (0.67H, br s), 6.88 (0.33H, br d, $J=8.6$ Hz), 6.69 (0.67H, br d, $J=9.2$ Hz), 4.90 (1H, t), 4.06 (0.33H, br dd, $J=14.5, 7.4$ Hz), 3.82 (0.67H, br dd, $J=13.7, 9.8$ Hz), 3.57-3.44 (1H, m), 3.16 (1H, s), 3.15 (2H, s), 2.98 (1H, s), 2.96 (2H, s), 2.87-2.63 (1H, m), 1.64-1.26 (4H, br m), 0.98 (3H, s), 0.94 (6H, s) and 0.90 (3H, t, $J=7.3$ Hz). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 175.8, 173.2, 172.0, 55.4, 54.9, 52.2, 48.7, 46.2, 45.0, 38.9, 38.9, 36.3, 36.1, 36.1, 32.7, 32.6, 27.0, 26.9, 20.9, 20.8 and 14.4. LRMS: +ve ion 338 [M+Na], -ve ion 314 [M-H].

Example 17


2R (or S)-[Formyl-hydroxy-amino)-methyl]-4-methyl-pentanoic acid -(1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide



Diastereoisomer A. White hygroscopic solid. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.41 (0.4H, s), 7.83 (0.6H, s), 6.65 (0.4H, d, $J=8.6$ Hz), 6.55 (0.6H, d, $J=9.0$ Hz), 4.91-4.83 (1H, m), 4.03-3.95 (0.4H, m), 3.84-3.74 (0.6H, m), 3.62-3.43 (1H, m), 3.16 (1H, s), 3.13 (2H, s), 2.98 (1H, s), 2.96 (2H, s), 2.89-2.79 (0.6H, m), 2.76-2.71 (0.4H, m), 1.69-1.34 (1.8H, m), 1.29-1.20 (1.2H, m), 1.0 (3.6H, s), 0.95 (5.4H, s) and 0.93-0.88 (6H, m). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 175.8, 173.3, 172.0, 171.7, 55.5, 55.0, 52.4, 49.1, 44.3, 43.2, 39.5, 39.4, 38.9, 38.8, 36.3, 36.1, 27.0, 26.9, 26.3, 26.0, 23.1, 23.0 and 22.8. LRMS: +ve ion 352 [$\text{M}+\text{Na}$], -ve ion 328 [$\text{M}-\text{H}$].

Example 18


3-Cyclohexyl-2R (or S)-[(formyl-hydroxy-amino)-methyl]-propionic acid (1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide



White solid. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.38 (0.25H, s), 7.82 (0.75H, s), 6.93 (0.25H, d, $J=8.9$ Hz), 6.74 (0.75H, d, $J=8.9$ Hz), 4.90 (1H, d, $J=9.4$ Hz), 4.02 (0.25H, dd, $J=9.7, 14.1$ Hz), 3.78 (0.75H, dd, $J=9.7, 14.1$ Hz), 3.46 (1H, m), 3.15 (3H, s), 2.96 (3H, s), 2.92 (1H, m), 1.65 (6H, m), 1.20 (5H, m), 0.98 (9H, s) and 0.87 (2H, m). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 176.4, 174.2, 172.4, 56.0, 55.6, 53.4, 49.9, 44.0, 43.3, 39.6, 39.4, 38.7, 38.5, 36.9, 36.7, 36.6, 34.8, 34.5, 27.5, 27.4 and 27.2. LRMS: +ve ion 370 $[\text{M}+\text{H}]$, 368 $[\text{M}-\text{H}]$.

Example 19


2R (or S)-Cyclopentyl-3-(Formyl-hydroxy-amino)-propionic acid-(1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide



Diastereoisomer A. Off-white foam. $^1\text{H-NMR}$; δ (CD_3OD , rotamers), 8.22 (0.33H, s), 7.79 (0.66H, s), 4.89 (1H, s), 3.87 (1H, m), 3.50 (1H, m), 3.19 (3H, s), 2.93 (3H, s), 2.82 (0.66H, m), 2.65 (0.33H, m), 1.89 (2H, m), 1.56 (5H, m), 1.24 (2H, m) and 0.98 (9H, s). $^{13}\text{C-NMR}$; δ (CD_3OD , rotamers), 176.0, 56.7, 53.2, 51.1, 42.7, 39.2, 36.5, 36.4, 32.0, 27.4, 26.4 and 26.2. IR (reflection disc) ν_{max} 3318, 2953, 1663, 1628, 1529, 1367, 1229, 1142, 1087, 877 cm^{-1} . LRMS: +ve ion 364 $[\text{M}+\text{Na}]$, -ve ion 340 $[\text{M}-\text{H}]$.

Example 20

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-octanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide




Diastereoisomer A. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.40 (0.4H, s), 7.83 (0.6H, s), 6.88 (0.4H, d, $J=8.9$ Hz), 6.68 (0.6H, d, $J=9.2$ Hz), 4.90 (1H, m), 4.05 (0.4H, m), 3.81 (0.6H, m), 3.50 (1H, m), 3.16 (1.2H, s), 3.15 (1.8H, s), 2.97 (1.2H, s), 2.96 (1.8H, s), 2.86 (0.6H, m), 2.69 (0.4H, m), 1.59-1.25 (10H, m), 1.14-0.95 (9H, m) and 0.89-0.77 (3H, m). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 175.2, 172.9, 171.6, 171.4, 54.9, 54.5, 54.3, 52.0, 48.4, 46.1, 45.7, 45.1, 44.7, 39.7, 38.5, 38.4, 35.8, 35.6, 35.6, 31.7, 31.5, 30.2, 30.1, 29.1, 29.1, 27.0, 26.4, 22.4 and 14.0. LRMS: +ve ion 380 $[\text{M}+\text{Na}]$, 358 $[\text{M}+\text{H}]$, -ve ion 356 $[\text{M}-\text{H}]$.

Example 21

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-nonanoic acid
(1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide


59



Diastereoisomer A: brown solid. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 9.30 (0.4H, s), 8.41 (0.6H, s), 7.83 (0.4H, s), 6.66 (0.4H, d, $J=8.9$ Hz), 6.52 (0.6H, d, $J=9.7$ Hz), 4.92-4.84 (1H, m), 4.06-3.97 (0.4H, m), 3.87-3.77 (0.6H, m), 3.63-3.45 (1H, m), 3.16 (1.2H, s), 3.14 (1.8H, s), 2.98 (1.2H, s), 2.96 (1.8H, s), 2.86-2.74 (0.6H, m), 2.66-2.63 (0.4H, m), 1.95-1.25 (12H, m), 1.00-0.95 (9H, m), and 0.90-0.84 (3H, m). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 175.5, 172.8, 171.4, 162.2, 156.1, 55.1, 54.5, 51.3, 50.8, 48.4, 46.3, 44.9, 38.4, 38.4, 35.8, 35.7, 33.9, 31.7, 30.3, 30.2, 29.4, 29.0, 27.1, 26.5, 26.5, 24.9, 22.6 and 14.0. LRMS: +ve ion 394 $[\text{M}+\text{Na}]$, 372 $[\text{M}+\text{H}]$, -ve ion 370 $[\text{M}-\text{H}]$.

Example 22


2R (or S)-[(Formyl-hydroxy-amino)-methyl]-decanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl- propyl)-amide



Diastereoisomer A: colourless oil. LRMS: +ve ion 408 [M+Na], 386 [M+H], -ve ion 384 [M-H].

Example 23


2R (or S)-[(Formyl-hydroxy-amino)-methyl]-5-methyl-hexanoic acid (1S-dimethyl-carbamoyl- 2,2-dimethyl-propyl)-amide



Diastereoisomer A: colourless oil. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 9.31 (0.4H, s), 8.40 (0.4H, s), 8.17 (0.6H, s), 6.77 (0.4H, d, $J=7.5$ Hz), 6.60 (0.6H, d, $J=8.0$ Hz), 4.89 (1H, m), 4.04 (0.4H, m), 3.83 (0.6H, m), 3.52 (1H, m), 3.16 (1.2H, s), 3.15 (1.8H, s), 2.98 (1.2H, s), 2.96 (1.8H, s), 2.70 (1H, m), 1.58-1.14 (5H, m), 1.00-0.95 (9H, m) and 0.87-0.84 (6H, m). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 172.9, 171.5, 162.2, 156.3, 55.1, 54.6, 51.4, 48.5, 46.4, 45.0, 38.5, 38.4, 36.2, 35.9, 35.6, 29.7, 28.1, 28.0, 27.9, 26.7, 26.6, 26.5 and 22.4. LRMS: +ve ion 366 [M+Na], 344 [M+H], -ve ion 342 [M-H].

Example 24

2R (or S)-[(Formyl-hydroxy-amino)-methyl] propanoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide




Diastereoisomer A: $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.41 (0.55H, s), 7.81 (0.45H, s), 6.67 (0.45H, d, $J=8.4$ Hz), 6.51 (0.45H, d, $J=7.2$ Hz), 4.88 (0.45H, d, $J=9.4$ Hz), 4.66 (0.55H, d, $J=7.7$ Hz), 3.76 (1H, m), 3.55 (0.55H, dd, $J=14.3, 9.8$ Hz), 3.44 (0.45H, dd, $J=14.2, 5.3$ Hz), 3.21 (1.65H, s), 3.14 (1.35H, s), 2.99 (1.65H, s), 2.97 (1.35H, s), 2.81 (1H, m), 1.21 (1.65H, d, $J=6.7$ Hz), 1.19 (1.35H, d, $J=6.8$ Hz), 1.01 (4.95H, s) and 0.98 (4.05H, s). LRMS: +ve ion 310 $[\text{M}+\text{Na}]$, -ve ion 286 $[\text{M}-\text{H}]$.

Diastereoisomer B: $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 9.47 (0.4H, br s), 8.41 (0.4H, s), 7.86 (0.6H, s), 6.96 (0.4H, br s), 6.74 (0.6H, d, $J=7.3$ Hz), 4.91 (1H, m), 3.99 (0.4H, dd, $J=14.2, 7.6$ Hz), 3.83 (0.6H, dd, $J=13.8, 9.0$ Hz), 3.50 (1H, m), 3.16 (1.2H, s), 3.15 (1.8H, s), 2.97 (3H, s), 2.90 (1H, m), 1.21 (1.2H, d, $J=6.8$ Hz), 1.15 (1.8H, d, $J=6.5$ Hz), 0.99 (3.6H, s) and 0.95 (5.4H, s). LRMS: +ve ion 310 $[\text{M}+\text{Na}]$, -ve ion 286 $[\text{M}-\text{H}]$.

Example 25


2R (or S)-[(Formyl-hydroxy-amino)-methyl]-3-methyl butyric acid (1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide



Diastereoisomer A: $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 9.33 (0.4H, s), 8.38 (0.4H, s), 7.81 (0.6H, s), 6.86 (0.4H, br s), 6.58 (0.6H, d, $J=8.6$ Hz), 4.90 (1H, m), 4.06 (0.4H, dd, $J=14.7, 7.3$ Hz), 3.91 (0.6H, dd, $J=13.8, 10.6$ Hz), 3.17 (1.2H, s), 3.15 (1.8H, s), 2.98 (1.2H, s), 2.96 (1.8H, s), 2.62 (0.6H, m), 2.48 (0.4H, m), 1.90 (1H, m), 1.09-0.86 (15H, m). LRMS: +ve ion 338 $[\text{M}+\text{Na}]$, -ve ion 314 $[\text{M}-\text{H}]$.

Example 26


2R (or S)-[(Formyl-hydroxy-amino)-methyl]-3-phenyl-propionylpropionic acid-(1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide



Diastereoisomer A . Colourless glass. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 9.33 (0.3H, br s), 8.95 (0.7H, br s), 8.43 (0.3H, br s), 7.83 (0.7H, br s), 7.27-7.10 (5H, m), 6.65 (0.3H, br s), 6.45 (0.7H, br d, $J=8.2$ Hz), 4.80-4.70 (1H, m), 4.22-4.10 (0.3H, m), 3.89 (0.7H, dd, $J=13.7, 9.6$ Hz), 3.63-3.47 (1H, m), 3.20-2.69 (3H, m), 3.04 (3H, br s), 2.86 (3H, br s), and 0.87 (9H, br s). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 137.9, 137.7, 128.8, 128.5, 126.6, 54.9, 54.5, 51.3, 48.3, 47.3, 46.6, 38.3, 38.2, 36.2, 36.1, 35.8, 35.7, 35.6, 35.5 and 26.4. LRMS: +ve ion 386 ($\text{M}+\text{Na}$), -ve ion 362 ($\text{M}-\text{H}$).

Example 27

2R (or S)-[(Formyl-hydroxy-amino)-methyl]-3-(4-methoxy-phenyl)-propionic acid-(1S-dimethyl carbamoyl-2,2-dimethyl-propyl)-amide




Diastereoisomer A: LRMS: +ve ion 416 ($\text{M}+\text{Na}$), 394 ($\text{M}+\text{H}$), -ve ion 392 ($\text{M}-\text{H}$).

The compounds of Examples 28 to 31 were prepared by analogy with Example 13, Method II, substituting the appropriate amino acid amide or benzyl ester for *tert*-leucine N,N-dimethylamide in Step E.

Example 28

2S-{2R-[Formyl-hydroxy-amino)-methyl]-hexanoylamino}-3-phenyl propionic acid




White foam. ¹H-NMR; δ (CD₃OD, rotamers), 8.11 (0.35H, s), 7.80 (0.65H, s), 7.31-7.16 (5H, m), 4.68 (1H, dd, J=8.7, 5.5Hz), 3.58 (1H, m), 3.39 (1H, m), 3.19 (1H, m), 2.98 (1H, m), 2.76 (1H, m), 1.55-1.26 (6H, m) and 0.90-0.85 (3H, m). ¹³C-NMR; δ (CD₃OD, rotamers), 176.1, 175.7, 174.7, 174.5, 138.6, 138.5, 130.3, 129.5, 129.4, 127.7, 55.0, 53.3, 49.8, 45.4, 38.4, 38.3, 31.0, 30.8, 30.1, 23.7 and 14.2. IR (reflection disc) ν_{\max} 2932, 2359, 1727, 1660, 1551, 1454, 1381, 1221, 882, 701cm⁻¹. LRMS: +ve ion 359 [M+Na], -ve ion 335 (M-H).

Example 29

2S-{2R-[Formyl-hydroxy-amino)-methyl]-hexanoylamino}-3,3-dimethyl butyric acid


64



White foam. $^1\text{H-NMR}$; δ (CD_3OD , rotamers), 8.25 (0.3H, s), 7.82 (0.7H, s), 4.31 (1H, s), 3.83-3.29 (2H, m), 3.10-2.89 (1H, m), 1.54-1.33 (6H, m), 1.03 (3H, s), 1.01 (6H, s) and 0.92-0.87 (3H, m). $^{13}\text{C-NMR}$; δ (CD_3OD , rotamers), 174.9, 172.9, 61.0, 52.4, 44.2, 44.0, 33.6, 30.1, 29.1, 26.2, 22.6 and 13.1. IR(reflection disc) ν_{max} 2959, 2359, 1644, 1537, 1371, 1218, 881 and 704 cm^{-1} . LRMS: +ve ion 325 ($\text{M}+\text{Na}$), -ve ion 301 ($\text{M}-\text{H}$).

Example 30

2S-[2R-(Formyl-hydroxy-amino)-methyl]-hexanoic acid {1-[(2S-hydroxymethyl)-pyrrolidine-1-carbamoyl]-2,2-dimethyl-propyl}-amide




Colourless oil. $^1\text{H-NMR}$; δ (CD_3OD , rotamers), 8.26 (0.4H, s), 7.84 (0.6H, s), 4.62 (0.4H, d, $J=8.2$ Hz), 4.39 (0.6H, d, $J=8.4$ Hz), 4.12 (1H, m), 3.91-3.37 (6H, br m), 2.93 (0.6H, m), 2.78 (0.4H, m), 1.93 (5H, m), 1.45 (2H, m), 1.39 (3H, m), 0.97 (3H, br s), 0.95 (3H, br s), and 0.89 (3H, t, $J=6.7$ Hz). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 174.8, 172.9, 65.3, 65.1, 59.6, 59.5, 55.9, 55.7, 51.9, 47.8, 44.7, 44.0, 31.5, 30.5, 29.3, 28.7, 28.1, 27.3, 23.8, 22.0, 21.2, 18.7, 18.3, 17.6, 14.7 and 13.3.

LRMS: +ve ion 394 (M+Na), 372 (M+H), -ve ion 370 (M-H).

Example 31

2S-[2R-(Formyl-hydroxy-amino)-methyl]-hexanoic acid {1-[(2-hydroxy-ethyl)methyl-carbamoyl]-2,2-dimethyl-propyl}-amide




White foam. $^1\text{H-NMR}$; δ (CD_3OD , rotamers), 8.25 (0.25H, s), 8.03 (0.125H, s), 7.82 (0.625H, s), 4.88 (1H, m), 3.83-3.54 (4H, br m), 3.41 (2H, m), 3.25 (2H, s), 2.96 (2H, s and m), 1.49 (2H, m), 1.23 (4H, m), 1.00 (6H, s), 0.99 (3H, s), and 0.88 (3H, m). $^{13}\text{C-NMR}$; δ (CD_3OD , rotamers), 173.6, 164.4, 61.1, 61.0, 56.9, 56.5, 54.2, 53.9, 52.2, 41.8, 38.9, 36.9, 36.3, 35.3, 31.6, 30.8, 27.5, 24.1 and 14.7. LRMS: +ve ion 382 [M+Na], -ve ion 358 [M-H].

The compounds of Examples 32 to 59 were prepared by analogy with Example 7, Method II, substituting the appropriate amine or amino acid amide/benzyl ester for tert-leucine N,N-dimethylamide in Step E. In some cases HOAt was used in Step E and hydrogenolytic deprotection (Step G) was performed under catalytic transfer conditions (cyclohexene, palladium on charcoal in ethanol)

Example 32

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid-(1R-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide


66



Colourless oil. LRMS: +ve ion 330 [M+H], -ve ion 328 [M-H].

Example 33

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2S-methyl-butyl)-amide




White foam. LRMS: +ve ion 352 [M+Na], -ve ion 328 [M-H].

Example 34

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2-methoxy-2-methyl-propyl)-amide


67



From racemic β -hydroxymethylvaline. Diastereoisomer A. Colourless oil. LRMS: +ve ion 368 [M+Na], 346 [M+H], -ve ion 344 [M-H]. Diastereoisomer B. LRMS: +ve ion 368 [M+Na], 346 [M+H], -ve ion 344 [M-H].

Example 35


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2-hydroxy-2-methyl-propyl)-amide



Colourless oil. LRMS: +ve ion 354 [M+Na], -ve ion 330 [M-H].

Example 36


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2-(4-chloro-phenyl)-1S-dimethyl-carbamoyl-ethyl]-amide



Colourless oil. LRMS: +ve ion 330 (M+H), -ve ion 328 (M-H).

Example 37


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [1S-dimethylcarbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide



Colourless oil. LRMS: +ve ion 402 (M+Na), 380 (M+H).

Example 38


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide



Colourless oil. LRMS: +ve ion 414 (M+H), -ve ion 412 (M-H).

Example 39


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (2-cyclohexyl-1S-dimethylcarbamoyl-ethyl)-amide



White foam. LRMS: +ve ion 392 (M+Na), 370 (M+H)

Example 40


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-phenyl-methyl)-amide



Colourless oil. LRMS: +ve ion 350(M+H), -ve ion 348 (M-H).

Example 41

2-{2R-[(Formyl-hydroxy-amino)-methyl]-hexanoyl}-1,2,3,4-tetrahydro-isoquinoline-3-S-carboxylic acid dimethylamide




LRMS: +ve ion 398 (M+Na), 376 (M+H), -ve ion 374 (M-H).

Example 42

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (4-amino-1S-dimethylcarbamoyl-butyl)-amide


71



Colourless oil. LRMS: +ve ion 345 (M+H), -ve ion 343 (M-H).

Example 43

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-2-hydroxy-ethyl)-amide




Colourless oil. LRMS: +ve ion 326 (M+Na), -ve ion 302 (M-H).


Example 44

N-Hydroxy-N-[2R-(4-methyl-piperazine-1-carbonyl)-hexyl]-formamide


72



LRMS: +ve ion 272 [M+H].

Example 45N-Hydroxy-N-[2R-(morpholine-4-carbonyl)-hexyl]-formamide


LRMS: +ve ion 281 (M+Na), 259 (M+H), -ve ion 257 (M-H).

Example 46N-Hydroxy-N-[2R-(2S-hydroxymethyl-pyrrolidine-1-carbonyl)-hexyl]-formamide

LRMS: -ve ion 271 (M-H).

Example 47


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-hydroxymethyl-2,2-dimethyl-propyl)-amide



LRMS: +ve ion 289 (M+H), -ve ion 287 (M-H).

Example 48


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-methoxymethyl-2,2-dimethyl-propyl)-amide



LRMS: +ve ion 303 (M+H), -ve ion 301 (M-H).

Example 49


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [1S-(4-benzyl-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide



LRMS: -ve ion 458 (M-H).

Example 50


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [1S-(benzyl-phenethyl-carbamoyl)-2,2-dimethyl-propyl]-amide



LRMS: +ve ion 496 (M+H), -ve ion 494 (M-H).

Example 51


2S-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2,2-dimethyl-1S-(pyrrolidine-1-carbonyl)-propyl]-amide



LRMS: +ve ion 356 (M+H), -ve ion 354 (M-H).

Example 52

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2,2-dimethyl-1S-(morpholine-4-carbonyl)-propyl]-amide




LRMS: +ve ion 372 (M+H), -ve ion 370 (M-H).

Example 53

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2,2-dimethyl-1S-(4-methyl-piperazine-1-carbonyl)-propyl]-amide


76



LRMS: +ve ion 385 (M+H), -ve ion 383 (M-H).

Example 54

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2,2-dimethyl-1S-(4-methyl-piperidine-1-carbonyl)-propyl]-amide




LRMS: +ve ion 384 (M+H), -ve ion 382 (M-H).

Example 55

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-cyclohexylcarbamoyl-2,2-dimethyl-propyl)-amide


77



LRMS: +ve ion 398 (M+H), -ve ion 396 (M-H).

Example 56

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [1S-(4-acetyl-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide




LRMS: +ve ion 412 (M+H), -ve ion 410 (M-H).

Example 57

1-(2S-{2R-[(Formyl-hydroxy-amino)-methyl]-hexanoylamino}-3,3-dimethyl-buteryl)-piperidine-4-carboxylic acid methyl ester


78



LRMS: +ve ion 442 (M+H), -ve ion 440 (M-H).

Example 58

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2,2-dimethyl-1S-(octahydroquinoline-1-carbonyl)-propyl]-amide




LRMS: +ve ion 424 (M+H), -ve ion 422 (M-H).

Example 59

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [1S-(3,4-dihydro-2H-quinoline-1-carbonyl)-2,2-dimethyl-propyl]-amide


79



LRMS: -ve ion 416 (M-H).


Example 60

2S-{3-Ethylsulfanymethyl-2R-[(formyl-hydroxy-amino)-methyl]propionyl amino}-
3,3,N,N-tetramethylbutyramide



A synthetic route to the title compound is outlined in Scheme 4 and is described in detail below.

Scheme 4



Reagents and conditions: A. 3-((thio-4-benzyl-oxazolidin-2-one, THF, -78°C; B. LiN(SiMe₃)₂, THF, -78°C then AcCl; C. HCl, H₂O, Bzl, NaOAc, aq ethanol; D. NaCNBH₃, AcOH, room temperature; E. HCOBt, THF; F. LiOH, aq THF, 0°C; G. H-Tie-NMe₂, HOAc, EDC, DMF; H. H₂, Pd/C, MeOH then separate diastereoisomers (HPLC)

Step A: 2-Ethylsulfanylmethyl-acrylic acid

A mixture of malonic acid (5.2 g, 50 mmol), paraformaldehyde (3.3 g, 110 mmol), dicyclohexylamine, 9.95 ml, 50 mmol) and ethanethiol 4.06 ml, 55 mmol) in dioxane (120 ml) was heated at 70 °C for 2 hours. The solvents were removed under reduced pressure, the residue was redissolved in ethyl acetate and the solution was extracted with saturated aqueous sodium hydrogen carbonate (4x20 ml). The combined aqueous layers were washed with ethyl acetate (20 ml) then acidified with 1 M hydrochloric acid. The resulting suspension was extracted into dichloromethane and the solution was dried over anhydrous magnesium sulfate, filtered and evaporated to provide the title compound as a white solid (3.76 g, 52%). ¹H-NMR; δ (CDCl₃), 9.89 (1H, br s), 6.35 (1H, s), 5.77 (1H, s), 3.39 (2H, s), 2.49 (2H, dd, J=7.4, 14.5 Hz) and 1.25 (3H, t, J=5.2 Hz).

Step B: 4S-Benzyl-3-(2-ethylsulfanylmethyl-acryloyl)-5,5-dimethyl-oxazolidin-2-one

2-Ethylsulfanylmethyl-acrylic acid (3.76g, 25.8mmol) was dissolved in dry THF (75 ml) and cooled to -78 °C under a blanket of argon. Triethylamine (4.6 ml, 33.5 mmol) and pivaloyl chloride (3.17 ml, 25.8 mmol) were added at such a rate that the temperature remained below -60 °C. The mixture was stirred at -78 °C for 30 minutes, warmed to room temperature for 2 hours and finally cooled back to -78 °C.

In a separate flask, 4S-benzyl-5,5-dimethyl-oxazolidin-2-one was dissolved in dry THF (75 ml) and cooled to -78 °C under a blanket of argon. n-Butyllithium (2.4M solution in hexanes, 12.9 ml, 30.9 mmol) was added slowly and the mixture was stirred for 30 minutes at room temperature. The resulting anion was transferred *via* a cannula into the original reaction vessel. The mixture was allowed to warm to room temperature and stirred overnight at room temperature. The reaction was quenched with saturated sodium hydrogen carbonate (20ml) and the solvents were removed under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was washed successively with saturated sodium hydrogen

carbonate, 1 M hydrochloric acid and brine, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel, 20% ethyl acetate in hexane) to provide the title compound as a yellow oil (6.5 g, 76%). ¹H-NMR; δ (CDCl₃), 7.29 (5H, m), 5.58 (1H, s), 5.49 (1H, s), 4.54 (1H, dd, J=3.9, 9.7 Hz), 3.52 (2H, dd, J=15.8, 3.1 Hz), 3.38 (1H, dd, J=3.9, 14.5 Hz), 2.84 (1H, dd, J=4.6, 14.3 Hz), 2.52 (2H, dd, J=7.2, 14.6 Hz), 1.42 (3H, s), 1.29 (3H, s) and 1.22 (3H, t, J=7.5 Hz). LRMS: +ve ion 356 (M+Na), 334 (M+H).

Step C: 4S-Benzyl-3-[2R-*tert*-butoxyamino-methyl]-3-ethylsulfanylmethyl-propionyl]-5,5-dimethyl-oxazolidin-2-one

4S-Benzyl-3-(2-ethylsulfanylmethyl-acryloyl)-5,5-dimethyl-oxazolidin-2-one (2.1 g, 6.3 mmol) was dissolved in ethanol (10 ml) and O-*tert*-butyl-hydroxylamine hydrochloride (0.95 g, 7.56 mmol) was added, followed by triethylamine (1.1 ml, 7.87 mmol). The mixture was stirred at 30 °C overnight. The solvents were removed under reduced pressure and the residue was dissolved in ethyl acetate. The organic solution was washed successively with 1 M hydrochloric acid, saturated sodium hydrogen carbonate and brine, dried over anhydrous magnesium sulphate and filtered. The filtrate was concentrated under reduced pressure to provide the title compound as a pale yellow oil (2.42 g, 91%; single diastereoisomer by HPLC). ¹H-NMR; δ (CDCl₃), 7.30 (5H, m), 5.09 (1H, br s), 4.54 (1H, dd, J=3.5, 9.9 Hz), 4.33 (1H, m), 3.19 (2H, m), 3.08 (1H, dd, J=5.4, 11.8 Hz), 2.80 (3H, m), 2.56 (2H, dd, J=7.4, 14.7 Hz), 1.41 (3H, s), 1.36 (3H, s), 1.23 (3H, t, J=7.3 Hz) and 1.13 (9H, s). LRMS: +ve ion 423 (M+H).

Step D: 2R-*tert*-butoxyamino-methyl)-3-ethylsulfanylmethyl-propionic acid

A solution of 4S-Benzyl-3-[2R-*tert*-butoxyamino-methyl)-3-ethylsulfanylmethyl-propionyl]-5,5-dimethyl-oxazolidin-2-one in (2.42 g, 5.72 mmol) THF (40ml) was cooled to 0 °C and a solution of lithium hydroxide (288 mg, 6.86 mmol) in water (10

ml) was added. The mixture was allowed to warm to room temperature then stirred for 5 hours. The solvent was removed under reduced pressure and the residue was partitioned between water and ethyl acetate. The aqueous layer was removed and the ethyl acetate layer was washed successively with water and saturated sodium hydrogen carbonate. The combined aqueous layers were washed with ethyl acetate (20 ml) before acidifying with 1 M hydrochloric acid. The resulting emulsion was extracted with dichloromethane (3x20 ml) and the combined organic layers were dried over anhydrous magnesium sulfate, filtered and evaporated to provide the title compound as a colourless oil (0.68 g, 50%). ¹H-NMR; δ (CDCl₃), 8.03 (2H, br s), 3.21 (2H, d, J=6.1 Hz), 2.89 (2H, m), 2.75 (1H, m), 2.57 (2H, dd, J=7.4, 14.8 Hz), 1.26 (3H, t, J=7.4 Hz) and 1.18 (9H, s). LRMS: +ve ion 236 [M+H], -ve ion 234 [M-H].

Step E: A solution of 2S-[2R-(*tert*-butoxy-amino-methyl)-3-ethylsulfanylmethyl-propionyl amino]-3,3,N,N-tetramethylbutyramide

2R-*tert*-butoxyamino-methyl)-3-ethylsulfanylmethyl-propionic acid (340 mg, 1.44 mmol) was dissolved in DMF (10 ml) and *tert*-leucine-N,N-dimethylamide (272 mg, 1.73 mmol), HOAt (19.6 mg, 0.14 mmol) and EDC (331 mg, 1.73 mmol) were added. The reaction was stirred overnight at room temperature. The solvent was removed under reduced pressure and the residue was dissolved in dichloromethane. The organic solution was washed successively with 1 M hydrochloric acid, 1 M sodium carbonate and brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to provide the required product as a colourless oil (440 mg, 82%). ¹H-NMR; δ (CDCl₃), 6.87 (1H, d, J=9.0 Hz), 5.11 (1H, br s), 4.93 (1H, d, J=9.3 Hz), 3.15 (3H, s), 3.11 (1H, m), 2.95 (3H, s), 2.79 (3H, m), 2.54 (3H, s), 1.22 (3H, t, J=7.6 Hz), 1.18 (9H, s) and 1.01 (9H, s). LRMS: +ve ion 398 [M+Na], 376 [M+1].

Step F: 2S-{2R-[(*tert*-Butoxy-formyl-amino)-methyl]-3-ethylsulfanylmethyl-propionyl amino}-3,3,N,N-tetramethylbutyramide

A solution of 2S-[2R-(*tert*-butoxy-amino-methyl)-3-ethylsulfanylmethyl-propionyl amino]-3,3,N,N-tetramethylbutyramide (220 mg, 0.58 mmol) in dichloromethane (5 ml) was cooled to 0 °C and treated with formic acetic anhydride (0.1 ml). The reaction was stirred at room temperature for 4 hours, then the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (silica gel, 50% ethyl acetate in hexane as eluent) to provide the title compound as a colourless oil (120 mg, 52%). ¹H-NMR; δ (CDCl₃, rotamers), 8.31 (1H, br s), 6.56 (1H, d, J=9.1Hz), 4.94 (0.33H, d, J=9.4 Hz), 4.88 (0.67H, d, J=9.2 Hz), 4.08 (0.67H, br m), 3.83 (1.34H, br m), 3.13 (3H, s), 2.95 (3H, s), 2.80 (2H, m), 2.61 (1H, dd, J=6.8, 14.0 Hz), 2.49 (2H, dd, J=7.4, 14.7 Hz), 1.29 (9H, s), 1.25 (3H, t, J=7.2 Hz) and 0.99 (9H, s). LRMS: +ve ion 426 [M+Na], 404 [M+H].

Step G: 2S-{3-Ethylsulfanylmethyl-2R-[(formyl-hydroxy-amino)-methyl]propionyl amino}-3,3,N,N-tetramethylbutyramide


A solution of 2S-{2R-[(*tert*-butoxy-formyl-amino)-methyl]-3-ethylsulfanylmethyl-propionyl amino}-3,3,N,N-tetramethylbutyramide (120 mg, 0.3 mmol) in deuteriochloroform (1 ml) was treated with TFA (4 ml) and allowed to stand at 4 °C overnight. The solvents were removed under reduced pressure and residual TFA was removed by azeotroping with toluene. The residue was purified by preparative HPLC to provide the title compound as a colourless oil (40 mg, 38%; 7:2 mixture of diastereomers by HPLC). ¹H-NMR; δ (CDCl₃, rotamers), 8.40 (0.33H, s), 7.87 (0.67H, s), 7.24 (0.33H, d, J=9.3 Hz), 6.98 (0.67H, d, J=9.3 Hz), 4.91 (0.67H, d, J=9.3 Hz), 4.90 (0.33H, d, J=9.3 Hz), 4.07 (0.33H, dd, J=7.5, 14.5 Hz), 3.86 (0.67H, dd, J=8.8, 14.2 Hz), 3.75 (0.67H, m), 3.68 (0.33H, m), 3.16 (1H, s), 3.15 (2H, s), 3.05 (1H, m), 2.96 (3H, s), 2.77 (1H, m), 2.66 (1H, m), 2.52 (2H, dd, J=7.4, 14.8 Hz), 1.22 (3H, t, J=7.3 Hz), 0.99 (3H, s) and 0.96 (6H, s). ¹³C-NMR; δ (CDCl₃, rotamers), 173.3, 171.6, 171.2, 55.2, 54.8, 51.1, 48.5, 45.2, 44.4, 38.5, 38.4, 35.9, 35.8, 35.7, 31.7, 31.4, 26.7, 26.6, 26.5 and 14.6. LRMS: +ve ion 370 [M+Na], 348 [M+H], -ve ion 346 [M-H].

The compound of Example 61 was prepared similarly using piperidine in place of

ethanethiol in Step A.

Example 61

2-{2-[(Formyl-hydroxy-amino)-methyl]-3-piperidin-1-yl-propionylamino}-3,3,N,N-tetramethyl-butamide




White solid (4:1 mixture of diastereoisomers by HPLC). $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.29 (1H, s), 7.95 (1H, br s), 4.87 (1H, d, $J=9.1$ Hz), 4.02 (1H, dd, $J=5.0$, 14.6 Hz), 3.56 (1H, dd, $J=8.2$, 14.6 Hz), 3.14 (3H, s), 2.96 (3H, s), 2.89 (1H, m), 2.69 (1H, m), 2.52 (5H, m), 1.65 (4H, m), 1.49 (2H, m) and 0.99 (9H, s). $^{13}\text{C-NMR}$; δ (CDCl_3), 172.2, 171.3, 60.4, 55.0, 54.9, 48.6, 42.4, 38.8, 36.2, 36.1, 27.0, 25.6 and 24.3. LRMS: +ve ion 371 $[\text{M}+\text{H}]$, -ve ion 369 $[\text{M}-\text{H}]$.

The compounds of Examples 62 to 65 were prepared by analogy with Example 7, Method II, substituting *O-tert*-butylhydroxylamine for *O*-benzylhydroxylamine in Step B and the appropriate amine or amino acid amide/benzyl ester for *tert*-leucine *N,N*-dimethylamide in Step E. Final deprotection was performed by acidolysis with TFA (see Example 60, above).

Example 62

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1R-dimethylcarbamoyl-2-methyl-2-methylsulfanyl-propyl)-amide

86




Colourless oil. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.4 (0.5H, s), 7.85 (0.5H, s), 7.11 (0.5H, d, $J=9.1$ Hz), 6.93 (0.5H, d, $J=9.1$ Hz), 5.15 (1H, d, $J=9.4$ Hz), 3.90 (0.5H, m), 3.73 (0.5H, m), 3.64 (0.5H, d, $J=14.3$ Hz), 3.48 (0.5H, dd, $J=14.0, 3.9$ Hz), 3.22 (3H, s), 2.97 (3H, s), 2.83 (0.5H, m), 2.70 (0.5H, m), 2.07 (1.5H, s), 2.04 (1.5H, s), 1.58 (1H, m), 1.36 (4H, m), 1.32 (3H, s), 1.28 (3H, s) and 0.86 (3H, t, $J=6.6$ Hz).

$^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 175.4, 173.5, 170.8, 63.6, 53.2, 53.1, 52.5, 49.5, 47.5, 46.1, 44.9, 41.6, 37.5, 36.5, 36.4, 35.4, 30.2, 29.8, 28.0, 14.3, 12.0 and 11.9.

LRMS: +ve ion 362 $[\text{M}+\text{H}]$, -ve ion 360 $[\text{M}-\text{H}]$.

Example 63

2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (2-benzylsulfanyl-1R-dimethyl-carbamoyl-2-methyl-propyl)-amide




White foam. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.37 (0.33H, s), 7.81 (0.66H, s), 7.31 (5H, m), 7.06 (0.33H, d, $J=8.8$ Hz), 6.89 (0.66H, d, $J=9.3$ Hz), 5.20 (1H, d, $J=9.3$ Hz), 3.94 (0.33H, dd, $J=8.3, 14.6$ Hz), 3.78 (2.66H, m), 3.61 (0.33H, dd, $J=3.5, 14.4$ Hz),

3.42 (0.66H, dd, $J=5.1, 14.9$ Hz), 3.21 (3H, s), 3.03 (3H, s), 2.82 (0.66H, m), 2.69 (0.33H, m), 1.61 (1H, m), 1.42 (1H, m), 1.37 (3H, s), 1.32 (3H, s), 1.26 (4H, m) and 0.86 (3H, t, $J=6.6$ Hz). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 175.3, 173.5, 171.0, 138.1, 137.4, 129.5, 129.3, 129.1, 129.0, 128.9, 127.6, 127.4, 55.9, 53.7, 52.5, 51.2, 49.6, 49.5, 46.1, 44.9, 39.0, 38.6, 36.6, 36.4, 33.9, 33.7, 30.3, 30.1, 29.7, 26.7, 26.1, 25.7, 25.5, 24.2, 22.9 and 14.3. LRMS: +ve ion 460 $[\text{M}+\text{Na}]$, 438 $[\text{M}+\text{H}]$, -ve ion 436 $[\text{M}-\text{H}]$.

Example 64


2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2-benzylsulfanyl-2-methyl-1R-(morpholine-4-carbonyl)-propyl]-amide



White foam. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.44 (0.5H, s), 8.37 (0.5H, s), 7.30 (5H, m), 6.88 (0.5H, d, $J=8.3$ Hz), 6.78 (0.5H, d, $J=9.2$ Hz), 5.12 (1H, d, $J=9.5$ Hz), 3.91 (1H, dd, $J=8.2, 14.6$ Hz), 3.78 (10H, m), 3.45 (1H, dd, $J=4.5, 14.2$ Hz), 2.80 (0.5H, m), 2.64 (0.5H, m), 1.61 (1H, m), 1.41 (1H, m), 1.36 (3H, s), 1.33 (3H, s), 1.29 (4H, m) and 0.87 (3H, t, $J=6.8$ Hz). $^{13}\text{C-NMR}$; δ (CDCl_3 , rotamers), 175.5, 173.4, 169.4, 137.8, 129.5, 129.3, 129.1, 129.0, 127.8, 127.5, 67.1, 67.0, 53.3, 53.2, 51.99, 49.6, 49.5, 49.2, 47.9, 46.5, 45.0, 43.2, 43.0, 34.0, 30.3, 30.2, 29.7, 26.8, 26.5, 25.9, 25.8, 22.9 and 14.3. LRMS: +ve ion 502 $[\text{M}+\text{Na}]$, 480 $[\text{M}+\text{H}]$, -ve ion 478 $[\text{M}-\text{H}]$.

Example 65

2-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2-benzylsulfanyl-2-methyl- 1R (or S)-(4-methyl-piperidine-1-carbonyl)-propyl]-amide



Diastereoisomer A. White solid. LRMS: +ve ion 514 [M+Na], 492 [M+H], -ve ion 490 [M-H].


Diastereoisomer B. Colourless gum. LRMS: +ve ion 514 [M+Na], 492 [M+H], -ve ion 490 [M-H].

The compounds of Examples 66 to 68 were prepared by analogy with Example 7, Method II, substituting the appropriate malonic acid for butylmalonic acid in Step A. *O-tert*-butylhydroxylamine for *O*-benzylhydroxylamine in Step C. Stereoselectivity in the Michael addition was variable. Final deprotection was performed by acidolysis with TFA (see Example 60, above).

Example 66

2R-[(Formyl-hydroxy-amino)-methyl]-pent-4-enoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide


89



Single diastereoisomer. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.40 (0.25H, s), 7.84 (0.75H, s), 7.05 (0.35H, d, $J=9.0\text{Hz}$), 6.74 (0.65H, d, $J=9.3\text{Hz}$), 5.70 (1H, m), 5.03-5.24 (2H, m), 4.88 (1H, dd, $J=9.4, 6.7\text{Hz}$), 3.98 (0.5H, m), 3.81 (0.5H, m), 3.55 (1H, m), 3.14 (3H, s), 2.97 (1.3H, s), 2.96 (1.7H, s), 2.75-2.92 (1H, m), 2.16-2.50 (2H, m), 0.98 (4.5H, s) and 0.94 (4.5H, s). LRMS: +ve ion 336 $[\text{M}+\text{Na}]$, -ve ion 312 $[\text{M}-\text{H}]$.

Example 67

2R-[(Formyl-hydroxy-amino)-methyl]-hex-5-enoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide




Diastereoisomer A: colourless oil. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.42 (0.45H, s), 7.84 (0.55H, s), 6.78 (0.45H, d, $J=8.4\text{Hz}$), 6.60 (0.55H, d, $J=9.3\text{Hz}$), 5.74 (1H, m), 5.03 (2H, m), 4.88 (1H, m), 4.14 (0.4H, m), 3.81 (0.6H, m), 3.55 (1H, m), 3.16 (1H, s), 3.15 (2H, s), 2.98 (1H, s), 2.97 (2H, s), 2.85 (0.7H, m), 2.68 (0.3H, m), 2.07 (2H, m), 1.73 (1.6H, m), 1.50 (0.4H, m), 0.99 (4H, s) and 0.95 (5H, s). LRMS: +ve ion 350 $[\text{M}+\text{Na}]$, -ve ion 326 $[\text{M}-\text{H}]$.

Diastereoisomer B: colourless oil. $^1\text{H-NMR}$; δ (CDCl_3 , rotamers), 8.41 (0.5H, s), 7.75 (0.5H, s), 6.58 (0.5H, d, $J=9.1\text{Hz}$), 6.36 (0.5H, d, $J=9.1\text{Hz}$), 5.75 (1H, m), 5.01

(2H, m), 4.86 (0.5H, d, J=9.5Hz), 4.64 (0.5H, d, J=7.5Hz), 3.42-3.82 (2H, m), 3.22 (1.5H, s), 3.07 (1.5H, s), 2.99 (3H, s), 2.87 (0.5H, m), 2.66 (0.5H, m), 2.13 (2H, m), 1.81 (1H, m), 1.49 (1H, m), 1.02 (4.5H, s) and 1.00 (4.5H, s). LRMS: +ve ion 350 [M+Na], -ve ion 326 [M-H].

Example 68

2R-[(Formyl-hydroxy-amino)-methyl]-hex-4-ynoic acid (1S-dimethylcarbamoyl-2,2-dimethyl-propyl)-amide




Diastereoisomer A: colourless oil. ¹H-NMR; δ (CDCl₃, rotamers), 8.39 (0.4H, s), 7.87 (0.6H, s), 7.20 (0.4H, d, J=8.4Hz), 6.94 (0.6H, d, J=9.3Hz), 4.90 (1H, m), 3.66-4.14 (2H, m), 3.16 (2H, s), 3.14 (2H, s), 2.96 (3H, s), 2.88 (1H, m), 2.41 (2H, m), 1.77 (3H, m), 1.00 (3.5H, s) and 0.96 (5.5H, s). LRMS: +ve ion 348 [M+Na], -ve ion 324 [M-H].

Diastereoisomer B: Colourless oil. ¹H-NMR; δ (CDCl₃, rotamers), 8.37 (0.5H, s), 7.81 (0.5H, s), 6.87 (1H, m), 4.91 (0.5H, d, J=9.4Hz), 4.79 (0.5H, d, J=8.2Hz), 3.76 (1.5H, m), 3.63 (0.5H, m), 3.19 (1.5H, s), 3.14 (1.5H, s), 2.98 (3H, s), 2.85 (1H, s), 2.41 (2H, m), 1.77 (3H, m), 1.03 (4.5H, s) and 1.01 (4.5H, s). LRMS: +ve ion 348 [M+Na], -ve ion 324 [M-H].

Example 69


2R-[1R (or S)-(Formyl-hydroxy-amino)-ethyl]-hexanoic acid (1S-dimethylcarbamoyl-

2,2-dimethyl-propyl)-amide



The title compound was prepared according to the route outlined in Scheme 5 and as described in detail below:

Scheme 5



Reagents and conditions: A. (CHO), EtSH, dicyclohexylamine, dioxane, 70°C, 2h; B. BIBuCOCl , Et₃N then 3-*tert*-butyl-4-benzyloxy-5,5-dimethyl-oxazolidin-2-one; C. $\text{HCl} \cdot \text{H}_2\text{NO} \cdot \text{Bu}$, Et₃N, α/n ; D. LiOH, aq THF, 0°C; E. $\text{H} \cdot \text{Leu} \cdot \text{NMe}_2$, HOAc, EDC, DMF; F. HCOAc , CH_2Cl_2 ; G. TFA, CDCl_3 .

Step A: 4-Benzyl-3-hexanoyl-oxazolidin-2-one

4S-Benzyl-oxazolidin-2-one (14.5 g, 81.7 mmol) was dissolved in dry THF (75 ml) under an argon atmosphere. The solution was cooled in an ice bath before slow addition of n-butyllithium (1.6 M in hexanes, 56 ml, 89.2 mmol). The lithium salt crystallised from the solution as a solid mass and was allowed to warm to room temperature overnight. The resulting orange suspension was cooled again in an ice bath during the addition of a cold solution of hexanoyl chloride (10.4 ml, 74.3 mmol) in dry THF (50 ml). The mixture was left to warm to room temperature and was then stirred for 3 hours. The reaction was quenched with 1M sodium carbonate solution (5 ml) and the solvent was removed under reduced pressure. The residue was partitioned between 1 M sodium carbonate (100 ml) and ethyl acetate (150 ml). The organic layer was removed and the aqueous layer was extracted with more ethyl acetate. The combined organic layers were washed successively with water, 1 M sodium carbonate and brine, dried over anhydrous magnesium sulphate and filtered. The filtrate was concentrated to leave an orange oil. Purification by flash chromatography afforded the title compound as a yellow oil (10.21 g, 50%).

¹H-NMR; δ (CDCl₃), 7.38-7.24 (3H, m), 7.24-7.16 (2H, m), 4.68 (1H, m), 4.24-4.12 (2H, m), 3.30 (1H, dd, J=13.4, 3.2 Hz), 3.02-2.86 (2H, m), 2.77 (1H, dd, J=13.4, 9.6 Hz), 1.77-1.63 (2H, m), 1.44-1.30 (4H, m) and 0.92 (3H, br t, J=6.9 Hz).

Step B: 1-(4S-Benzyl-2-oxo-oxazolidin-3-yl)-2R-butyl-butane-1,3-dione

4-Benzyl-3-hexanoyl-oxazolidin-2-one (10.2g, 37.1 mmol) was dissolved in THF (150ml) under an argon atmosphere and cooled to -78 °C. Lithium hexamethyldisilazide (1 M in THF, 41 ml, 41 mmol) was added *via* a cannula over a few minutes and the resulting green solution was stirred at -78°C for 2 hours. Acetyl chloride (3.3 ml, 46.3 mmol) was added slowly and the reaction mixture was stirred for 3.5 hours. A solution of citric acid (3.0 g, 14 mmol) in water (15 ml) was added quickly to quench the reaction. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water, washed with brine,

dried over anhydrous magnesium sulphate and filtered. The filtrate was concentrated to provide the title compound as a yellow oil (12.11 g, contains residual solvent) which was used without further purification in Step C. ¹H-NMR; δ (CDCl₃), 7.37-7.21 (5H, m), 4.68 (1H, m), 4.53 (1H, dd, J=9.6, 3.7 Hz), 4.23-4.13 (2H, m), 3.43 (1H, dd, J=13.5, 3.3 Hz), 2.75 (1H, dd, J=13.5, 9.9 Hz), 2.33 (3H, s), 2.03 (1H, m), 1.77 (1H, m), 1.46-1.26 (4H, m) and 0.98-0.86 (3H, m).

Step C: 1-(4S-Benzyl-2-oxo-oxazolidin-3-yl)-2R-butyl-butane-1,3-dione 3-(O-benzyl-oxime)

To a solution of 1-(4S-benzyl-2-oxo-oxazolidin-3-yl)-2R-butyl-butane-1,3-dione (12.11g, 38.15mmol) in water (10ml) and ethanol (90ml) was added sodium acetate (3.75g, 45.78mmol) and O-benzyl hydroxylamine hydrochloride (7.31g, 45.78mmol). The resulting suspension was left to stir at room temperature overnight. The product (7.3g, 45%, single oxime isomer) crystallised directly from the reaction and was filtered, washed with aqueous ethanol (1:1) and dried under vacuum. Further material (5.31 g, 33%, mixture of oxime isomers) was obtained as a yellow oil from the mother liquors by acid-base extraction followed by column chromatography. ¹H-NMR; δ (CDCl₃, major oxime isomer), 7.34-7.20 (8H, m), 7.12-7.07 (2H, m), 5.14-5.02 (2H, m), 4.53 (1H, m), 4.13 (1H, dd, J=9.4, 4.0 Hz), 4.04 (1H, br t, J=8.4 Hz), 3.91 (1H, dd, J=9.0, 2.7 Hz), 3.16 (1H, dd, J=13.4, 2.9 Hz), 2.09 (3H, s), 1.97 (1H, m), 1.75 (1H, dd, J=13.4, 10.8 Hz), 1.67 (1H, m), 1.45-1.22 (4H, m) and 0.91 (3H, br t, J=6.9 Hz).

Step D: 4S-Benzyl-3-[2R-(1R (or S)-benzyloxyamino-ethyl)-hexanoyl]-oxazolidin-2-one

The mixture of oximes from Step C (5.31 g, 12.5 mmol) was dissolved in acetic acid (30 ml) and cooled in an ice-water bath before addition of sodium cyanoborohydride (0.8 g, 12.5 mmol) in one portion. Effervescence subsided after a few minutes and a further portion of borohydride (0.8 g) was added. The reaction was allowed to

warm to room temperature and stirred overnight. The acetic acid was removed under reduced pressure and the residue was azeotroped with toluene. The resulting oil was dissolved in ethyl acetate, washed with water, 1 M sodium carbonate and brine, dried over anhydrous magnesium sulphate and filtered. The filtrate was evaporated to leave a pale yellow oil which was purified by flash chromatography (silica gel, 10% to 25% ethyl acetate in hexane as eluant). Yield 3.43 g, 64%).

¹H-NMR; δ (CDCl₃, mixture of α -diastereoisomers), 7.36-7.17 (10H, m), 5.80 (0.45H, br s), 5.55 (0.55H, br d, J=8.9 Hz), 4.72-4.59 (3H, m), 4.20-4.05 (2H, m), 3.97 (0.45H, m), 3.82 (0.55H, m), 3.47-3.22 (2H, m), 2.45 (1H, m), 1.90-1.48 (2H, m), 1.40-1.14 (7H, m) and 0.95-0.84 (3H, m).

Step E: N-[2R-(4S-Benzyl-2-oxo-oxazolidine-3-carbonyl)-1R (or S)-methyl-hexyl]-N-benzyloxy- formamide

4S-Benzyl-3-[2R-(1R (or S)-benzyloxyamino-ethyl)-hexanoyl]-oxazolidin- 2-one (3.08 g, 7.3 mmol) was dissolved in dry THF and treated with N-formylbenzotriazole (1.60 g, 10.9 mmol). The reaction was stirred for 4 hours at room temperature. The solvent was removed under reduced pressure and the remaining oil was partitioned between dichloromethane (40 ml) and 1 M sodium hydroxide solution (30 ml). The organic layer was removed, washed with more sodium hydroxide then brine, dried over anhydrous magnesium sulphate, filtered and evaporated. Purification by flash chromatography (silica gel, 20% to 50% ethyl acetate in hexane) gave the title compound as a pale yellow solid (2.50 g, 76%. ¹H-NMR; δ (CDCl₃, mixture of α -diastereoisomers and rotamers), 8.22 (1H, br m), 7.54-7.13 (10H, m), 5.22-3.92 (7H, br m), 3.30 (1H, m), 2.48 (1H, br m), 1.85-1.13 (9H, br m) and 0.93-0.83 (3H, m).

Step F: 2R-[1R (or S)-(Benzyloxy-formyl-amino)-ethyl]-hexanoic acid

N-[2R-(4S-Benzyl-2-oxo-oxazolidine-3-carbonyl)-1R (or S)-methyl-hexyl]-N-benzyloxy- formamide (1.50 g, 3.31 mmol) was dissolved in THF (25 ml) and water (5 ml) and the solution was cooled in an ice-water bath. Hydrogen peroxide

solution (27% w/w), 13.26 mmol) was added followed immediately by lithium hydroxide (167 mg, 3.98 mmol). The reaction was allowed to warm to room temperature and stirred for a further 3 hours. The solution was cooled again before addition of sodium nitrite (0.92 g, 13.3 mmol). After 10 minutes, most of the solvent was removed under reduced pressure to leave a white paste which was partitioned between ethyl acetate (25 ml) and 1M sodium carbonate (30 ml). The organic layer was washed with more sodium carbonate solution and the combined aqueous extracts were washed with ethyl acetate. The aqueous layer was cooled and acidified with 1 M hydrochloric acid and extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous magnesium sulphate, filtered and evaporated to provide the title compound as a green oil (839 mg, 86%). ¹H-NMR; δ (CDCl₃, mixture of α -diastereoisomers and rotamers), 8.40-7.64 (2H, br m), 7.48-7.27 (5H, m), 5.23-4.80 (2H, m), 4.16 (1H, br m), 2.79 (1H, m), 1.67-1.47 (2H, m), 1.47-1.18 (7H, m) and 0.95-0.82 (3H, m).

Step G: 2R-[1R (or S)-(Benzyloxy-formyl-amino)-ethyl]-hexanoic acid (1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide

2R-[1R (or S)-(Benzyloxy-formyl-amino)-ethyl]-hexanoic acid (839 mg, 2.86 mmol), tert-leucine N,N-dimethyl amide (498 mg, 3.15 mmol) and EDC (658 mg, 3.43 mmol) were dissolved together in DMF (15 ml) and a catalytic amount of HOAt (60 mg) was added. The solution was left to stir for several days at room temperature. The solvent was removed under reduced pressure and the remaining oil was partitioned between ethyl acetate and 1 M hydrochloric acid (75 ml). The organic layer was washed successively with 1 M hydrochloric acid, 1 M sodium carbonate and brine, dried over anhydrous magnesium sulphate filtered and evaporated to leave a yellow foam (1.08 g, 82%). ¹H-NMR; δ (CDCl₃, mixture of α -diastereoisomers and rotamers), 8.13 (1H, br m), 7.52-7.31 (5H, m), 6.28 (1H, br m), 5.36-4.67 (3H, br m), 4.09 (1H, br m), 3.14 (3H, s), 2.95 (1.2H, s), 2.93 (1.8H, s), 2.48 (1H, br m), 1.61-1.04 (9H, m), 0.99 (3.6H, s), 0.95 (5.4H, s) and 0.89-0.75 (3H, m).

Step H: 2R-[1R (or S)-(Formyl-hydroxy-amino)-ethyl]-hexanoic acid (1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide

2R-[1R (or S)-(Benzyloxy-formyl-amino)-ethyl]-hexanoic acid (1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide (200 mg, 0.46 mmol) was dissolved in methanol (15 ml) and placed under a blanket of argon. A suspension of 10% palladium on charcoal (20 mg) in ethyl acetate was added and the mixture was stirred under an atmosphere of hydrogen for 3 hours. The catalyst was removed by filtration and the filtrate was evaporated to leave a colourless oil (163 mg, quant.).


The two diastereoisomeric products were separated by preparative HPLC.

Diastereoisomer A (27mg): $^1\text{H-NMR}$; δ (CDCl_3 , mainly one rotamer), 8.67 (0.9H, br s), 8.33 (0.1H, br s), 7.92 (1H, s), 6.74 (0.1H, br m), 6.54 (0.9H, d, $J=9.4$ Hz), 4.93 (0.9H, d, $J=9.4$ Hz), 4.64 (0.1H, br m), 3.89 (1H, qd, $J=6.6, 2.6$ Hz), 3.16 (3H, s), 2.96 (3H, s), 2.62-2.48 (1H, m), 1.52-1.06 (6H, m), 1.35 (3H, d, $J=6.6$ Hz), 1.00 (9H, s) and 0.82 (3H, t, $J=6.9$ Hz). $^{13}\text{C-NMR}$; δ (CDCl_3), 173.0, 171.3, 57.2, 54.4, 50.4, 38.4, 35.6, 29.9, 29.1, 26.6, 22.5, 17.2 and 13.9. LRMS: +ve ion 366 $[\text{M}+\text{Na}]$, -ve ion 342 $[\text{M}-\text{H}]$.

Diastereoisomer B (42mg): $^1\text{H-NMR}$; δ (CDCl_3 , mixture of rotamers), 9.15 (0.6H, s), 8.60 (0.4H, br s), 8.42 (0.6H, s), 7.84 (0.4H, s), 6.83 (0.6H, d, $J=9.2$ Hz), 6.55 (0.4H, d, $J=9.4$ Hz), 4.91 (0.6H, d, $J=9.2$ Hz), 4.89 (0.4H, d, $J=9.4$ Hz), 4.69 (0.6H, qd, $J=7.0, 4.3$ Hz), 3.92 (0.4H, dq, $J=9.1, 6.8$ Hz), 3.15 (3H, s), 2.97 (1.8H, s), 2.95 (1.2H, s), 2.59 (0.4H, td, $J=9.8, 4.3$ Hz), 2.39 (0.6H, td, $J=7.4, 4.3$ Hz), 1.92-1.07 (6H, m), 1.37 (1.2H, d, $J=6.8$ Hz), 1.31 (1.8H, d, $J=7.0$ Hz), 1.01 (5.4H, s), 0.96 (3.6H, s), 0.85 (1.8H, t, $J=7.2$ Hz) and 0.83 (1.2H, t, $J=7.2$ Hz). $^{13}\text{C-NMR}$; δ (CDCl_3 , mixture of rotamers), 175.7, 173.2, 171.3, 170.7, 56.7, 55.0, 54.4, 53.2, 50.8, 49.9, 38.3, 35.7, 35.6, 35.5, 35.4, 30.3, 29.5, 29.3, 26.5, 26.4, 22.5, 22.4, 16.0, 15.4 and 13.8. LRMS: +ve ion 366 $[\text{M}+\text{Na}]$, -ve ion 342 $[\text{M}-\text{H}]$.

Example 70

N-cyclohexyl-2-{2-[(formyl-hydroxy-amino)-methyl]-3-phenyl-propionylamino}-3,3-dimethyl-butamide




Stock solutions of 1 M ammonia in methanol (1 ml, 1 mmol) and 1 M trimethylacetaldehyde in methanol (1ml, 1mmol) were mixed in a boiling tube and allowed to stand for 1 hour. A 1 M solution of cyclohexyl isocyanide in methanol (1 ml, 1 mmol) was added followed by 0.5 M 2RS-[(benzyloxy-formyl-amino)-methyl]-hexanoic acid in methanol (2 ml, 1 mmol). The reaction mixture was allowed to stir at room temperature for 2 days. The solvent was removed using a Savant Speedvac and the reaction mixture was crystallised from ethylacetate-hexane to provide 2-{2-[(benzyloxy-formyl-amino)-methyl]-3-phenyl-propionylamino}-N-cyclohexyl-3,3-dimethyl-butamide as a white solid (93 mg, 18%), which was deprotected by catalytic transfer hydrogenolysis (hydrogen gas, 10% palladium on charcoal, methanol-ethyl acetate) to provide the title compound (75 mg, 99%). White solid. LRMS: +ve ion 440 [M+Na], 418 [M+H], -ve ion 416 [M-H].

The compounds of Examples 71 to 77 were prepared in parallel using the Ugi 4 component condensation reaction, as described above. All products were obtained in >85% purity as determined by HPLC.

Example 71


2-{2-[(Formyl-hydroxy-amino)-methyl]-3-phenyl-propionylamino}-3,3-dimethyl-hexanoic acid cyclohexyl amide



White solid (90 mg). ¹H-NMR; δ (CD₃OD), 7.82 (1H, s), 7.29-7.08 (5H, m), 4.20 (1H, d, J=5.0 Hz), 3.89 (1H, m), 3.19 (1H, m), 2.95-2.67 (2H, m), 1.88-1.58 (5H, br m), 1.44-1.05 (9H, br m) and 0.89 (9H, s). LRMS: +ve ion 468 [M+Na], 446 [M+H], -ve ion 444 [M-H].

Example 72

2-{2-[(Formyl-hydroxy-amino)-methyl]-3-phenyl-propionylamino}-3,3-dimethyl-hexanoic acid phenylmethyl amide




White solid (77 mg). ¹H-NMR; δ (CD₃OD), 7.82 (1H, s), 7.35-7.11 (10H, m), 4.38-4.19 (3H, m), 3.85 (1H, m), 3.52 (1H, m), 2.97-2.63 (3H, m), 1.37-1.11 (4H, m)

and 0.93-0.78 (9H, m). LRMS: +ve ion 476 [M+Na], 454 [M+H].

Example 73


2-{2-[(Formyl-hydroxy-amino)-methyl]-3-phenyl-propionylamino}-3,3-dimethyl-butyrlic acid tert-butyl amide



White solid (47 mg). $^1\text{H-NMR}$; δ (CD_3OD), 7.82 (1H, s), 7.45 (1H, m), 7.30-7.09 (5H, m), 4.12 (1H, d, $J=7.2$ Hz), 3.89 (1H, m), 3.41 (1H, m), 3.15 (1H, m), 2.97-2.68 (2H, m), 1.28 (9H, s) and 0.92 (9H, s). LRMS: +ve ion 414 [M+Na], 392 [M+H], -ve ion 390 [M-H].

Example 74


2-{2-[(formyl-hydroxy-amino)-methyl]-3-phenyl-propionylamino}-3,3-dimethyl-hexanoic acid (1,1,3,3-tetramethyl)-butyramide



White solid (65 mg). $^1\text{H-NMR}$; δ (CD_3OD), 7.79 (1H, s), 7.42-7.21 (1H, m), 7.20-7.10 (5H, m), 4.23 (1H, d, $J=9.1$ Hz), 3.86 (1H, m), 3.51 (1H, m), 3.23 (1H, m), 3.00-2.56 (2H, m), 1.50-1.15 (12H, m) and 1.02-0.83 (18H, m). LRMS: +ve ion 498 $[\text{M}+\text{Na}]$, 476 $[\text{M}+\text{H}]$, -ve ion 474 $[\text{M}-\text{H}]$.

Example 75

N-(Cyclohexyl-cyclohexylcarbamoyl-methyl)-2-[(formyl-hydroxy-amino)-methyl]-3-phenyl-propionamide




White solid (98 mg). $^1\text{H-NMR}$; δ (CD_3OD), 7.38-7.08 (5H, m), 4.01 (1H, m), 3.81 (1H, m), 3.68-3.35 (2H, m), 3.15 (1H, m), 2.98-2.65 (2H, m), 1.88-1.49 (10H, br m) and 1.45-0.83 (11H, br m). LRMS: +ve ion 466 $[\text{M}+\text{Na}]$, 444 $[\text{M}+\text{H}]$, -ve ion 442 $[\text{M}-\text{H}]$.

Example 76

N-(Cyclohexyl-phenylmethylcarbamoyl-methyl)-2-[(formyl-hydroxy-amino)-methyl]-3-phenyl-propionamide


102



White solid (34 mg). $^1\text{H-NMR}$; δ (CD_3OD), 7.35-7.10 (10H, m), 4.44-4.23 (2H, m), 4.05 (1H, m), 3.87-3.35 (2H, m), 3.09 (1H, m), 2.85-2.72 (2H, m), 1.65-1.46 (4H, m), 1.38-0.93 (5H, br m) and 0.75-0.51 (2H, br m). LRMS: +ve ion 474 $[\text{M}+\text{Na}]$, -ve ion 450 $[\text{M}-\text{H}]$.

Example 78

N-[Cyclohexyl-(1,1,3,3-tetramethyl-butylcarbamoyl)-methyl]-2-[(Formyl-hydroxy-amino)-methyl]-3-phenyl-propionamide



White solid (51 mg). $^1\text{H-NMR}$; δ (CD_3OD), 7.80 (1H, s), 7.36-7.10 (5H, m), 4.05 (1H, m), 3.85 (1H, m), 3.49 (1H, m), 3.15 (1H, m), 2.91 (1H, m), 2.68 (1H, m), 1.90 (1H, m), 1.80-1.48 (7H, m), 1.40-1.12 (10H, m) and 1.08-0.83 (10H, m). LRMS: +ve ion 496 $[\text{M}+\text{Na}]$, 474 $[\text{M}+\text{H}]$, -ve ion 472 $[\text{M}-\text{H}]$.

Biological Example A

Demonstration of antibacterial effect of compound 1 (Example 1) and compound 2 (Example 2).

a).

Minimal inhibitory concentrations (MIC) of inhibitors against *E. coli* strain DH5 α (Genotype; F- ϕ 80d/lacZ Δ M15 Δ (lacZYA-argF)U169 *deoR recA1 endA1 hsdR17*(r_k⁻,m_k⁺)*phoA supE44* λ *thi-1 gyrA96 relA1*) obtained from GibcoBRL Life Technologies, *Enterobacter cloacae* (American Type Culture Collection number 13047), *Klebsiella pneumoniae* (American Type Culture Collection number 13883) or *Staphylococcus capitis* (American Type Culture Collection number 35661) were determined as follows. Stock solutions of test compound (Compounds 1 and 2 from Examples 1 and 2 respectively (both isomer A)) and three standard laboratory antibiotics, carbenicillin (Sigma, catalogue No. C3416), kanamycin (Sigma, catalogue No. K4000) and chloramphenicol (Sigma, catalogue No. C1919), were prepared by dissolution of each compound in dimethylsulfoxide at 10mM. For the determination of the minimal inhibitory concentration, two fold serial dilutions were prepared in 2xYT broth (typtone 16g/1, yeast extract 10g/1, sodium chloride 5g/1 obtained from BIO 101 Inc, 1070 Joshua Way, Vista, CA92083, USA) to yield 0.05 ml compound-containing medium per well. Inocula were prepared from cultures grown overnight in 2xYT broth at 37°C. Cell densities were adjusted to absorbance at 660nm (A_{660}) = 0.1; the optical density-standardized preparations were diluted 1:1000 in 2xYT broth; and each well inoculated with 0.05ml of the diluted bacteria. Microtiter plates were incubated at 37°C for 18 hours in a humidified incubator. The MIC (μ M) was recorded as the lowest drug concentration that inhibited visible growth.

Table 1

	MIC μ M				
	carbenicillin	chloramphenicol	kanamycin	compound 1	compound 2
<i>E. coli</i> DH5 α	25	3.12	12.5	12.5	6.25
<i>Staphylococcus capitis</i>	<1.56	6.25	<1.56	100	25
<i>Enterobacter cloacae</i>	>200	25	50	50	25
<i>Klebsiella pneumoniae</i>	200	12.5	25	25	12.5

b).

Minimal inhibitory concentrations (MIC) of inhibitors against *Mycobacterium ranae* (American Type Culture Collection number 110), *Pseudomonas aeruginosa* (American Type Culture Collection number 9027), *Klebsiella pneumoniae* (American Type Culture Collection number 10031), *Helicobacter pylori* (American Type Culture Collection number 43504), clinical isolates of aminoglycoside and erythromycin resistant *Streptococcus pneumoniae* and methicillin-resistant (MR) *Staphylococcus aureus* (American Type Culture Collection number 33591) were determined as follows. Stock solutions of test compounds 1 and 2 (isomer A for each) and three standard laboratory antibiotics, gentamycin (G), ampicillin (A) and erythromycin (E), were prepared by dissolution of each compound at 10mg/ml in dimethylsulfoxide. Methods used were as for a) except that the medium of *Mycobacterium ranae* was used with Brain Heart Infusion broth (GIBCO) and incubated at 37°C for 48 hours, *Staphylococcus aureus* (MR), *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* were used with Nutrient Broth (DIFCO) and incubated at 37°C for 20 hours, *Helicobacter pylori* was used with Columbia agar base (OXOID) containing 7% sheep blood and incubated at 35°C for 72 hours and, *Streptococcus*

pneumoniae was used with tryptic soy broth (DIFCO) containing 7% calf serum and incubated at 37°C for 48 hours. The MIC ($\mu\text{g/ml}$) was recorded as the lowest drug concentration that inhibited visible growth.

Positive vehicle control (1% DMSO; no test agent) caused growth of all microorganisms.

Negative blank control (absence of microorganisms; + test agent) revealed no growth of microorganisms.

Table 2.

	MIC $\mu\text{g/ml}$				
	compound 1.	compound 2.	antibiotic		
			G	A	E
<i>M. ranae</i>	0.78	0.2	0.2	nd	nd
<i>S. aureus (MR)</i>	3.13	1.56	0.78	nd	nd
<i>K. pneumoniae</i>	0.2	0.1	0.39	nd	nd
<i>P. aeruginosa</i>	12.5	12.5	0.78	100	nd
<i>H. pylori</i>	0.1	0.1	0.78	0.1	nd
<i>S. pneumoniae</i>	50	12.5	100	3.13	100

nd = not determined.

In another experiment, minimal inhibitory concentrations of compounds 1 and the product of Example 4 (compound 3) against a range of Gram-positive and Gram-negative bacteria were determined using the Microdilution Broth Method according to the approved standard of the National Committee for Clinical Laboratory Standards procedure (Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-Fourth Edition ISBN 1-56238-309-4)

Activity against Gram-positive bacteria

Bacterial Strain	MIC µg/ml		
	Compound 3	Compound 1	Vancomycin
<i>Staphylococcus aureus</i> ATCC 29213 MSSA	8	32	0.25
<i>Staphylococcus aureus</i> ATCC 25923 MSSA	16	16	0.5
<i>Staphylococcus aureus</i> ATCC 6538 MSSA	4	8	0.5
<i>Staphylococcus epidermidis</i> ATCC 1228	4	8	0.5
<i>Staphylococcus epidermidis</i> ATCC 27626	2	8	0.5
<i>Enterococcus faecalis</i> ATCC 29212	32	32	1
<i>Enterococcus faecalis</i> (Vancomycin resistant strain)	8	128	>128
<i>Micrococcus luteus</i> ATCC 9341	0.5	0.5	0.25

Activity against Gram-negative bacteria

Bacterial Strain	MIC µg/ml		
	Compound 3	compound 1	Ciprofloxacin
<i>Escherichia coli</i> ATCC 25922	4	4	<0.125

<i>Escherichia coli</i> ATCC 12014	4	4	<0.125
<i>Pseudomonas aeruginosa</i> ATCC 27853	128	>128	<0.125
<i>Enterobacter cloacae</i> ATCC 13047	32	32	<0.125
<i>Morganella morganii</i> ATCC 36030	>128	128	<0.125
<i>Klebsiella pneumoniae</i> ATCC 13883	16	16	<0.125

The activities of compound 3 and the product of Example 14 (compound 4) against a multi-resistant *Enterococcus faecalis* clinical isolate, assessed by the method used for the immediately preceding results, are set out in the following table, and compared with the results obtained by the same method for known antibacterial agents:

Activity against a multi-resistant *Enterococcus faecalis* clinical isolate:

Bacterial Strain	MIC µg/ml							
	Cpd 3	Cpd 4	Ampicillin	Ceftazidime	Imipenem	Erythromycin	Ciprofloxacin	Vancomycin
<i>Enterococcus faecalis</i> ATCC 29212	32	8	0.5	128	1	2	0.5	1
<i>Enterococcus faecalis</i> Vancomycin resistant strain	8	4	>128	>128	>128	>128	>128	>128

Biological Example B

i) *Cloning of the Escherichia coli PDF gene.*

The *E. coli* PDF gene was cloned in pET24a(+) (designated pET24-PDF) and was used to transform BL21 DE3 cells from Novagen Inc, (Madison, Wisconsin). Clones were selected at 37°C on YT agar plates (8g/l typtone, 5g/yeast extract, NaCl 5g/l, agar 15g/l) supplemented with 30µg/ml kanamycin.

ii) *Expression of PDF*

A 20ml overnight culture of BL21 DE3 cells harbouring pET24-PDF was used to infect 500ml 2xYT broth (16g/l typtone, 10g/l yeast extract, NaCl 5g/l) containing 30ug/ml kanamycin in a 2 litre baffled flask and grown at 37°C with shaking to an OD₆₀₀ 0.6. The culture was then induced by adjusting the medium to 1.0mM isopropyl β-D thiogalactopyranoside (IPTG). The induction was allowed to proceed for a further 3 hours at 37°C, the cells were harvested by centrifugation and the cell pellet washed with 250ml phosphate buffered saline (PBS) and the pellet stored at -70°C.

iii) *Preparation of soluble protein fraction.*

The cells from a 1 litre expression were resuspended in 2x 25ml of ice cold phosphate buffered saline. The cell suspension was sonicated on ice using an MSE Soniprep 150 fitted with a medium probe and at an amplitude of 20-25 microns in 6x20 second pluses. The resulting suspension was then cleared by centrifugation at 20,000 xg for 15 minutes. The supernatant was then used for further purification of the enzyme.

iv) *PDF Purification*

E. coli lysate from a 1l culture in phosphate buffered saline (PBS) were adjusted to 2M ammonium sulphate. A 15ml phenyl sepharose column was equilibrated with PBS/2M ammonium sulphate at 4°C. The lysate was loaded on the column and washed with equilibration buffer. The column was eluted by reducing the ammonium sulphate concentration from 2M to 0M over 10 column volumes. 5ml fractions were collected and analysed by SDS-PAGE. The fractions containing the majority of the 20kDa PDF were pooled. The pooled fractions were concentrated using a 3kDa cutoff membrane to a volume of 5ml. The fraction was then loaded onto a Superdex 75 (size exclusion chromatography) column equilibrated in PBS. The concentrated PDF pool eluted at one ml/min at 4°C and 5ml fractions collected and analysed by SDS-PAGE. The purest fractions were pooled and stored at -70°C.

(v) *PDF in vitro assay*

The assay was performed in a single 96 well plate in a final volume of 100µl containing:

- 20µl PDF (4µg/ml)
- 20µl 100mM Hepes pH 7.0 + 1M KCl + 0.05% Brij
- 10µl serial dilution of test compound in 20% DMSO
- 50µl formyl-Met-Ala-Ser (8mM)

The assay was incubated at 37°C for 30 minutes. The free amino group of the deformedylated (Met-Ala-Ser) product was detected using fluorescamine, by the following additions:

- 50µl 0.2M borate pH 9.5
- 50µl fluorescamine (150µg/ml in dry dioxane)

Fluorescence was quantified on SLT Fluostar plate reader using an excitation wavelength of 390nm and an emission wavelength of 485nm. Standard control

reactions are a no inhibitor reaction which provides the zero inhibition figure and a no enzyme and no inhibitor reaction which provides the 100% inhibition figure. The data was analysed by conversion of the fluorescence units to % inhibition and the inhibitor concentration plotted against % inhibition. The data was fitted to a sigmoidal function : $y = A + ((B-A)/(1 + ((C/x)^D)))$, wherein A represents zero inhibition, B represents 100% inhibition and C represents the IC_{50} , D represents the slope. The IC_{50} represents the concentration of inhibitor (nM) required to decrease enzyme activity by 50%.

Compounds of the invention were found to inhibit bacterial PDF *in vitro*. In addition, actinonin (Sigma Cat. No. A-6671) was also found to inhibit bacterial PDF *in vitro*.

Biological Example C

Demonstration that compound 2 inhibits PDF in vivo.

1 *Blocking the tRNAⁱ-Met transformylation reaction confers resistance to Compound 2 (diastereomer/isomer A).*

Trimethoprim specifically inhibits dihydrofolate reductase, thereby depressing the pools of tetrahydrofolate (THF) derivatives, including formyl tetrahydrofolate (fTHF), the substrate of the methionyl-tRNA formyltransferase (EC 2.1.2.9). If all essential metabolites whose biosynthesis involves THF derivatives, eg pantothenate, methionine, glycine, purine nucleotides and thymidine are supplied exogenously in the form of precursor compounds in rich medium supplemented with thymidine, then bacteria grown in rich medium plus thymidine (0.3mM) and trimethoprim (100µg/ml) can synthesize all the chemical components of normal cells except f-Met-tRNAⁱ (Baumstark *et al.*, J. Bacteriol. 129:457-471, 1977). Unformylated Met-tRNAⁱ is used instead, resulting in the formation of polypeptides devoid of a formyl group at their N-terminus, independently of the action of deformylase. As predicted by the inventors, DH5α cells grown in LB medium (typtone 10g/l, yeast extract 5g/l NaCl 10g/l pH7.5) supplemented with trimethoprim and thymidine, were found to be resistant to

compound 2 (diastereomer A). The demonstration that cells that undergo the normal formylation process on expressed proteins are inhibited by compound 2A whereas, unformylated proteins, as produced in the cells grown under these conditions, are not inhibited by compound 2A demonstrates that compound 2A is likely to work by inhibiting the deformylation reaction carried out by PDF.

Table 3.

growth conditions	minimal inhibitory concentration μM
LB	15
LB trimethoprim (100 $\mu\text{g/ml}$), thymidine (0.3mM)	>200

2 *Treatment of bacteria with compound 2A leads to the accumulation of N-terminally blocked proteins.*

If the compounds of the invention do actually inhibit PDF *in vivo*, then a consequence of treatment of bacteria with compound 2 (Example 2, diastereomer A) will be the accumulation of N-formyl methionine at the N-terminus of newly synthesised proteins. Such proteins will be N-terminally blocked and will be unable to be used as a substrate for N-terminal sequencing by Edman degradation chemistry.

To test this hypothesis a desired protein is expressed in the presence or absence of the test compound. The protein is isolated, purified and then subjected to Edman degradation protein sequencing using techniques known to the person skilled in the art.

Bacterial cells transformed with an expression vector allowing expression of the human calpain small regulatory subunit, were grown to an OD_{600} of 0.6 and then subjected to IPTG to induce expression of the heterologous protein in the presence

of 200 μ M compound 2A, in the presence of 240 μ M carbenicillin or, in the presence of vehicle control for 2.5 hours. Protein extracts were separated by SDS-PAGE, the calpain subunit eluted and the protein sequence determined by Edman degradation chemistry using the ABI automated protein sequencer. Equal quantities of protein were sequenced. The inventors found that the yield of the compound 2A treated protein was significantly reduced by 85% compared to vehicle and carbenicillin treated controls.


Calpain small regulatory subunit was cloned from messenger RNA obtained from a gastric tumour biopsy using the InVitrogen Micro Fast Track™ mRNA isolation kit version 2.2 (catalogue number K1520-02). Copy DNA from this mRNA was synthesised using the Promega Riboclone™ cDNA synthesis system M-MLV-RT(H-), NotI (Promega, Catalogue number C1660) according to the manufactures instructions. Two oligonucleotide primers for use in the polymerase chain reaction (PCR) were synthesised by Applied Biosystems, Inc., Custom Services, based on the published calpain small subunit sequence (EMBL Accession number X04106).

The *HindIII/XhoI* calpain fragment was then cloned into *HindIII* and *XhoI* digested expression vector pET24d(+) from Novagen Inc, (Madison, WI, USA) using standard procedures. The ligation mixture was used to transform competent DH5 α cells (Life Technologies, Inc, Grand Island, NY, USACat # 18265-017). Colonies were selected by growth overnight at 37°C on YT plates plus 30 μ g/ml kanamycin. Plasmid DNA was prepared as using the Promega Plus SV miniprep kit and clones with the calpain insert were identified using standard procedures. The DNA sequence was confirmed using the PE Applied Biosystems cycle sequencing as described above.

The *E. coli* gene cloned in pET24d(+) (designated pET24-CANS) was used to transform BL21 DE3 cells from Novagen Inc, (Madison, Wisconsin). Clones were selected at 37°C on YT agar plates (8g/l typtone, 5g/yeast extract, NaCl 5g/l, agar 15g/l) supplemented with 30 μ g/ml kanamycin.

Claims

1. The use of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof in the preparation of an antibacterial composition:



wherein:

R_1 represents hydrogen, or C_1 - C_6 alkyl or C_1 - C_6 alkyl substituted by one or more halogen atoms;

R_2 represents a group R_{10} -(X) $_n$ -(ALK) $_m$ - wherein


R_{10} represents hydrogen, or a C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C_1 - C_6)alkyl, (C_1 - C_6)alkoxy, hydroxy, mercapto, (C_1 - C_6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, $-COOH$, $-CONH_2$, $-COOR^A$, $-NHCOR^A$, $-CONHR^A$, $-NHR^A$, $-NR^A R^B$, or $-CONR^A R^B$ wherein R^A and R^B are independently a (C_1 - C_6)alkyl group, and

ALK represents a straight or branched divalent C_1 - C_6 alkylene, C_2 - C_6 alkenylene, or C_2 - C_6 alkynylene radical, and may be interrupted by one or more non-adjacent $-NH-$, $-O-$ or $-S-$ linkages,

X represents $-NH-$, $-O-$ or $-S-$, and

m and n are independently 0 or 1; and

A represents (i) a group of formula (IA), (IB), (IC) or (ID)



wherein:

R_3 represents hydrogen and R_4 represents the side chain of a natural or non-natural alpha amino acid or R_3 and R_4 when taken together with the nitrogen and carbon atoms to which they are respectively attached form an optionally substituted saturated heterocyclic ring of 5 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring,

R_5 and R_6 , independently represent hydrogen, or optionally substituted C_1 - C_8 alkyl, cycloalkyl, aryl, aryl(C_1 - C_6 alkyl), heterocyclic, or heterocyclic(C_1 - C_6 alkyl), or R_5 and R_6 when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring, and

R_7 represents hydrogen, C_1 - C_6 alkyl, or an acyl group.

2. A method for the treatment of bacterial infections in humans and non-human mammals, which comprises administering to a subject suffering such infection an antibacterially effective dose of a compound of formula (I) as defined in claim 1.
3. The use as claimed in claim 1 or a method as claimed in claim 2 wherein in the compound of formula (I):

R₁ represents hydrogen, or C₁-C₆ alkyl;

R₂ represents a group R₁₀-(X)_n-(ALK)- wherein

R₁₀ represents hydrogen, a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, a cycloalkyl, aryl, or heteroaryl group, any of which may be unsubstituted or substituted by (C₁-C₆)alkyl, (C₁-C₆)alkoxy, hydroxy, mercapto, (C₁-C₆)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C₁-C₆)alkyl group, and

ALK represents a straight or branched divalent C₁-C₆ alkylene, C₂-C₆ alkenylene, C₂-C₆ alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages,

X represents -NH-, -O- or -S-, and

n is 0 or 1; and

R₃ represents hydrogen or C₁-C₆ alkyl, and

R₄ represents the side chain of a natural or non-natural alpha amino acid, and


R₅ and R₆, independently represent hydrogen or C₁-C₆ alkyl, or R₅ and R₆ when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms, and

R₇ represents hydrogen or an acyl group.

4. An antibacterial pharmaceutical or veterinary composition comprising a compound of formula (I) as defined in claim 1 and an antibacterial agent other than

one of formula (I) as defined in claim 1, together with a pharmaceutically or veterinarily acceptable excipient or carrier.

5. A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof



R_1 represents hydrogen, C_1 - C_6 alkyl or C_1 - C_6 alkyl substituted by one or more halogen atoms;


R_2 represents a group R_{10} -(ALK) $_m$ - wherein

R_{10} represents hydrogen, or a C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, a cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C_1 - C_6)alkyl, (C_1 - C_6)alkoxy, hydroxy, mercapto, (C_1 - C_6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C_1 - C_6)alkyl group,

ALK represents a straight or branched divalent C_1 - C_6 alkylene, C_2 - C_6 alkenylene, C_2 - C_6 alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages, and

m represents 0 or 1;

A represents (i) a group of formula (IA), (IB), (IC) or (ID)



wherein:

R_3 represents hydrogen and R_4 represents the side chain of a natural or non-natural alpha amino acid or R_3 and R_4 when taken together with the nitrogen and carbon atoms to which they are respectively attached form an optionally substituted saturated heterocyclic ring of 5 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring,

R_5 and R_6 , independently represent hydrogen, or optionally substituted C_1 - C_8 alkyl, cycloalkyl, aryl(C_1 - C_6 alkyl), non-aromatic heterocyclic, or heterocyclic(C_1 - C_6 alkyl), or R_5 and R_6 when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring, and

R_7 represents hydrogen, C_1 - C_8 alkyl, or an acyl group.

PROVIDED THAT (i) when A is a group of formula (IA) or (IB) and R_2 is C_2 - C_5 alkyl then R_4 is not the side chain of a natural alpha amino acid or the side chain of a natural alpha-amino acid in which any functional substituents are protected, any amino groups are acylated, and any carboxyl groups are esterified; (ii) when A is a group of formula (IA) or (IB) then R_4 is not a bicyclicarylmethylene group; and (iii) when A is a group of formula (IA) and R_2 is cyclopropylmethyl, cyclobutylmethyl or cyclopentylmethyl and one of R_5 and R_6 is hydrogen, then R_4 is not tert-butyl.

6. A compound as claimed in claim 5 wherein:

R₁ represents hydrogen, or C₁-C₆ alkyl;

R₂ represents a group R₁₀-(ALK)- wherein

R₁₀ represents hydrogen, a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, a cycloalkyl, aryl, or heteroaryl group, any of which may be unsubstituted or substituted by (C₁-C₆)alkyl, (C₁-C₆)alkoxy, hydroxy, mercapto, (C₁-C₆)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C₁-C₆)alkyl group, and

ALK represents a straight or branched divalent C₁-C₆ alkylene, C₂-C₆ alkenylene, C₂-C₆ alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages;

R₃ represents hydrogen or C₁-C₆ alkyl,

R₄ represents the side chain of a natural or non-natural alpha amino acid,

R₅ and R₆, independently represent hydrogen or C₁-C₆ alkyl, or R₅ and R₆ when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms, and

R₇ represents hydrogen or an acyl group;

PROVIDED THAT when A is a group of formula (IA) then (i) R₄ is not the side chain of a natural alpha amino acid or the side chain of a natural alpha-amino acid in which any functional substituents are protected, any amino groups are acylated, and any carboxyl groups are esterified, (ii) R₄ is not a fused bicyclicarylmethylene group, and (iii) R₄ is not tert-butyl when R₂ is cycloalkyl(C₁-C₆ alkyl).

7. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_1 is hydrogen.

8. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_2 is:

optionally substituted C_1 - C_8 alkyl, C_3 - C_6 alkenyl, C_3 - C_6 alkynyl or cycloalkyl;

phenyl(C_1 - C_8 alkyl)-, phenyl(C_3 - C_6 alkenyl)- or phenyl(C_3 - C_6 alkynyl)-
optionally substituted in the phenyl ring;

cycloalkyl(C_1 - C_8 alkyl)-, cycloalkyl(C_3 - C_6 alkenyl)- or cycloalkyl(C_3 - C_6 alkynyl)-
optionally substituted in the cycloalkyl ring;

heterocyclyl(C_1 - C_8 alkyl)-, heterocyclyl(C_3 - C_6 alkenyl)- or heterocyclyl(C_3 - C_6 alkynyl)- optionally substituted in the heterocyclyl ring; or

$CH_3(CH_2)_pO(CH_2)_q-$ or $CH_3(CH_2)_pS(CH_2)_q-$, wherein p is 0, 1, 2 or 3 and q is 1, 2 or 3.

9. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_2 is methyl, ethyl, n- or iso-propyl, n- and iso-butyl, n-pentyl, iso-pentyl, 3-methyl-but-1-yl, n-hexyl, n-heptyl, n-acetyl, n-octyl, methylsulfanylethyl, ethylsulfanylmethyl, 2-methoxyethyl, 2-ethoxyethyl, 2-ethoxymethyl, 3-hydroxypropyl, allyl, 3-phenylprop-3-en-1-yl, prop-2-yn-1-yl, 3-phenylprop-2-yn-1-yl, 3-(2-chlorophenyl)prop-2-yn-1-yl, but-2-yn-1-yl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, furan-2-ylmethyl, furan-3-methyl, tetrahydrofuran-2-ylmethyl, tetrahydrofuran-2-ylmethyl, piperidinylmethyl, phenylpropyl, 4-

chlorophenylpropyl, 4-methylphenylpropyl, 4-methoxyphenylpropyl, benzyl, 4-chlorobenzyl, 4-methylbenzyl, or 4-methoxybenzyl.

10. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_2 is n-butyl, benzyl or cyclopentylmethyl.

11. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_3 is hydrogen.

12. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_4 is:

the characterising group of a natural α amino acid, for example benzyl, or 4-methoxyphenylmethyl, in which any functional group may be protected, any amino group may be acylated and any carboxyl group present may be amidated; or

a group $-[Alk]_nR_9$ where Alk is a (C_1-C_6) alkylene or (C_2-C_6) alkenylene group optionally interrupted by one or more -O-, or -S- atoms or $-N(R_{12})$ - groups [where R_{12} is a hydrogen atom or a (C_1-C_6) alkyl group], n is 0 or 1, and R_9 is hydrogen or an optionally substituted phenyl, aryl, heterocyclyl, cycloalkyl or cycloalkenyl group or (only when n is 1) R_9 may additionally be hydroxy, mercapto, (C_1-C_6) alkylthio, amino, halo, trifluoromethyl, nitro, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C_1-C_6) alkyl group; or

a benzyl group substituted in the phenyl ring by a group of formula -OCH₂COR₈ where R₈ is hydroxyl, amino, (C_1-C_6) alkoxy, phenyl (C_1-C_6) alkoxy,

(C₁-C₈)alkylamino, di((C₁-C₆)alkyl)amino, phenyl(C₁-C₈)alkylamino; or

a heterocyclic(C₁-C₆)alkyl group, either being unsubstituted or mono- or disubstituted in the heterocyclic ring with halo, nitro, carboxy, (C₁-C₆)alkoxy, cyano, (C₁-C₆)alkanoyl, trifluoromethyl (C₁-C₆)alkyl, hydroxy, formyl, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, mercapto, (C₁-C₆)alkylthio, hydroxy(C₁-C₆)alkyl, mercapto(C₁-C₆)alkyl or (C₁-C₆)alkylphenylmethyl; or

a group -CR_aR_bR_c in which:

each of R_a, R_b and R_c is independently hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl(C₁-C₆)alkyl, (C₃-C₈)cycloalkyl; or

R_c is hydrogen and R_a and R_b are independently phenyl or heteroaryl such as pyridyl; or

R_c is hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl(C₁-C₆)alkyl, or (C₃-C₈)cycloalkyl, and R_a and R_b together with the carbon atom to which they are attached form a 3 to 8 membered cycloalkyl or a 5- to 6-membered heterocyclic ring; or

R_a, R_b and R_c together with the carbon atom to which they are attached form a tricyclic ring (for example adamantyl); or

R_a and R_b are each independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl(C₁-C₆)alkyl, or a group as defined for R_c below other than hydrogen, or R_a and R_b together with the carbon atom to which they are attached form a cycloalkyl or heterocyclic ring, and R_c is hydrogen, -OH, -SH, halogen, -CN, -CO₂H, (C₁-C₄)perfluoroalkyl, -CH₂OH, -CO₂(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -O(C₂-C₆)alkenyl, -S(C₁-C₆)alkyl, -SO(C₁-C₆)alkyl, -SO₂(C₁-C₆)alkyl, -S(C₂-C₆)alkenyl, -SO(C₂-C₆)alkenyl, -SO₂(C₂-

C₈)alkenyl or a group -Q-W wherein Q represents a bond or -O-, -S-, -SO- or -SO₂- and W represents a phenyl, phenylalkyl, (C₃-C₈)cycloalkyl, (C₃-C₈)cycloalkylalkyl, (C₄-C₈)cycloalkenyl, (C₄-C₈)cycloalkenylalkyl, heteroaryl or heteroarylalkyl group, which group W may optionally be substituted by one or more substituents independently selected from, hydroxyl, halogen, -CN, -CO₂H, -CO₂(C₁-C₆)alkyl, -CONH₂, -CONH(C₁-C₆)alkyl, -CONH(C₁-C₆alkyl)₂, -CHO, -CH₂OH, (C₁-C₄)perfluoroalkyl, -O(C₁-C₆)alkyl, -S(C₁-C₆)alkyl, -SO(C₁-C₆)alkyl, -SO₂(C₁-C₆)alkyl, -NO₂, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, -NHCO(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₈)cycloalkyl, (C₄-C₈)cycloalkenyl, phenyl or benzyl.

13. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R₄ is methyl, ethyl, benzyl, 4-chlorobenzyl, 4-hydroxybenzyl, phenyl, cyclohexyl, cyclohexylmethyl, pyridin-3-ylmethyl, tert-butoxymethyl, naphthylmethyl, iso-butyl, sec-butyl, tert-butyl, 1-benzylthio-1-methylethyl, 1-methylthio-1-methylethyl, 1-mercapto-1-methylethyl, 1-methoxy-1-methylethyl, 1-hydroxy-1-methylethyl, 1-fluoro-1-methylethyl, 2-hydroxyethyl, 2-carboxyethyl, 2-methylcarbamoylethyl, 2-carbamoylethyl, or 4-aminobutyl.

14. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R₄ is tert-butyl, iso-butyl, benzyl or methyl.

15. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R₃ and R₄ when taken together with the nitrogen and carbon atoms to which they are respectively attached may form an optionally substituted saturated heterocyclic ring of 5 to 8 atoms.

16. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_3 and R_4 form a bridge between the nitrogen and carbon atoms to which they are attached, said bridge being represented by the divalent radical - $(CH_2)_{3-8}$ -, or $-(CH_2)_r-O-(CH_2)_s-$, or $-(CH_2)_r-S-(CH_2)_s-$, wherein r and s are each independently 1, 2 or 3 with the proviso that $r+s = 2, 3, 4$, or 5.
17. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_5 and R_6 are independently hydrogen, methyl, ethyl, tert-butyl, cyclopentyl, cyclohexyl, 1,1,3,3-tetramethylbutyl, benzyl, or 2-hydroxyethyl.
18. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_5 and R_6 when taken together with the nitrogen atom to which they are attached form a saturated 5- to 8-membered monocyclic N-heterocyclic ring which is attached via the N atom and which optionally contains $-N(R_{11})-$ wherein R_{11} is hydrogen or C_1-C_6 alkyl, benzyl, acyl, or an amino protecting group, O, S, SO or SO_2 as a ring member, and/or is optionally substituted on one or more C atoms by hydroxy, C_1-C_6 alkyl, hydroxy(C_1-C_6 alkyl)-, C_1-C_6 alkoxy, oxo, ketalised oxo, amino, mono(C_1-C_6 alkyl)amino, di(C_1-C_6 alkyl)amino, carboxy, C_1-C_6 alkoxycarbonyl, hydroxymethyl, C_1-C_6 alkoxymethyl, carbamoyl, mono(C_1-C_6 alkyl)carbamoyl, di(C_1-C_6 alkyl)carbamoyl, or hydroxyimino.
19. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_5 and R_6 when taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted 1-pyrrolidinyl, piperidin-1-yl, 1-piperazinyl, hexahydro-1-pyridazinyl, morpholin-4-yl, tetrahydro-1,4-thiazin-4-yl, tetrahydro-1,4-thiazin-4-yl 1-oxide, tetrahydro-1,4-thiazin-4-yl 1,1-dioxide, thiazolidin-3-yl, hexahydroazipino, or octahydroazocino ring.

20. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_5 and R_6 when taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted 1-pyrrolidinyl, piperidin-1-yl, 1-piperazinyl, hexahydro-1-pyridazinyl, morpholin-4-yl, tetrahydro-1,4-thiazin-4-yl, tetrahydro-1,4-thiazin-4-yl 1-oxide, tetrahydro-1,4-thiazin-4-yl 1,1-dioxide, hexahydroazipino, or octahydroazocino. Substituted examples of the foregoing are 2-(methylcarbamoyl)-1-pyrrolidinyl, 2-(hydroxymethyl)-1-pyrrolidinyl, 4-hydroxypiperidino, 2-(methylcarbamoyl)piperidino, 4-hydroxyiminopiperidino, 4-methoxypiperidino, 4-methylpiperidin-1-yl, 4-benzylpiperidin-1-yl, 4-acetylpiperidin-1-yl, 4-methyl-1-piperazinyl, 4-phenyl-1-piperazinyl, 1,4-dioxo-8-azaspiro[4,5]decan-8-yl, hexahydro-3-(methylcarbamoyl)-2-pyridazinyl, and hexahydro-1-(benzyloxycarbonyl)-2-pyridazinyl, decahydroisoquinolin-2-yl, or 1,2,3,4-tetrahydroisoquinolin-2-yl ring.
21. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_7 is hydrogen, or a group $R_{20}C(O)-$ where R_{20} is a (C_1-C_6) alkyl group such as methyl or ethyl.
22. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) R_{20} is methyl or ethyl.
23. The use as claimed in claim 1, a method as claimed in claim 2, a composition as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) A represents a group of formula (IA), R_1 represents hydrogen, R_2 represents n-butyl, benzyl or cyclopentylmethyl, R_3 is hydrogen, R_4 is tert-butyl, isobutyl, benzyl or methyl, R_5 is hydrogen or methyl and R_6 represents methyl.
24. The use as claimed in claim 1, a method as claimed in claim 2, a composition

as claimed in claim 4 or a compound as claimed in claim 5 wherein in the compound of formula (I) A represents a group of formula (IB), R_1 represents hydrogen, R_2 represents n-butyl, benzyl or cyclopentylmethyl, R_3 is hydrogen, and R_4 is tert-butyl, iso-butyl, benzyl or methyl.

25. 2R (orS)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-ethyl)-amide or a pharmaceutically or veterinarily acceptable salt thereof.


26. 2R (or S)-[(Formyl-hydroxy-amino)-methyl]-3-cyclopentyl-propionic acid (1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide or a pharmaceutically or veterinarily acceptable salt thereof.

27. A compound as claimed in claim 5, which is disclosed in any of Examples 1-3, 5-13, or 15-78 herein, or a pharmaceutically or veterinarily acceptable salt thereof.

28. An antibacterial pharmaceutical or veterinary composition comprising a compound as claimed in any of claims 5 to 27 together with a pharmaceutically or veterinarily acceptable excipient or carrier.

29. A method for the identification of antibacterial compounds, comprising
 (i) screening test compounds for activity as inhibitors of PDF *in vitro*,
 (ii) screening those compounds which exhibit said PDF inhibitory activity for ability to inhibit bacterial growth.

30. Use of a compound which inhibits the activity of bacterial PDF, in the preparation of an antibacterial composition or agent, provided that (i) the compound is not of formula (XI)




wherein,

- (a) R is a cyclic amino group, W is hydrogen, methyl, isopropyl, isobutyl or benzyl, and Y is hydrogen, C₁-C₆ alkyl, phenyl, benzyl, 4-chlorophenylmethyl, 4-nitrophenylmethyl, or 4-aminophenylmethyl; or,
- (b) R is 2-pyridylamino or 2-thiazolylamino, W is isopropyl and Y is n-pentyl; or,
- (c) R is diethylamino, W is methyl or isopropyl and Y is n-pentyl;

or (ii) the compound is not one containing a divalent piperazin-1, 6-diyl group.

31. A method of treating bacterial infection or contamination by administering to a patient suffering such infection or contamination, or applying to the site of such infection or contamination, an antibacterially effective amount of a compound which inhibits the activity of bacterial PDF enzyme, provided that (i) the compound is not of formula (XI)



wherein,

- (a) R is a cyclic amino group, W is hydrogen, methyl, isopropyl, isobutyl or benzyl, and Y is hydrogen, C₁-C₆ alkyl, phenyl, benzyl, 4-chlorophenylmethyl, 4-nitrophenylmethyl, or 4-aminophenylmethyl; or,
- (b) R is 2-pyridylamino or 2-thiazolylamino, W is isopropyl and Y is n-pentyl; or,
- (c) R is diethylamino, W is methyl or isopropyl and Y is n-pentyl;

or (ii) the compound is not one containing a divalent piperazin-1,6-diyl group.

INTERNATIONAL SEARCH REPORT

In **ational Application No**
PCT/GB 99/00386

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/16 A61K31/535 A61K31/165 A61K31/44 A61K31/40
 A61K31/195 A61K31/47 A61K31/495 A61K31/445 A61K31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 38179 A (GLAXO) 3 September 1998 cited in the application see abstract see page 1, line 1 - line 20 see page 2, line 9 - line 22 see page 4, line 3 - line 34; claims; examples; tables 1A-1C ---	1,2,5,8, 10-13,27
P, X	Y. JIN ET AL.: "Inhibition stereochemistry of hydroxamate inhibitors for thermolysin" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 24, 1998, pages 3515-3518, XP002106374 see the whole document --- -/--	5-10,16, 27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 June 1999

Date of mailing of the international search report

30/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3018

Authorized officer

Hoff, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/00386

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 94 10990 A (BRITISH BIO-TECHNOLOGY) 26 May 1994</p> <p>see abstract see page 1, paragraph 1 - paragraph 4 see page 9, last paragraph - page 10 see page 13, last paragraph - page 14, paragraph 3 see page 15, paragraph 4; claims 1,3,18,20,21; examples</p>	<p>1-4, 7-13,16, 22,27</p>
X	<p>DE 33 20 175 A (BOEHRINGER MANNHEIM GMBH) 6 December 1984</p> <p>see abstract see claims 1,4 see page 19, line 32 - page 20, line 3 see page 25, line 1 - line 3; example 87</p>	<p>1,2,4,7, 10-13,27</p>
X	<p>WO 94 07527 A (BRITISH BIO-TECHNOLOGY) 14 April 1994</p> <p>see abstract see page 2, paragraph 3 see page 3 - page 4; claims 1,2,6</p>	<p>1-4, 7-13,16, 22,27</p>
X	<p>WO 97 38705 A (BRISTOL-MYERS SQUIBB) 23 October 1997</p> <p>cited in the application see abstract see page 9, line 20 - line 31 see page 56; examples 13-17</p>	<p>5,7-13, 27</p>
X	<p>M-C FOURNIE-ZALUSKI ET AL.: "New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties" JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, no. 9, 1985, pages 1158-1169, XP002019770 see abstract see tables I,II</p>	<p>5,7-12, 16,27</p>
X	<p>EP 0 082 088 A (ROQUES B.) 22 June 1983 cited in the application see page 10 to page 18 compounds 36,38,63-65,71,73,75 see claims; examples</p>	<p>5,7-12, 16,27</p>
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 99/00386

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H.N. WELLER ET AL.: "design of conformationally constrained angiotensin-converting enzyme inhibitors" BIOCHEMICAL AND BIOPHYSICAL RESAERCH COMMUNICATIONS, vol. 125, no. 1, 1984, pages 82-89, XP002106375 see abstract; table 2 ---	5,7, 10-13, 17-19,27
X	WO 95 32944 A (BRITISH BIOTECH PHARMACEUTICALS) 7 December 1995 see abstract see page 20, last paragraph - page 21, paragraph 3; example 21 ---	5-8, 10-13, 16,27
P,X	EP 0 879 879 A (SMITHKLINE BEECHAM) 25 November 1998 see abstract see page 2, line 1 - line 12 see page 2, line 50 - page 3, line 49 see page 14, line 20 - page 15, line 27; claims ---	28,29
P,X	EP 0 863 152 A (SMITHKLINE BEECHAM) 9 September 1998 see abstract see page 2, line 1 - line 12 see page 3, line 2 - line 21 see page 11, line 40 - page 12, line 38; claims ---	28,29
X	D. MAZEL ET AL.: "genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation" EMBO, vol. 13, no. 4, 1994, pages 914-923, XP002043973 cited in the application see abstract see page 921, right-hand column, last paragraph ---	28,29
X	P.T. RAVI RAJAGOPALAN ET AL.: "Peptide Deformylase: A New Type of Mononuclear Iron Protein" J. AM.CHEM. SOC., vol. 119, 1997, pages 12418-21419, XP002106376 cited in the application see the whole document ---	28,29

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/00386

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 3 166 587 A (J. BERNSTEIN ET AL.) 19 January 1965 see the whole document ---	1-29
A	WO 96 16027 A (SYNTEX) 30 May 1996 cited in the application see abstract; claims; example 53 ---	1-29
A	EP 0 236 872 A (HOFFMANN-LA ROCHE) 16 September 1987 cited in the application see abstract; claims; examples -----	1-29

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/00386

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 2,3,7-23,28
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/00386

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9838179	A	03-09-1998	AU 6822398 A		18-09-1998
			HR 980096 A		31-12-1998
WO 9410990	A	26-05-1994	AT 150300 T		15-04-1997
			AU 5430194 A		08-06-1994
			DE 69309094 D		24-04-1997
			DE 69309094 T		31-07-1997
			EP 0667770 A		23-08-1995
			ES 2101358 T		01-07-1997
			JP 8505605 T		18-06-1996
			US 5691382 A		25-11-1997
DE 3320175	A	06-12-1984	NONE		
WO 9407527	A	14-04-1994	AU 4831693 A		26-04-1994
WO 9738705	A	23-10-1997	AU 2609497 A		07-11-1997
			EP 0894003 A		03-02-1999
EP 82088	A	22-06-1983	FR 2518088 A		17-06-1983
			AT 18902 T		15-04-1986
			JP 1679823 C		13-07-1992
			JP 3046463 B		16-07-1991
			JP 58150547 A		07-09-1983
			US 4618708 A		21-10-1986
			US 4738803 A		19-04-1988
WO 9532944	A	07-12-1995	AU 2572295 A		21-12-1995
			EP 0763012 A		19-03-1997
			JP 10500986 T		27-01-1998
EP 879879	A	25-11-1998	CA 2232811 A		21-11-1998
EP 863152	A	09-09-1998	CA 2223008 A		10-08-1998
US 3166587	A	19-01-1965	NONE		
WO 9616027	A	30-05-1996	AU 705439 B		20-05-1999
			AU 4289796 A		17-06-1996
			BR 9509802 A		30-09-1997
			CN 1173170 A		11-02-1998
			CZ 9701565 A		12-11-1997
			EP 0793643 A		10-09-1997
			FI 972160 A		22-05-1997
			HU 77533 A		28-05-1998
			JP 10509719 T		22-09-1998
			NO 972307 A		22-07-1997
			PL 321024 A		24-11-1997
EP 236872	A	16-09-1987	AT 82753 T		15-12-1992
			AU 588437 B		14-09-1989
			AU 6990287 A		17-09-1987
			CA 1314655 A		16-03-1993
			DE 3782751 A		07-01-1993
			DK 77487 A		12-09-1987
			IE 60128 B		01-06-1994
			JP 1902991 C		08-02-1995
			JP 6029228 B		20-04-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/GB 99/00386

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 236872	A	JP 62230757 A	09-10-1987
		PH 26637 A	04-09-1992
		US 4996358 A	26-02-1991
<hr/>			

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB99/00386

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-28,30-39,42-47, as originally filed
49-79,81-91,93-107,
109-113

29,41,48,80,92, as received on 26/03/1999 with letter of 26/03/1999
108

Claims, No.:

1-30 as received on 05/02/2000 with letter of 03/02/2000

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
☒ claims Nos. 2, 3, 6-23, 30 in respect of industrial applicability.

because:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB99/00386

- ☒ the said international application, or the said claims Nos. 2, 3, 6-23, 30 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

- ☐ no international search report has been established for the said claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	14, 15, 17-21, 23-25
	No:	Claims	1-13, 16, 22, 26-30
Inventive step (IS)	Yes:	Claims	14, 15, 17-21, 23-25
	No:	Claims	1-13, 16, 22, 26-30
Industrial applicability (IA)	Yes:	Claims	1, 4, 5, 24-29
	No:	Claims	-

2. Citations and explanations

see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB99/00386

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item III**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claims 2, 3, 6-23, 30 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Re Item V**Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Reference is made to the following documents:

D1: D. MAZEL ET AL.: 'genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation' EMBO, vol. 13, no. 4, 1994, pages 914-923, XP002043973 cited in the application

D2: P.T. RAVI RAJAGOPALAN ET AL.: 'Peptide Deformylase: A New Type of Mononuclear Iron Protein' J. AM.CHEM. SOC., vol. 119, 1997, pages 12418- 21419, XP002106376 cited in the application

D3: WO 94 10990 A (BRITISH BIO-TECHNOLOGY) 26 May 1994

D4: WO 94 07527 A (BRITISH BIO-TECHNOLOGY) 14 April 1994

D5: WO 97 38705 A (BRISTOL-MYERS SQUIBB) 23 October 1997 cited in the application

D6: M-C FOURNIE-ZALUSKI ET AL.: 'New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties' JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, no. 9, 1985, pages 1158-1169, XP002019770

D7: EP-A-0 082 088 (ROQUES B.) 22 June 1983 cited in the application

D8: H.N. WELLER ET AL.: 'design of conformationally constrained angiotensin-converting enzyme inhibitors' BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 125, no. 1, 1984, pages 82-89, XP002106375

D9: WO 95 32944 A (BRITISH BIOTECH PHARMACEUTICALS) 7 December 1995

D10: DE 33 20 175 A (BOEHRINGER MANNHEIM GMBH) 6 December 1984

2/D3 claims hydroxamic acid derivatives as inhibitors of TNF whereby the compounds with the formula (Ib) on page 9 (see also claims 1, 3, 18-21) correlate with the compounds in claims 1-3, 6-8, 10-13, and 16. These compounds are used in any disease state where TNF is a mediator of host injury, e.g. in mycobacterial infection and meningitis (claims 1, 18, 20, 21; p. 14, paragr. 3), in general in acute infections, and they can be combined with bactericidal and fungicidal agents (p. 15, paragr. 4), but they have not been disclosed explicitly for use as an antibacterial agent. However, the indication mycobacterial infection clearly is a disease mediated by bacteria, and the skilled man in the art is taught to use the claimed compounds in mycobacterial infections by D3. The mechanism of action is of no importance since he would get the same result, namely the management of the disease. Therefor the use claims 1-3 cannot be regarded as novel over D3 in regard to the preparation of an antibacterial composition. Claims 6-8, 10-13, and 16 concerning the compounds per se also cannot be considered as novel.

In D5, N-formyl hydroxylamine containing compounds are used against cardiovascular diseases. The substances in examples 13 to 17 have the same structure as the compounds of claims 4, 6-13, 22, and 26 of the present invention whereby A is represented by a group of formula (IA). In addition, claim 27 is not novel since the compounds "as claimed in any of claims 4 to 26" are not novel and acceptable excipients and carriers are already known in the prior art.

Moreover, documents D6-D9 provide partly the same substances or groups of compounds with a different purpose, namely:

D6: N-formyl-N-hydroxy-peptides (see compounds 7, 9-10 in Table I) as inhibitors of in vitro metabolism of enkephalins whereby compound 7 also is novelty destroying for claim 5 of the present application (A is represented by a group of formula (IB)),

D7: aminoacid derivatives (compounds 36, 38, 63-65, 73, and 75 in claim 3) as enkephalinase inhibitors,

D8: substituted propanoyl dipeptides (compound 6 in Table 2) as ACE inhibitors.

D9: succinyl hydroxamic acid, N-formyl-N-hydroxy-amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors whereby R_2 represents a linear saturated or unsaturated C_{13} - C_{24} hydrocarbon chain possibly interrupted by -O- or -S- atoms or $C(=O)$ - and other groups (see p. 6, l. 8-20; claims).

The proviso (v) in claim 4 and (iv) in claim 5 concerning R_2 is not excluding sufficiently prior art D9. The present application also may have a R_2 chain interrupted by -NH-, -O-, or -S-

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/00386

linkages (see part ALK) which is not excluded by disclaimer (v).

Even if all the disclaimers had been correct, still claims 4 and 5 would have been novelty destroyed by D5-D7.

D4 describes the same compound with a slight difference in R_1 (see claim 1, substance 5) as inhibitors of endothelin, and D10 claims the same compound with another R_2 as antibacterial substance (example 87, lines 29-30).

Hence, in view of D3 and D5 to D9, claims 1-13, 16, 22, 26, and 27 are not novel therefore not meeting the requirements of Article 33(2) PCT.

In regard to claims 28-30, information about peptide deformylase (PDF) and the indication to use it as a target for antibacterial chemotherapy (D1: abstract, lines 21-23), moreover to create specific inhibitors as new generation of antibacterial agents (D2: abstract, lines 11-13), is disclosed in documents D1 and D2. D1 also teaches the inactivation of the deformylase gene of *Escherichia coli*, def, by trimethoprim, a known bacteriostatic agent. Therefore and due to the unspecific definition of compounds as inhibitors of PDF in claims 28 to 30, these claims cannot be regarded as novel (Art. 33(2) PCT).

3. D1 and D2 are considered to represent the most relevant state of the art.

Regarding the use of the compounds in the preparation of an antibacterial composition and in the treatment of bacterial infections, D4 as well as D10 teach the use of certain N-formyl-N-hydroxy-peptides (see V.2) in endotoxin shock and septicemia (D4: claim 6) and in combatting bacterial infections (D10: claim 4). If in the independent claims 1 and 2 novelty was given the following would apply: Since there is no pointer to the different rests R_1 and R_2 from the above cited compounds of D4 and D10 and since there is another mechanism of action, the skilled person would not have the possibility to arrive at the features as set out in independent claims 1 and 2.

The subject-matter of claims 3, 20, 21 and 23 also would not be obvious to the skilled in the art in order to arrive to the same result.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/00386

Since the features R_3 and R_4 as well as R_5 and R_6 when taken together and forming rings are not straightforward possibilities from which the skilled person would select, in order to solve the problem posed, claims 14, 15, and 17-19 seem to be inventive, too.

The explicitly mentioned substances in claims 24 and 25 seem to be novel and inventive.

4. For the assessment of the present claims 2, 3, 6-23, 30 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Re Item VI

Certain documents cited

Certain published documents (Rule 70.10)

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO 98 38179 A	3 September 1998	24 February 1998	26 February 1997
EP-A-0 879 879	25 November 1998	21 May 1998	21 May 1997
EP-A-0 863 152	9 September 1998	5 February 1998	10 February 1997

Re Item VII

Certain defects in the international application

1. The broader definition of R_3 in dependent claims 3 and 5 does not fall within the scope of independent claim 1 or claim 4 resp. because no C_1 - C_6 alkyl is mentioned in claims 1 or 4 resp. (only hydrogen). Therefore, claims 3 and 5 are not appropriately formulated as claims dependant on claims 1 or 4 resp. (Rule 6.4 PCT).

2. The description lacks example 77 (see p. 102).

Re Item VIII

Certain observations on the international application

1. More than originally claimed is excluded by proviso (v) in claim 4 because for the present application the maximum chain length for R_2 is 18C atoms and the disclaimer excludes a C_{13} - C_{24} hydrocarbon chain (prior art D9). Therefore, claim 4 does not meet the requirements of Article 6 PCT in that the matter for which protection is sought is unclear.
2. Concerning the admissibility of a disclaimer, it has to be stated that a disclaimer can only be used by way of exception for avoiding claim anticipation if the subject-matter of a claim could not be restricted on the basis of the original disclosure in positive terms without unduly impairing its clarity and conciseness. New claims 4 and 5 have disclaimers arising from not less than 7 documents (not taken into consideration that they are still novelty destroyed by other documents, see item V) and are by no means concise. Hence, both claims are likely not to be accepted in the form they are drafted even if all disclaimers are correct.
3. The feature of claims 3 and 5, that R_3 represents C_1 - C_6 alkyl, is not referred to in the description. Claims 3 and 6 are therefore not supported by the description as required by Article 6 PCT.
4. The feature of claim 18, that R_5 and R_6 form a thiazolidin-3-yl, is not referred to in the description. Claim 18 is therefore also not supported by the description as required by Article 6 PCT.
5. The above remarks apply mutatis mutandis for claim 29 in regard to formula (XI), namely the part ---NH-CO(Y)-CH--- .
6. Claim 26 is not clear as it relies on references to the description in respect to specific compounds therefore not being in accordance with Rule 6.2a PCT.
7. Since the subject-matter of independent claims 29 and 30 is defined by means of negative features and on the other hand by the result to be achieved it does not meet the requirements of Article 6 PCT. The functional characterisation does not enable the skilled


INTERNATIONAL PRELIMINARY

International application No. PCT/GB99/00386

EXAMINATION REPORT - SEPARATE SHEET


person to determine which technical features are necessary to perform the stated functions and represents an undue burden to find out.

-29-




Reagents and conditions: A. piperidine, HCHO, EtOH, 80°C, o/n; B. H₂NOBzl, 80°C a/n; C. HCOOH, Ac₂O;
 D. Pentafluorophenol, EDC, CH₂Cl₂; E. H-tert-LeuNHMe, DMF, 35°C; F. H₂, 10% Pd/C, EtOAc/EtOH.

-48-




Reagents and conditions: A. piperidine, HCHO, EtOH, 80°C, o/n; B. BuCOCl, EtN then 3-ethyl-4-benzyl-5,5-dimethyl-oxazolidin-2-one, room temp, o/n then pTsOH, EtOAc; D. LiOH, aq THF, 0°C; E. H-TetNMg, HOBT, EDC, DMF; F. HCOBT, THF; G. H, Pd/C, EtOH.

Scheme 4



Reagents and conditions: A. 3-allyloxy-4-benzyl-oxazolidin-2-one, THF, -78°C; B. LiN(SiMe₃)₂, THF, -78°C then AcCl; C. HCl, H₂O, NaOAc, aq ethanol; D. NaCNBH₃, AcOH, room temperature; E. HCOBI, THF; F. LiOH, aq THF, 0°C; G. H-Tle-NMe₂, HOAT, EDC, DMF; H. H₂, Pd/C, MeOH then separate diastereoisomers (HPLC)

Scheme 5



Reagents and conditions: A. (CHO), EtSH, dicyclohexylamine, dioxane, 70°C, 2h; B. EtSH, dicyclohexylamine, dioxane, 70°C, 2h; C. EtSH, dicyclohexylamine, dioxane, 70°C, 2h; D. EtSH, dicyclohexylamine, dioxane, 70°C, 2h; E. EtSH, dicyclohexylamine, dioxane, 70°C, 2h; F. EtSH, dicyclohexylamine, dioxane, 70°C, 2h; G. EtSH, dicyclohexylamine, dioxane, 70°C, 2h.

28-03-1999

JPC/GB/99/00386

PC17/95 G 1540/SC26

03 MARCH 1999

-108-

Activity against a multi-resistant *Enterococcus faecalis* clinical isolate:

Bacterial Strain	MIC µg/ml							
	Cpd 3	Cpd 4	Ampicillin	Ceftazidime	Imipenem	Erythromycin	Ciprofloxacin	Vancomycin
<i>Enterococcus faecalis</i> ATCC 29212	32	8	0.5	128	1	2	0.5	1
<i>Enterococcus faecalis</i> Vancomycin resistant strain	8	4	>128	>128	>128	>128	>128	>128

Printed 25-10-1999

BNSDOCID: 42 00038604


SUBSTITUTE SHEET (RULE 26)

6

14 05.02.00

Claims

1. The use of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof in the preparation of an antibacterial composition:



wherein:

R₁ represents hydrogen, or C₁-C₆ alkyl or C₁-C₈ alkyl substituted by one or more halogen atoms;

R₂ represents a group R₁₀-(X)_n-(ALK)_m wherein

R₁₀ represents hydrogen, or a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C₁-C₆)alkyl, (C₁-C₆)alkoxy, hydroxy, mercapto, (C₁-C₆)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano; nitro, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C₁-C₆)alkyl group, and


ALK represents a straight or branched divalent C₁-C₆ alkylene, C₂-C₆ alkenylene, or C₂-C₆ alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages,

15 05.02.00


X represents -NH-, -O- or -S-, and

m and n are independently 0 or 1; and


A represents (I) a group of formula (IA), (IB), (IC) or (ID)



(IA)



(IB)



(IC)



(ID)

wherein:

R₃ represents hydrogen and R₄ represents the side chain of a natural or non-natural alpha amino acid or R₃ and R₄ when taken together with the nitrogen and carbon atoms to which they are respectively attached form an optionally substituted saturated heterocyclic ring of 5 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring,

R₅ and R₆, independently represent hydrogen, or optionally substituted C₁-C₈ alkyl, cycloalkyl, aryl, aryl(C₁-C₆ alkyl), heterocyclic, or heterocyclic(C₁-C₆ alkyl), or R₅ and R₆ when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring, and

R₇ represents hydrogen, C₁-C₆ alkyl, or an acyl group.

AMENDED SHEET

16 05.02.00

2. A method for the treatment of bacterial infections in humans and non-human mammals, which comprises administering to a subject suffering such infection an antibacterially effective dose of a compound of formula (I) as defined in claim 1.

3. The use as claimed in claim 1 or a method as claimed in claim 2 wherein in the compound of formula (I):

R_1 represents hydrogen, or C_1 - C_6 alkyl;

R_2 represents a group R_{10} -(X)_n-(ALK)- wherein

R_{10} represents hydrogen, a C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, a cycloalkyl, aryl, or heteroaryl group, any of which may be unsubstituted or substituted by (C_1 - C_6)alkyl, (C_1 - C_6)alkoxy, hydroxy, mercapto, (C_1 - C_6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C_1 - C_6)alkyl group, and

ALK represents a straight or branched divalent C_1 - C_6 alkylene, C_2 - C_6 alkenylene, C_2 - C_6 alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages,

X represents -NH-, -O- or -S-, and

n is 0 or 1; and

R_3 represents hydrogen or C_1 - C_6 alkyl, and

AMENDED SHEET


17 05.02.00

R_4 represents the side chain of a natural or non-natural alpha amino acid, and

R_5 and R_6 , independently represent hydrogen or C_1 - C_6 alkyl, or R_5 and R_6 when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms, and

R_7 represents hydrogen or an acyl group.

4. A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof



wherein

R_1 represents hydrogen, C_1 - C_6 alkyl or C_1 - C_6 alkyl substituted by one or more halogen atoms;

R_2 represents a group R_{10} -(ALK)_m- wherein


R_{10} represents hydrogen, or a C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, a cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C_1 - C_6)alkyl, (C_1 - C_6)alkoxy, hydroxy, mercapto, (C_1 - C_6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, -COOH, -CONH₂, -COOR^A, -NHCOR^A, -CONHR^A, -NHR^A, -NR^AR^B, or -CONR^AR^B wherein R^A and R^B are independently a (C_1 - C_6)alkyl group,

11 05 02 00


ALK represents a straight or branched divalent C₁-C₆ alkylene, C₂-C₆ alkenylene, C₂-C₆ alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages, and

m represents 0 or 1;


A represents (i) a group of formula (IA), (IB), (IC) or (ID)



(IA)



(IB)



(IC)



(ID)

wherein:

R₃ represents hydrogen and R₄ represents the side chain of a natural or non-natural alpha amino acid or R₃ and R₄ when taken together with the nitrogen and carbon atoms to which they are respectively attached form an optionally substituted saturated heterocyclic ring of 5 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring,

R₅ and R₆, independently represent hydrogen, or optionally substituted C₁-C₆ alkyl, cycloalkyl, aryl(C₁-C₆ alkyl), non-aromatic heterocyclic, or heterocyclic(C₁-C₆ alkyl), or R₅ and R₆ when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring, and

11:05:02:00

R_7 represents hydrogen, C_1 - C_6 alkyl, or an acyl group.

PROVIDED THAT

(i) when A is a group of formula (IA) or (IB) and R_2 is C_2 - C_5 alkyl then R_4 is not the side chain of a natural alpha amino acid or the side chain of a natural alpha-amino acid in which any functional substituents are protected, any amino groups are acylated, and any carboxyl groups are esterified;

(ii) when A is a group of formula (IA) or (IB) then R_4 is not a bicyclicarylmethyl group; and

(iii) when A is a group of formula (IA) and R_2 is cyclopropylmethyl, cyclobutylmethyl or cyclopentylmethyl and one of R_5 and R_6 is hydrogen, then R_4 is not tert-butyl;

(iv) when R_1 is hydrogen, and A is a group of formula (IA) wherein $-NR_5R_6$ is a 2-carboxyl-pyrrolidino group, R_4 is methyl, and R_3 is hydrogen, then R_2 is not hydrogen;

(v) R_2 is not a linear saturated or unsaturated C_{13} - C_{24} hydrocarbon chain optionally substituted by $(C_1$ - $C_6)$ alkyl, hydroxy, methoxy, amino, halo (including fluoro, chloro, bromo and iodo), $-COOH$, $-CONH_2$, $-COOR^A$, $-NHCOR^A$, $-CONHR^A$, $-NHR^A$, $-NR^AR^B$, or $-CONR^AR^B$ wherein R^A and R^B are independently methyl; and

(vi) when R_1 is hydrogen, and A is a group of formula (ID) wherein R_5 is methyl and R_6 is hydrogen, then R_2 is not benzyl.

5. A compound as claimed in claim 4 wherein:

AMENDED SHEET

11:05:02:00

R_1 represents hydrogen, or C_1-C_6 alkyl;

R_2 represents a group $R_{10}-(ALK)-$ wherein

R_{10} represents hydrogen, a C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, a cycloalkyl, aryl, or heteroaryl group, any of which may be unsubstituted or substituted by (C_1-C_6) alkyl, (C_1-C_6) alkoxy, hydroxy, mercapto, (C_1-C_6) alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, nitro, $-COOH$, $-CONH_2$, $-COOR^A$, $-NHCOR^A$, $-CONHR^A$, $-NHR^A$, $-NR^A R^B$, or $-CONR^A R^B$ wherein R^A and R^B are independently a (C_1-C_6) alkyl group, and

ALK represents a straight or branched divalent C_1-C_6 alkylene, C_2-C_6 alkenylene, C_2-C_6 alkynylene radical, and may be interrupted by one or more non-adjacent $-NH-$, $-O-$ or $-S-$ linkages;

R_3 represents hydrogen or C_1-C_6 alkyl,

R_4 represents the side chain of a natural or non-natural alpha amino acid,

R_5 and R_6 , independently represent hydrogen or C_1-C_6 alkyl, or R_5 and R_6 when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms, and

R_7 represents hydrogen or an acyl group;

PROVIDED THAT

AMENDED SHEET

121 05.00.00

(a) when A is a group of formula (IA) then (i) R_4 is not the side chain of a natural alpha amino acid or the side chain of a natural alpha-amino acid in which any functional substituents are protected, any amino groups are acylated, and any carboxyl groups are esterified, (ii) R_4 is not a fused bicyclicarylmethyl group, and (iii) R_4 is not tert-butyl when R_2 is cycloalkyl(C_1 - C_6 alkyl); and (iv) R_2 is not a linear saturated or unsaturated C_{13} - C_{24} hydrocarbon chain optionally substituted by (C_1 - C_6)alkyl, hydroxy, methoxy, amino, halo (including fluoro, chloro, bromo and iodo), $-COOH$, $-CONH_2$, $-COOR^A$, $-NHCOR^A$, $-CONHR^A$, $-NHR^A$, $-NR^A R^B$, or $-CONR^A R^B$ wherein R^A and R^B are independently methyl; and

(b) when R_1 is hydrogen, and A is a group of formula (ID) wherein R_5 is methyl and R_6 is hydrogen, then R_2 is not benzyl

6. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) R_1 is hydrogen.

7. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) R_2 is:

optionally substituted C_1 - C_8 alkyl, C_3 - C_6 alkenyl, C_3 - C_6 alkynyl or cycloalkyl;

phenyl(C_1 - C_6 alkyl)-, phenyl(C_3 - C_6 alkenyl)- or phenyl(C_3 - C_6 alkynyl)- optionally substituted in the phenyl ring;

123 05.03.00

10. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) R_3 is hydrogen.

11. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) R_4 is:

the characterising group of a natural α amino acid, for example benzyl, or 4-methoxyphenylmethyl, in which any functional group may be protected, any amino group may be acylated and any carboxyl group present may be amidated; or

a group $-[Alk]_nR_9$ where Alk is a (C_1-C_6) alkylene or (C_2-C_6) alkenylene group optionally interrupted by one or more -O-, or -S- atoms or $-N(R_{12})-$ groups where R_{12} is a hydrogen atom or a (C_1-C_6) alkyl group, n is 0 or 1, and R_9 is hydrogen or an optionally substituted phenyl, aryl, heterocyclyl, cycloalkyl or cycloalkenyl group or (only when n is 1) R_9 may additionally be hydroxy, mercapto, (C_1-C_6) alkylthio, amino, halo, trifluoromethyl, nitro, -COOH, $-CONH_2$, $-COOR^A$, $-NHCOR^A$, $-CONHR^A$, $-NHR^A$, $-NR^AR^B$, or $-CONR^AR^B$ wherein R^A and R^B are independently a (C_1-C_6) alkyl group; or

a benzyl group substituted in the phenyl ring by a group of formula $-OCH_2COR_8$ where R_8 is hydroxyl, amino, (C_1-C_6) alkoxy, phenyl (C_1-C_6) alkoxy, (C_1-C_6) alkylamino, di (C_1-C_6) alkylamino, phenyl (C_1-C_6) alkylamino; or

a heterocyclic (C_1-C_6) alkyl group, either being unsubstituted or mono- or di-substituted in the heterocyclic ring with halo, nitro,

124 05.02.00

carboxy, (C₁-C₆)alkoxy, cyano, (C₁-C₆)alkanoyl, trifluoromethyl (C₁-C₆)alkyl, hydroxy, formyl, amino, (C₁-C₆)alkylamino, di-(C₁-C₆)alkylamino, mercapto, (C₁-C₆)alkylthio, hydroxy(C₁-C₆)alkyl, mercapto(C₁-C₆)alkyl or (C₁-C₆)alkylphenylmethyl; or

a group -CR_aR_bR_c in which:

each of R_a, R_b and R_c is independently hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl(C₁-C₆)alkyl, (C₃-C₈)cycloalkyl; or

R_c is hydrogen and R_a and R_b are independently phenyl or heteroaryl such as pyridyl; or

R_c is hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl(C₁-C₆)alkyl, or (C₃-C₈)cycloalkyl, and R_a and R_b together with the carbon atom to which they are attached form a 3 to 8 membered cycloalkyl or a 5- to 6-membered heterocyclic ring; or

R_a, R_b and R_c together with the carbon atom to which they are attached form a tricyclic ring (for example adamantyl); or

R_a and R_b are each independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl(C₁-C₆)alkyl, or a group as defined for R_c below other than hydrogen, or R_a and R_b together with the carbon atom to which they are attached form a cycloalkyl or heterocyclic ring, and R_c is hydrogen, -OH, -SH, halogen, -CN, -CO₂H, (C₁-C₄)perfluoroalkyl, -CH₂OH, -CO₂(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -O(C₂-C₆)alkenyl, -S(C₁-C₆)alkyl, -SO(C₁-C₆)alkyl, -SO₂(C₁-C₆)alkyl, -S(C₂-

18. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) R_5 and R_6 when taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted 1-pyrrolidiny, piperidin-1-yl, 1-piperaziny, hexahydro-1-pyridaziny, morpholin-4-yl, tetrahydro-1,4-thiazin-4-yl, tetrahydro-1,4-thiazin-4-yl 1-oxide, tetrahydro-1,4-thiazin-4-yl 1,1-dioxide, thiazolidin-3-yl, hexahydroazipino, or octahydroazocino ring.

19. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) R_5 and R_6 when taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted 1-pyrrolidiny, piperidin-1-yl, 1-piperaziny, hexahydro-1-pyridaziny, morpholin-4-yl, tetrahydro-1,4-thiazin-4-yl, tetrahydro-1,4-thiazin-4-yl 1-oxide, tetrahydro-1,4-thiazin-4-yl 1,1-dioxide, hexahydroazipino, or octahydroazocino. Substituted examples of the foregoing are 2-(methylcarbamoil)-1-pyrrolidiny, 2-(hydroxymethyl)-1-pyrrolidiny, 4-hydroxypiperidino, 2-(methylcarbamoil)piperidino, 4-hydroxyliminopiperidino, 4-methoxypiperidino, 4-methylpiperidin-1-yl, 4-benzylpiperidin-1-yl, 4-acetyl piperidin-1-yl, 4-methyl-1-piperaziny, 4-phenyl-1-piperaziny, 1,4-dioxa-8-azaspiro[4,5]decan-8-yl, hexahydro-3-(methylcarbamoil)-2-pyridaziny, and hexahydro-1-(benzyloxycarbonyl)-2-pyridaziny, decahydroisoquinolin-2-yl, or 1,2,3,4-tetrahydroisoquinolin-2-yl ring.

20. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) R_7 is hydrogen, or a group $R_{20}C(O)-$ where R_{20} is a (C_1-C_6) alkyl group such as methyl or ethyl.

128 05.02.00

21. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) R_{20} is methyl or ethyl.

22. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) A represents a group of formula (IA), R_1 represents hydrogen, R_2 represents n-butyl, benzyl or cyclopentylmethyl, R_3 is hydrogen, R_4 is tert-butyl, iso-butyl, benzyl or methyl, R_5 is hydrogen or methyl and R_6 represents methyl.

23. The use as claimed in claim 1, a method as claimed in claim 2 or a compound as claimed in claim 4 wherein in the compound of formula (I) A represents a group of formula (IB), R_1 represents hydrogen, R_2 represents n-butyl, benzyl or cyclopentylmethyl, R_3 is hydrogen, and R_4 is tert-butyl, iso-butyl, benzyl or methyl.

24. 2R (orS)-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid (1S-dimethylcarbamoyl-ethyl)-amide or a pharmaceutically or veterinarily acceptable salt thereof.

25. 2R (or S)-[(Formyl-hydroxy-amino)-methyl]-3-cyclopentyl-propionic acid (1S-dimethyl-carbamoyl-2,2-dimethyl-propyl)-amide or a pharmaceutically or veterinarily acceptable salt thereof.

26. A compound as claimed in claim 4, which is disclosed in any of Examples 1-3, 5-13, or 15-78 herein, or a pharmaceutically or veterinarily acceptable salt thereof.

AMENDED SHEET



European Patent
Office

**SUPPLEMENTARY
EUROPEAN SEARCH REPORT**

Application Number
EP 96 91 6547

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	WO 92 10578 A (BIOPTION AB) 25 June 1992 (1992-06-25) * the whole document * -----	20-37	C12N15/14 C12N15/86 C12N7/01 C12N5/10
X	WO 95 07994 A (VIAGENE INC) 23 March 1995 (1995-03-23) * the whole document * -----	1,2,4-8, 12-16, 20-37	A61K39/12 A61K48/00
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C12N A61K
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search THE HAGUE		Date of completion of the search 18 October 2000	Examiner Blanco Urgoiti, B
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 96 91 6547

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-10-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9210578 A	25-06-1992	AU 656545 B	09-02-1995
		AU 9078791 A	08-07-1992
		CA 2098292 A	14-06-1992
		EP 0561890 A	29-09-1993
		FI 932678 A	27-07-1993
		JP 6504198 T	19-05-1994
		US 5739026 A	14-04-1998
WO 9507994 A	23-03-1995	AU 3682699 A	07-10-1999
		AU 703653 B	01-04-1999
		AU 5645098 A	04-06-1998
		AU 690583 B	30-04-1998
		AU 7835894 A	03-04-1995
		CA 2158937 A	23-03-1995
		EP 0694070 A	31-01-1996
		EP 0711829 A	15-05-1996
		EP 0716148 A	12-06-1996
		EP 0814154 A	29-12-1997
		EP 0982405 A	01-03-2000
		FI 954601 A	23-02-1996
		JP 9503657 T	15-04-1997
		NO 953901 A	04-01-1996
		US 6015686 A	18-01-2000
		US 5814482 A	29-09-1998
		US 5843723 A	01-12-1998
		US 5789245 A	04-08-1998
		US 6015694 A	18-01-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.